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'There is something fascinating about science. O n e gets such wholesale
returns o f conjecture out o f such a trifling investment o f fact."

-Mark Twain
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Abstract
This thesis describes the discovery, cloning, and initial characterization of StarD4,
sterol-regulated gene encoding a StAR-related lipid transfer (START) protein, and its
close homologues, StarD5 and StarD6. StarD4 was identified using cDNA microarrays, as

liver StarD4 expression decreased three-fold in mice fed a high cholesterol diet. Star

also sterol-regulated in cultured cells, and a functional sterol regulatory element (S

identified in its promoter. StarD4 was preferentially activated in mouse liver by SREB

rather than SREBP-1, supporting a role in cholesterol rather than fatty acid metabolis

X-ray crystal structure of StarD4 was solved, revealing a hydrophobic lipid binding c
described for other START domains. StarD5 and StarD6 were identified by homology to

StarD4, and these three genes constituted a novel subfamily most similar to the choles
binding START domains of StAR and MLN64. StarD4 and StarD5 were ubiquitously

expressed with highest mRNA levels in liver, while StarD6 expression was limited to ma

germ cells of the testis. StarD5 was not activated by SREBP or LXR transcription facto

well-characterized regulators of cholesterol metabolism, but rather by the ER stress r

a recently-described means by which cholesterol regulates gene expression. The nematod
C. elegans has one StarD4 subfamily protein, K02D3.2. Reporter studies indicated that

gene was not regulated by cholesterol or ER stress, and it was only expressed in hypod

seam cells of embryos and larvae. Overexpression of StarD4 and StarD5 revealed functio
activity in three cell culture assays: (1) StAR-like activation of steroidogenesis by
mitochondrial P450 side chain cleavage enzyme, (2) repression of an SREBP-regulated

reporter, and (3) activation of an LXR-regulated reporter. The START domains of StAR a

MLN64 were active in these assays, while the related phosphatidylcholine transfer prot

(PCTP) was an inactive negative control. Based on these results, the novel StarD4 subf
is likely to play roles in the intracellular transport and metabolism of cholesterol.
1-

C h a p t e r 1:

Introduction

Cholesterol is a 27-carbon, four-ringed planar lipid that plays key roles in health and
disease. It is a fundamental component of cell membranes, where it packs with fatty acyl
chains of phosholipids to increase bilayer rigidity 0 abas, 2002a). Lipid rafts, membrane
microdomains that coalesce to form platforms for signal transduction, are enriched in
cholesterol and sphingolipids (Simons and Hhehalt, 2002). Cholesterol, along with its
precursors and metabolites, also functions in cell signaling events regulating diverse
processes including fertility. Some proteins are covalently modified with cholesterol,
nohibly the Hedgehog morphogen that plays vital roles in patterning during embryonic
development (Jeong and McMahon, 2002). Cholesterol also is the substrate for biosynthesis
of all steroid hormones and bile acids. Mammals obtain cholesterol from both dietary
sources and endogenous de novo synthesis. While cholesterol is essential for normal
physiology of cells and organisms, cholesterol surplus has pathological effects. Excess
cellular free cholesterol is cytotoxic, and excess biliary cholesterol causes gallstones
(I'ortincasa cl al., 2003). Elevated plasma low density lipoprotein (LDL) cholesterol is a

major risk factor for atherosclerotic vascular disease, resulting in coronary heart disease and
stroke (Steinberg and Golto, 1999). These are the leading causes of death among Americans,
accounting for 39% of deaths, compared to 23% for cancer and 38% for all other causes.
Cholesterol has also been linked to the pathogenesis of Alzheimer's disease (Puglielli et al.,
2003). Therefore, cholesterol homeostasis must be finely regulated to assure adequate supply
and proper distribution of this essential lipid, yet to avoid excess and mislocalization which
can be toxic.

Cholesterol Regulation of Gene Expression

Most regulation of cholesterol homeostasis is at the level of gene transcription,

though there are examples of post-transcriptional regulation (Edwards and Ericsson, 199

Two transcription factor families, the sterol regulatory element binding proteins (SRE

and liver X receptors (LXRs), are implicated in gene regulation by cholesterol and its

oxysterol metabolites (Schoonjans et al., 2000). When sterols are low, SREBPs activate
genes involved in the synthesis and uptake of cholesterol and fatty acids (Horton et
2002). Conversely, when sterols are in excess, LXRs activate target genes involved in

cholesterol efflux and reverse cholesterol transport (Repa and Mangelsdorf, 2002). Rece

cholesterol was shown to activate a third transcriptional pathway, as free cholesterol

macrophages trigger the endoplasmic reticulum (ER) stress response (Feng et al., 2003a

The sterol regulatory element binding proteins: SREBPs share a common tripartite

structure: (1) an N-terminal basic helix-loop-helix leucine zipper transcription facto
domain, (2) a central membrane anchor with two transmembrane a-helices, and (3) a Cterminal regulatory domain that binds the SREBP cleavage activating protein (SCAP)

(Brown and Goldstein, 1999). When cellular sterols are abundant, SREBPs are retained in

the ER membrane in a complex with SCAP and the ER retention protein Insig-1 or Insig-2

(Figure 1.1). SCAP has a sterol-sensing domain and undergoes a conformation change up
ER cholesterol depletion, releasing Insig and allowing the SREBP-SCAP complex to

translocate to the Golgi apparatus (Yang et al., 2002). In the Golgi, the site 1 and si
proteases (SIP and S2P) cleave SREBP to release the N-terminal transcription factor
(nSREBP) into the cytosol. Upon translocation to the nucleus, nSREBPs bind promoter

sterol regulatory elements (SREs) and cooperate with other transcription factors like
-3-

r

cholesterol
oxysterols

Figure 1.1: Gene activation by SREBPs upon cholesterol depletion.
When cellular cholesterol or certain oxysterols are abundant, SREBPs remain in the E R as inactive
precursors associated with SCAP and Insig. When sterols are scarce, SCAP releases Insig allowing
SREBP-SCAP trafficking to the Golgi apparatus, where the site 1 and site 2 proteases (SIP and S2P)
cleave SREBP. This releases the N-terminal transcription factor nSREBP, which translocates to the
nucleus and binds promoter SREs.

nSREBPs cooperate with other factors like NF-Y to activate

transcription of target genes involved in the synthesis and uptake of cholesterol and fatty acids.

activate target genes (Edwards et al., 2000). nSREBPs are inactivated by polyubiquitination
and proteosomal degradation (Hirano et al., 2001), as well as covalent attachment of the
small ubiquitin-related modifier SUMO-1 (Hirano et al., 2003).
Localization of SREBPs to the ER reflects the important regulatory role this
compartment plays in cholesterol homeostasis. Though the surface areas of the plasma
membrane (PM) and ER are similar in many cells, 60-80% of total cellular cholesterol is in
PM while only 0.5-1% is in ER (Maxfield and Wustner, 2002). However, the cholesterolpoor ER is exquisitely sensitive to changes in cellular cholesterol levels: modest -50%
changes in PM cholesterol (by addition or removal with cyclodextrin) result in large 10-fold
changes in ER cholesterol (Lange et al., 1999). In addition to affecting SCAP-SREBP, ER
cholesterol also regulates two important enzymes in cholesterol metabolism. First, ER
cholesterol accelerates the degradation of HMG CoA reductase (HMGR), the rate-limiting
enzyme in cholesterol biosynthesis, by promoting association of its sterol-sensing domain
-4-

with Insig-1 (Sever et al., 2003). Second, E R cholesterol allosterically activates the acyl-

coenzyme A:cholesterol acyltransferase (ACAT) enzyme, which generates cholesterol este
for storage in cytosolic lipid droplets (Chang et al., 1998).
There are two SREBP genes that encode three distinct proteins: SREBP-la, SREBPlc, and SREBP-2. Alternative promoters of the same gene generate SREBP-la and SREBP-

lc, which differ only in the length of their N-terminal transactivation domains. SREBP
a stronger transcriptional activator, but SREBP-lc is the predominant form of SREBP-1

expressed in liver. Transgenic mice have been developed with liver overexpression of e

truncated nuclear SREBP, such that target genes are constitutively activated (Horton e
2002). nSREBP-la preferentially activates genes for lipogenic enzymes like fatty acid

synthase (FAS), resulting in a 26-fold increase in the rate of hepatic fatty acid synt

only a 5-fold increase in cholesterol synthesis (Shimano et al., 1996). nSREBP-lc weak

activates the same genes, giving a 4-fold increase in fatty acid synthesis and no chan
cholesterol synthesis (Shimano et al., 1997). Conversely, nSREBP-2 transgenic mice
increase hepatic cholesterol synthesis 28-fold and fatty acid synthesis only 4-fold,
preferential activation of cholesterogenic enzymes like HMGR (Horton et al., 1998).

Proteolytic cleavage of SREBP-1 and SREBP-2 is differentially regulated in rodent mode
drugs that deplete cholesterol cause increased processing of SREBP-2 but not SREBP-1

(Sheng et al., 1995; Shimomura et al., 1997), while dietary polyunsaturated fatty acids
decrease processing of SREBP-1 but not SREBP-2 (Xu et al., 2002). SREBPs are also

differentially regulated at the level of transcription. Most significantly, only the S

transcript is regulated by LXRs, insulin, and glucagon (Repa et al., 2000a), and SREBPexpression in adipocytes is repressed by the hormone leptin (Soukas et al., 2000).
While SREBP-1 primarily regulates fatty acid metabolism and SREBP-2 primarily

regulates cholesterol metabolism, there appears to be considerable cross-talk. In Dros

there is only one S R E B P whose cleavage is regulated by phosphatidylethanolamine,

indicating that the SREBP pathway evolved to monitor cell membrane lipids and regulate
synthesis accordingly (Dobrosotskaya et al., 2002). SREBPs also mediate the effects of
statins, a widely-used class of drugs to lower LDL cholesterol. By inhibiting hepatic

and cholesterol synthesis, statins stimulate SREBP-mediated activation of the LDL rece
resulting in clearance of plasma LDL cholesterol.

The liver X receptors: The two mammalian LXRs, LXRa and LXRp, are encoded by

separate genes. LXRa is expressed only in liver, adipose tissue, intestine, kidney, an
macrophages, while LXR(3 is more widely expressed. LXRs belong to the nuclear hormone
receptor family, which have N-terminal DNA binding domains and C-terminal domains

responsible for ligand binding, dimerization, and transcriptional regulation. LXRs for
obligate heterodimers with retinoid X receptors (RXRs) and bind direct repeat 4 (DR4)
motifs in promoters (Repa and Mangelsdorf, 2000). LXR/RXR is constitutively bound to

target promoters associated with transcriptional corepressors (Hu et al., 2003; Wagner

2003). Ligand binding causes a conformational change (Farnegardh et al., 2003), releasin
corepressors and binding coactivators to activate transcription (Figure 1.2). Ligands
either LXR or RXR will activate transcription by LXR/RXR, and combinations act

synergistically. RXR ligands alone non-specifically activate other heterodimeric nucle
receptors (Repa et al., 2000b). Oxysterols are specific LXR agonists, though the
physiologically relevant ligands are uncertain, as described in the next section.
Most known LXR target genes function in reverse cholesterol transport, a process by

which high density lipoproteins (HDL) transport cholesterol from peripheral cells to t

where it is excreted in bile as free cholesterol or bile acids (Repa and Mangelsdorf, 2

This pathway likely accounts for the major atheroprotective effects of HDL. Consistent
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Figure 1.2: Gene activation by L X R s upon cholesterol excess.
LXRs bind to direct repeat 4 03R4) elements as obligate heterodimers with RXR, recruiting corepressors to suppress target gene expression. When cholesterol is abundant, oxysterols are generated
and serve as L X R agonists, causing the release of co-repressors and recruitment of co-activators. L X R
target genes are generally involved in cholesterol efflux and reverse cholesterol transport.

LXR

activation of reverse cholesterol transport, multiple studies have s h o w n that L X R

activation inhibits atherosclerosis, while L X R deficiency in macrophages increases lesion
formation (Tontonoz and Mangelsdorf, 2003).
In macrophages, L X R s activate the A T P binding cassette transporter A B C A 1 (Costet
et al., 2000), which mediates cholesterol efflux to nascent H D L .

Other macrophages L X R

targets like A B C G 1 (Venkateswaran et al., 2000) and the apolipoprotein E/C-I/C-IV/C-II
gene cluster ( M a k et al., 2002) m a y also function in this efflux pathway.

T w o plasma lipid

transfer proteins that remodel H D L particles, C E T P (Luo and Tall, 2000) and P L T P (Laffitte
et al., 2003), are L X R targets. In liver, L X R s activate expression of scavenger receptor B-l
(SRB-1), which mediates selective uptake of cholesterol from H D L (Malerod et al., 2002),
and A B C G 5 and A B C G 8 , which secrete free cholesterol into the bile ( Y u et al., 2003). In
the intestine, L X R s activate A B C A 1 , A B C G 5 , and A B C G 8 to decrease absorption of dietary
cholesterol. L X R a , but not L X R p \ positively feeds back on its o w n transcription (Li et al.,
2002), potentially amplifying these responses.

Several species differences in L X R target

genes between h u m a n s and mice have been described: (1) only mice s h o w L X R activation of

hepatic cholesterol 7a-hydroxylase (Cyp7Al), which initiates the conversion of cholesterol

to bile acids (Agellon et al., 2002), (2) mice lack CETP, and (3) human macrophages sh

much stronger activation of ABCG1, ApoE, and LXRa in response to LXR ligands (Laffitte
et al., 2001; Lund et al., 2003).
There is also cross-talk between LXRs and other transcriptional pathways in lipid

metabolism. LXRs stimulate fatty acid synthesis by activating SREBP-lc expression (Rep

et al., 2000a), causing hypertriglyceridemia and hepatic steatosis in mice treated wit

synthetic LXR ligands (Schultz et al., 2000). However, arachidonate and other unsaturat

fatty acids serve as competitive inhibitors of LXR activation, result in negative feed
SREBP-lc (Ou et al., 2001). Consistent with LXR activation of SREBP-lc, LXRa knockout

mice show lower hepatic expression of SREBP-1 and its target genes (Peet et al., 1998)
However, these mice also show higher expression of SREBP-2 and its target genes,
suggesting that LXRs may repress SREBP-2 and cholesterol synthesis by an unknown
mechanism (Millatt et al., 2003). Cholesterol synthesis may reciprocally inhibit LXRs,

intermediate geranylgeranyl pyrophosphate blocks LXR activation by preventing co-acti

recruitment (Forman et al., 1997; Gan et al., 2001). There is also cross-talk between L

and peroxisome proliferator activated receptors (PPARs), which also heterodimerize wit
RXR but are activated by fatty acid ligands. PPAR8 and perhaps PPARa activate

transcription of LXRa (Millatt et al., 2003), and there is reciprocal competition betwe

PPARs and LXRs at the level of target gene promoters (Ide et al., 2003; Yoshikawa et a

2003). LXR activation of rodent Cyp7Al is blocked by small heterodimeric partner (SHP)

which binds the promoter indirectly and is induced by the bile acid-activated FXR nuc

receptor (Goodwin et al., 2000; Lu et al., 2000). Lipid metabolism thus appears finely
regulated by a complex web of interactions among SREBPs, LXRs, PPARs, FXRs, and other
transcription factors.
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The generation and metabolism of oxysterols:

Oxysterols, 27-carbon hydroxylated

derivatives of cholesterol, are present at very low levels in vivo but have at least

important functions (Russell, 2000). First, oxysterols are intermediates in the hepatic

synthesis of bile acids, which proceeds via the classic pathway initiated by microsom
Cyp7Al and the alternative pathway initiated by mitochondrial sterol 27-hydroxylase
(Cyp27) (Fuchs, 2003). Second, oxysterols are transport forms of cholesterol, allowing

movement in plasma from peripheral tissues to the liver for elimination (Bjorkhem, 200

This process may be an HDL-independent pathway for reverse cholesterol transport. Cyp

in peripheral tissues, especially alveolar macrophages, generates 27-hydroxycholestero

which travels to the liver for bile acid synthesis starting with Cyp7Bl (oxysterol 7a-

hydroxlase). Likewise, microsomal Cyp46 (cholesterol 24-hydroxylase) in brain generate

24(S)-hydroxycholesterol, which crosses the blood-brain barrier, travels to the liver,
converted to bile acids via a pathway initiated by Cyp39 (24-hydroxycholesterol 7ahydroxylase). Third, some oxysterols also function as positive regulators of LXRs and

negative regulators of SREBPs. Most oxysterols can serve multiple roles in cholestero
metabolism (Figure 1.3).
Many natural and synthetic oxysterols have been tested in vitro for LXR activation

(Janowski et al., 1999; Janowski et al., 1996), but the physiological molecules are unc
and may differ among tissues. 24(S)-hydroxycholesterol is a high affinity LXR ligand,

is only produced in the brain, its levels elsewhere are low, and hepatic Cyp39 rapidly

inactivates it as an LXR ligand (Russell, 2000). 24(S),25-epoxycholesterol, produced by

shunt in the cholesterol biosynthetic pathway, is also a high affinity LXR ligand (Sp

al., 2001). Statin drugs, which inhibit cholesterol synthesis at mevalonate generation
activation of LXRE reporter constructs by LXR/RXR (Forman et al., 1997) and decrease

transcription of the LXR-target SREBP-lc in hepatoma cells (DeBose-Boyd et al., 2001).
-9-
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Figure 1.3: T h e generation and metabolism of oxysterols.
Various tissue-specific hydroxylase enzymes convert cholesterol to oxysterols, which have several
fates. They serve as intermediates in the generation of bile acids and steroid hormones. The brain and
other peripheral tissues use oxysterols as transport forms of cholesterol, which are delivered to liver for
bile acid synthesis and excretion. Oxysterols also regulate S R E B P and L X R transcription factors.

both cases, mevalonate or LXR agonists overcome statin-mediated inhibition, consistent with
an endogenous LXR ligand like 24(S),25-epoxycholesterol generated by cholesterol
biosynthesis. However, it is unclear whether this oxysterol is produced in non-hepatic cells.
Two other high affinity LXR ligands, 22(R)-hydroxycholesterol and 20(S)-hydroxycholesterol, are made only in steroidogenic tissues as transient intermediates in the three-step
activity of the P450 side chain cleavage enzyme (P450scc/Cypl 1A1) (Miller, 2002). Given
the limited distribution and low levels of high affinity LXR agonists, the relevant oxysterols
may actually be weaker agonists like 25- and 27-hydroxycholesterol.
27-hydroxycholesterol, the most abundant oxysterol in plasma, is a potent repressor
of SREBP processing and a weak partial LXR agonist. Cholesterol loading of macrophages
activates LXR targets and results in dose-dependent generation of 27-hydroxycholesterol, but
not any high affinity LXR ligands (Fu et al., 2001). In the human disease cerebrotendinous
xanthomatosis (CTX), mutations in Cyp27 result in defective bile acid synthesis, cholesterol
10

accumulation

in

multiple

tissues, and

premature

atherosclerosis

(Bjorkhem,

2002).

Cholesterol accumulation could indicate defective elimination from cells as 27-hydroxycholesterol, but it could also reflect defective generation of oxysterol LXR ligands to
stimulate cholesterol efflux. Consistent with the latter hypothesis, cells from CTX patients
fail to activate the LXR target ABCA1 in response to cholesterol-loading, but activate it
normally when supplied with exogenous 24(S),25-epoxycholesterol (Fu et al., 2001). This
supports a role for 27-hydroxycholesterol in macrophage LXR activation, but others have
questioned the physiological relevance of this oxysterol (Bjorkhem, 2002).
25-hydroxycholesterol has similar effects on SREBPs and LXRs to 27-hydroxycholesterol. Most tissues express low levels of cholesterol 25-hydroxylase, a non-P450
transmembrane protein localized to ER and Golgi (Lund et al., 1998). 25-hydroxycholesterol
can be a substrate for the synthesis of bile acids via Cyp7Bl (Russell, 2000) or steroid
hormones via P450scc (Lukyanenko et al., 2001). Since 25-hydroxycholesteol is the most
potent negative regulator of SREBP processing, it was thought that SCAP may sense this
oxysterol. However, recent data indicate that SCAP senses cholesterol itself, as it undergoes
a conformational change in response to cholesterol but not 25- or 27-hydroxycholesterol
(Brown et al., 2002). Likewise, even though oxysterols increase ACAT activity in cells,
cholesterol itself was shown to be the most potent allosteric activator of this enzyme in vitro
(Zhang et al., 2003). Therefore, oxysterols may affect the ER regulatory compartment
indirectly by causing intracellular cholesterol transport to the ER.
It is also notable that cholesterol, oxysterols, and steroids can also be sulfonated by
specific sulfotransferase enzymes (Javitt et al., 2001). The physiological function of this
modification is uncertain, but oxysterol sulfates are LXR antagonists (Song et al., 2001) and
cholesterol sulfates inhibit steroid hormone production (Xu and Lambeth, 1989).
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The endoplasmic reticulum stress response: W h e n E R function is perturbed by unfolded
proteins, E R stress signals are transduced to the nucleus to activate gene transcription by
three routes (Figure 1.4): the P E R K - A T F 4 , IREl-Xbpl, and A T F 6 pathways (Harding et al.,
2002; Kaufman, 2002). In one pathway, the E R transmembrane kinase P E R K , after stressinduced dimerization and autophosphorylation, phosphorylates the translation factor eIF2a to
transiently inhibit global protein translation, thus reducing E R protein load. However, some
m R N A s are translated more efficiently in this condition, including the A T F 4 transcription
factor that activates E R stress target genes. In the second pathway, the E R membrane protein
IRE-1 has a cytosolic ribonuclease domain that, upon E R stress, mediates non-traditional
splicing of the Xbpl m R N A , allowing synthesis of this transcription factor. In the third
pathway, the E R membrane protein A T F 6 translocates to the Golgi upon E R stress, where it
is cleaved analogous to SREBPs by the proteases SIP and S2P to yield an active nuclear
transcription factor.

elF2a-P
/

\

Inhibition of
translation

40|ffiBfe

Figure 1.4: Three E R stress response pathways.
E R stress signals are transduced to the nucleus via three parallel pathways, activating the A T F 4 , X b p l ,
and A T F 6 transcription factors. The P E R K pathway transiently inhibits global translation but activates
translation of A T F 4 .

IRE1 mediates non-traditional splicing of the X b p l m R N A to increase its

synthesis, while A T F 6 is activated by proteolysis in the Golgi similar to S R E B P processing. The E R
chaperone B i P negatively regulates all three pathways, which m a y converge in the nucleus with
comolex interactions on taraet eene Dromoters with E R stress response elements (ERSEsY

12-

BiP, an ER-resident Hsp70-family chaperone, may be the master U P R regulator, as
luminal BiP binds and inhibits activation of PERK, IRE-1, and ATF6 (Kaufman, 2002).

Misfolded proteins in the ER sequester BiP, resulting in activation of all three pathw
ER stress response is often referred to as the unfolded protein response (UPR), since
stress agents disrupt ER protein folding. For instance, tunicamycin inhibits N-linked

glycosylation, reducing agents block disulfide bond formation, and the calcium pump bl

thapsigargin or the calcium ionophore A23187 cause dysfunction of calcium-dependent E

chaperones. Known UPR target genes function to ameliorate these stresses, including ER
chaperones like BiP and RAMP4 (Yamaguchi et al., 1999), ER calcium pumps like

SERCA2b (Hojmann Larsen et al., 2001), and components of the secretory pathway and ER-

associated protein degradation (ERAD) (Travers et al., 2000). However, prolonged or sev

ER stress results in apoptosis via multiple mechanisms, including expression of the pr

apoptotic transcription factor CHOP and activation of the ER procaspase-12 (Ma et al.
2002).
The three ER stress transcription factors, ATF4, Xbpl, and ATF6, belong to the basic

leucine zipper family, and several studies have addressed their promoter binding sites

target genes have ER stress response elements (ERSEs) with the tripartite structure CC
No-CCACG, where the 9 bp spacer is GC-rich (Roy and Lee, 1999; Yoshida et al., 1998).

The three elements of this ERSE bind to NF-Y, TFII-I, and ATF6, respectively (Parker e

2001; Yoshida et al., 2001b). Xbpl appears to act at the same element as ATF6 (Yoshida

al., 2001a), but some target genes only respond to Xbpl (Yoshida et al., 2003), and the

factors may form homo- or heterodimers. An alternate ERSE-II has been described with a
inverted CCAAT box spaced one nucleotide from the putative ATF6/Xbpl site (ATTGG-NCCACG) (Kokame et al., 2001). The promoters for CHOP and BiP both contain ERSEs as

well as additional elements to bind ATF4 (Luo et al., 2003; Ma et al., 2002). Further s
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are necessary to clarify the roles of the different E R stress transcription factors, and to
identify the responsible elements in target genes that lack consensus ERSEs.
The two main functions of the ER are protein secretion and lipid synthesis, so lipids
may also affect ER stress. A microarray study of tunicamycin-treated yeast identified
multiple phospholipid biosynthetic enzymes as UPR targets (Travers et al., 2000).

Conversely, inhibition of phospholipid synthesis in CHO cells induces CHOP and apoptos

though BiP activation was not observed (van der Sanden et al., 2003). ER cholesterol h

been linked to protein secretion, as excess cholesterol inhibits protein translocation

microsomes in vitro (Nilsson et al., 2001). ER membrane proteins like the translocon a

likely adapted to the low cholesterol environment of the ER. Less protein translocati

might be expected to reduce ER stress, but cholesterol-induced dysfunction of other ER
proteins like calcium pumps would certainly activate the UPR. It is also notable that

SREBPs and ATF6 are cleaved by the same Golgi proteases. Their regulation is thought t

be independent, since sterol depletion activates SREBPs but not ATF6, and ATF6 cleavag

SCAP-independent (Ye et al., 2000). However, they may be coordinately regulated in some

cases, as some ER stressors in HepG2 cells activate the UPR as well as SREBP-target ge

(Werstuck et al., 2001). In response to high ER cholesterol, SREBP processing is repres
while recent evidence described below indicates that the UPR is activated.
The ER is thought to handle excess cholesterol primarily by ACAT-mediated

esterification. It may also accommodate some excess free cholesterol via its large sur
area and ability to synthesize phospholipids, thus maintaining an acceptable
cholesterokphospholipid ratio (Blanchette-Mackie, 2000; Tabas, 2002b). When cultured

macrophages are loaded with free cholesterol, via treatment with acetylated LDL and an
ACAT inhibitor, the phospholipid biosynthetic response is overwhelmed and apoptosis

ensues (Tabas, 2002b). It was initially proposed that excess PM cholesterol triggers t
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apoptotic response (Kellner-Weibel et al., 1999), but directly loading the P M with cholesterol

does not trigger cell death (Feng et al., 2003a). Furthermore, this apoptosis is marke

inhibited in two experimental systems that prevent LDL-derived cholesterol from reach
the ER, but allow it to reach the PM (Feng et al., 2003a).
Since ER cholesterol was strongly implicated in macrophage apoptosis, Feng, Tabas,
and coworkers showed that cholesterol-loaded macrophages trigger the UPR, activating
1, PERK, ATF4, Xbpl, and CHOP (Feng et al., 2003a). These macrophages have depleted

ER calcium stores, suggesting that ER calcium pumps are indeed cholesterol-sensitive a

the proximal cause for UPR activation. The UPR is initially protective, as PERK knocko
macrophages are more susceptible to apoptosis upon cholesterol loading. However, CHOP
induction ultimately causes apoptosis, as CHOP knockout macrophages are resistant to

apoptosis upon cholesterol loading. Macrophages in atherosclerotic lesions show elevat

in CHOP, so ER stress is likely relevant to macrophage apoptosis in vivo (Feng et al.,
Furthermore, NPC 1-heterozygous ApoE-deficient mice, which have defective cholesterol

trafficking to ER, show less apoptosis in atherosclerotic lesions (Feng et al., 2003b)
macrophage ER stress model also provides a mechanism whereby hyperhomocysteinemia, an

independent risk factor for atherosclerosis, could contribution to lesion formation, a
homocysteine can activate the UPR (Werstuck et al., 2001). The connection between
cholesterol and ER stress is a new field of research, and it is still unclear whether
to other cells types besides macrophages. It is clear that ER cholesterol can trigger

so along with SREBPs and LXRs, ER stress marks a third way that cholesterol can imping
on gene regulation.
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Intracellular Cholesterol Transport

Cholesterol must be synthesized by a multi-enzyme pathway, transported between
compartments within cells, moved in and out of cells by transmembrane proteins, and
transported in the plasma by lipoproteins. While many relevant genes and pathways in
cholesterol metabolism have been identified, molecular understanding of intracellular
cholesterol transport has lagged behind. Due in part to technical difficulties such as
measuring cholesterol levels of intracellular membranes, many features of intracellular
cholesterol transport are only vaguely understood.
There are three general ways cholesterol can move between intracellular
compartments (Figure 1.5) (Maxfield and Wustner, 2002; Prinz, 2002). Cholesterol is
transported in the membranes of intracellular vesicles, and these movements typically require
ATP and an intact cytoskeleton. Cholesterol can spontaneously desorb from membranes, but
it is only sparingly soluble in water and will usually return to the same membrane. However,
if different membranes are closely juxtaposed, perhaps brought together by specialized
proteins, then cholesterol may transfer between them by diffusion or by movement along
contact sites. Non-vesicular cholesterol transport is also mediated by diffusible carrier
proteins, with hydrophobic cavities to bind cholesterol and transport it across the aqueous
cytosol. For any given pathway, several transport mechanisms may act simultaneously or
redundantly, making their relative contributions difficult to determine.
Cholesterol shuttles among cellular locations, including the major compartment in the
PM, the site of synthesis in the ER, and the site of uptake in the endocytic pathway (Simons
and Ikonen, 2000). There are marked asymmetries in cholesterol concentration among
intracellular membranes, despite transport pathways that might be expected to equilibrate
cholesterol distribution. Transport vesicles may have active sorting mechanisms to exclude
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Figure

1.5:

Three

mechanisms

of

cholesterol transfer between membranes.
Cholesterol (*) is highly hydrophobic and
requires

special

transport

mechanisms

between subcellular compartments.

(A)

Cholesterol can move in the membranes of
vesicles.

(B) Cholesterol can transfer

between two closely juxtaposed membranes.
(C) Hydrophobic cavity lipid transfer protein
can shuttle cholesterol between membranes.

or incorporate cholesterol (Prinz, 2002), and intracellular shuttling proteins must have
specificity in targeting. Specificity could arise from interactions with receptor proteins on
target membranes; alternatively m e m b r a n e s m a y have intrinsic differences in ability to
accept cholesterol (Maxfield and Wustner, 2002). It is uncertain h o w intracellular gradients
between compartments are formed and maintained, and h o w cholesterol m o v e s with and
against these gradients.

Even within the same subcellular compartment, there m a y be

different pools of cholesterol with different kinetics of mobilization to various pathways.

Cholesterol biosynthesis and precursor sterol transport: The early steps in cholesterol
biosynthesis from acetyl C o A produce mevalonate, which is phosphorylated to generate
isoprenoids that condense to give 15-carbon farnesyl pyrophosphate (FPP).

F P P is the

precursor for dolichol, h e m e , ubiquinone, and isoprenylated proteins, as well as the 30carbon linear squalene.

Squalene cyclization generates the four-ringed sterol lanosterol,

which is modified by 9 enzymes in 19 steps (rearranging double bonds and removing three
methyl groups from the a-face of the rings) to generate the 27-carbon cholesterol. The postlanosterol enzymatic steps are independent of one another, and they occur in different
sequences to generate a number of sterol intermediates (Phillips and Johnson, 1998). Prelanosterol sterol biosynthesis is essential for viability, as squalene synthase knockout mice
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die by fetal day 12.5 even when the maternal diet is supplemented with squalene or

cholesterol (Tansey and Shechter, 2000). However, inborn errors in post-lanosterol synt

allow live births but generally result in congenital anomalies and mental retardation.
in the final enzyme of cholesterol synthesis, 7-dehydrocholesterol reductase (7DHCR),
Smith-Lemli-Opitz syndrome, while five other human malformation syndromes have other

enzyme defects (Porter, 2002). Precursor sterols fail to substitute for cholesterol, an

accumulation has deleterious effects, underscoring the exquisite adaptation of the cho
molecule. Precursors abundance varies widely among cell types, and certain precursors

have physiological functions (Lusa et al., 2003). For instance, 7-dehydrocholestereol i
converted to vitamin D in skin, and other precursors activate meiosis in the gonads.
The ER is the primary site of cholesterol synthesis (Reinhart et al., 1987). Some

reactions and enzymes also localize to peroxisomes (Olivier et al., 2000), though cell

lacking functional peroxisomes appear to have normal cholesterol synthesis (Hogenboom

al., 2002). Precursors like zymosterol also reach the PM, and rapidly return to the ER

conversion to cholesterol (Lange et al., 1991). Therefore, hydrophobic intermediates in
cholesterol synthesis may move among compartments like ER, PM, and peroxisomes, or

even between domains of the same compartment. There was an extensive literature in the
1970s and 1980s on soluble proteins that stimulate enzymatic steps of cholesterol

biosynthesis. Sterol-carrier protein 2 (SCP-2) was originally purified as an activator

7DHCR activity in liver microsomes in vitro, but it binds many other lipids and its in

role is unclear (Seedorf et al., 2000). The supernatant protein factor (SPF), which inc

squalene epoxidase activity, was recently cloned and structurally characterized as a m
of the CRAL-TRIO lipid binding family (Shibata et al., 2001; Stacker et al., 2002).

However, SPF also shows ligand promiscuity, binding phosphatidylinositol and y-tocophe
with higher affinity than squalene (Panagabko et al., 2003). Cholesterol biosynthesis
18

requires cytosolic transport proteins for hydrophobic precursor sterols, but none have been
definitively described to date.

Cholesterol transport from ER to PM: Newly synthesized cholesterol can be metabolical

labeled by adding H-acetate to cells, and its arrival at the PM is typically assayed b

cholesterol oxidase susceptibility or extraction with cyclodextrin (Lange, 1998). Since

ER is cholesterol-poor, nascent cholesterol moves against a steep concentration gradie

reach the PM. However, some have speculated this gradient may not exist if ER choleste
only exchanges with the minority of PM cholesterol outside of lipid rafts (Simons and

Ikonen, 2000). In certain cells types, precursor sterols also reach the PM, and there a

marked differences in rates of arrival among precursors and cholesterol, perhaps confo
interpretation of some experiments (Lusa et al., 2003).
Vesicular transport along the protein secretory pathway is one possible path from ER

to PM, and there is evidence that the cholesterol-enriched lipid rafts assemble in th

(Simons and Ikonen, 2000). Energy poisons or low temperature inhibit the rapid ER to P

transport of nascent cholesterol (DeGrella and Simoni, 1982; Urbani and Simoni, 1990),

supporting a vesicular mechanism. However, inconsistent with vesicles, disruption of a

filaments or microtubules has no effect on ER to PM transport (Kaplan and Simoni, 1985
Furthermore, the drug Brefeldin A, which causes Golgi disassembly and fusion with ER,

blocks over 90% of protein secretion but only decreases nascent cholesterol transport

-20% in the same cells (Heino et al., 2000; Urbani and Simoni, 1990). Therefore, while

vesicular transport through the Golgi may bring some nascent cholesterol to the PM, i
the major pathway.
Most ER to PM cholesterol movement bypasses the Golgi, but the molecular

mechanisms are uncertain. While some have proposed nontraditional vesicles (Urbani and
-19

Simoni, 1990), non-vesicular transport by membrane contacts or shuttling proteins is more

likely. Contact sites between ER and PM could allow sterol transfer (Menon, 2002), and
yeast data indicate that ER subfractions near the PM are enriched with sterol and
phospholipid biosynthetic enzymes (Pichler et al., 2001). However, in mammalian cells,
phagocytosis of latex beads promotes ER-PM contact but fails to increase cholesterol

at the PM (Lusa et al., 2003). As described later, cytosolic shuttling by caveolin comp

or SCP-2 has been proposed, and other hydrophobic cavity proteins could play important
roles in ER to PM cholesterol transport.

Cholesterol transport from PM to ER: Arrival of cholesterol at the ER is typically

measured by cholesterol ester formation by the ER-localized ACAT enzyme. There are two

variations of this assay, the in vivo rate of esterification and the more quantitative

run-off assay (Lange et al., 1999). It is clear that cholesterol travels from PM to ER
different route than nascent cholesterol leaving the ER (Field et al., 1998), as PM to

transport is sensitive to cytoskeletal inhibitors and requires intermediate filaments

and Munn, 1999). It has been proposed that only non-raft cholesterol in the liquid diso

phase of the PM is transported to the ER (Simons and Ikonen, 2000). Consistent with th

hypothesis, the bacterial enzyme sphingomyelinase digests the sphingolipids of lipid r

releasing cholesterol for esterification via an ATP-independent vesicularization of 15
the PM (Zha et al., 1998). The oxysterol 25-hydroxycholesterol also increases ER
cholesterol by an unknown mechanism (Lange, 1998), resulting in decreased SREBP
processing and activation ACAT as described earlier.
The Golgi and/or the endocytic pathway may be intermediates in PM to ER

cholesterol transport (Neufeld, 1998), but data have been inconsistent. In yeast, PM to

sterol transport is independent of the protein secretory pathway through the Golgi (Pr
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2002). In Niemann-Pick C (NPC) or U18666A-treated cells, which accumulate cholesterol

in late endosomes as described in the next section, cholesterol esterification is defe

response to sphingomyelinase, but normal in response to 25-hydroxycholesterol (Lange e

2000; Neufeld et al., 1996; Underwood et al., 1996). In these NPC cells, newly synthesi

cholesterol reaches the PM normally, but its return to the ER for esterification is ma

defective (Cruz and Chang, 2000; Reid et al., 2003). However, other groups have shown t
PM cholesterol reaches ACAT normally in NPC cells (Wojtanik and Liscum, 2003). Given

this conflicting data, PM cholesterol may take at least two paths to the ER: a vesicul
via the endosomes or Golgi and a potentially non-vesicular alternative route (Simons
Ikonen, 2000; Underwood et al., 1998; Wojtanik and Liscum, 2003).
Two mutant CHO cell lines have been described with defective cholesterol transport

to the ER, but no defects in other transport pathways. Mutant cells designated 3-6 hav

normal PM cholesterol levels, but defective PM to ER cholesterol movement both basally

and in response to sphingomyelinase, suggesting altered lipid raft organization (Liscu
1998). A similar phenotype was observed in Nrel-4 cells that cannot synthesize

plasmalogens, special phospholipids of unknown function with sn-1 vinyl ether bonds to

chain fatty alcohols. In these cells, delivery of cholesterol to the ER is specificall
and rescued by restoration of plasmalogen synthesis (Munn et al., 2003). Both 3-6 and

Nrel-4 mutant cells still increase ACAT activity in response to 25-hydroxycholesterol,
the phenotypes are distinct. The 3-6 mutant was identified in a screen for resistance

amphotericin B, an antibiotic that kills cells by forming pores in the cholesterol-ri

while Nrel-4 cells are sensitive like normal CHO cells (Munn et al., 2003). The mutate

gene in 3-6 cells has not been cloned and the role of plasmalogens is unclear, so chol
movement to the ER remains poorly understood. Figure 1.6 summarizes ER cholesterol
transport pathways.
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Figure 1.6: E R cholesterol transport pathways.
T h e E R is the site of cholesterol synthesis and esterification. Synthesis m a y also occur in peroxisomes,
and cholesterol precursors m a y shuttle a m o n g and within compartments (left). M o v e m e n t of nascent
cholesterol from E R to P M proceeds primarily via a Golgi-independent pathway, though vesicular
transport through the Golgi m a y account for s o m e transport (middle). Likewise, there m a y be multiple
routes from P M to E R , only s o m e requiring endosomes (endo) and Golgi vesicles (right). R e d arrows
indicate candidate pathways for non-vesicular transport.

Cholesterol transport from late endosomes and Niemann Pick C:

L D L binds to cell

surface L D L receptors for endocytosis in clathrin-coated pits, and L D L cholesterol esters are
hydrolyzed in the endocytic pathway.

This newly hydrolyzed free cholesterol can be

metabolically labeled by introducing 3H- or 14C-cholesterol esters into L D L . Most of this
cholesterol appears back at the P M , where it can subsequently move to the E R for reesterification, though about one third of endocytosed cholesterol moves directly to the E R
bypassing the P M (Liscum and Munn, 1999). Therefore, cholesterol follows at least two
pathways from endosomes to ER, one PM-dependent and the other PM-independent, and
their relative contributions may vary in different cells types or conditions.

The P M -

dependent pathway uses the Golgi as an intermediate, consistent with filipin electron
microscopy studies (Blanchette-Mackie and Pentchev, 1998).

Furthermore, Brefeldin A

blocks the PM-dependent pathway, causing all LDL-derived cholesterol to bypass the P M for
direct delivery to ER.

This result indicates either that the PM-independent pathway can

substitute completely, or that cholesterol normally bound for the P M is delivered to the
merged Golgi-ER (Blanchette-Mackie, 2000). Endosome to E R cholesterol transport was
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initially described as vesicular, since it was inhibited by actin polymerization, ionophores

that affect vesicle sorting, and energy poisons (Skiba et al., 1996; Underwood et al.,

However, these studies may have only assayed the PM and Golgi-dependent pathway, and i
is possible that the PM-independent pathway is non-vesicular.
The fatal neurodegenerative disease Niemann Pick C (NPC) is an autosomal recessive

lipid storage disorder characterized by intracellular free cholesterol accumulation i

tissues. Neurons accumulate glycosphingolipids rather than cholesterol, but both lipid
found in rafts, so the pathway defective in NPC may normally mobilize multiple raft

components (Simons and Ikonen, 2000). Most intracellular cholesterol in NPC cells appe
in multilamellar storage bodies, a hybrid compartment derived from late endosomes

(Mukherjee and Maxfield, 1999), though accumulation in the Golgi has also been observe

(Blanchette-Mackie, 2000). Late endosomes are normally dynamic multivesicular structure
but they become static, enlarged, and cholesterol-rich in NPC cells (Ko et al., 2001).

LDL is considered the primary source of this intracellular cholesterol, newly synthesi

cholesterol also accumulates at a slower rate (Cruz et al., 2000). The NPC phenotype c

reproduced by treatment of normal cells with progesterone or hydrophobic amines (clas
amphiphiles) like U18666A. The mechanism of U18666A action is unknown, though U18R

mutant CHO cells are resistant to it (Liscum and Collins, 1991), and a putative membran
protein binding site has been described but not identified (Underwood et al., 1996).
Despite increased cholesterol content, NPC cells have repressed ACAT activity, high
LDL receptor activity, and elevated cholesterol synthesis, all of which suggest low

cholesterol in the ER regulatory pool. NPC cells are resistant to amphotericin B, so i
proposed that they have low PM cholesterol reflected in the ER (Lange et al., 1999).

However, NPC cells have normal PM cholesterol, and amphotericin B resistance is due to

sequestration of drug in the intracellular cholesterol-rich compartments, thus protect
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P M (Lange et al., 2002). Recent data show that N P C cells also have normal E R cholesterol

levels, but that they fail to repress SREBPs and activate LXRs in response to LDL (Fro

al., 2003). These defects in transcriptional regulation in NPC cells correlate with up

decreased generation of 25- and 27-hydroxycholeterol from LDL-cholesterol, and additio

these oxysterols corrects the cholesterol accumulation. Therefore, defective oxysterol

generation and transcriptional regulation of cholesterol homeostasis may contribute t
NPC phenotype.
Two NPC disease complementation groups were identified, and both causative genes
have been cloned. NPC1 is a late endosomal membrane protein with 13 predicted
transmembrane segments, including a sterol sensing domain like those found in SCAP,
HMGR, 7DHCR, and Patched, the receptor for Hedgehog (Prinz, 2002). NPC1 also shows

homology to bacterial permeases, and NPC1 expression in E. coli increases the uptake o

fatty acids, though not cholesterol in this assay (Davies et al., 2000). NPC2 is a sol

cholesterol-binding protein that resides in the lumen of late endosomes and lysosomes

(Friedland et al., 2003; Naureckiene et al., 2000). Mutant NPC1 proteins that fail to r
late endosomes also cause mislocalization of NPC2 (Blom et al., 2003). NPC1 and NPC2

could directly participate in the vesicular or non-vesicular trafficking of cholester
endosomes, or they could function indirectly as regulatory cholesterol sensors (Prinz,
The M87 mutant CHO cell line shows an NPC-like cholesterol-rich compartment despite
wild type NPC1 and NPC2 and normal NPC 1-containing multivesicular late endosomes

(Frolov et al., 2001), but the defective gene has not been cloned. Other genes, such as

hydrophobic cavity protein MLN64 described below, also may function in the NPC pathway
There has been conflicting data on the transport defect in NPC cells. Two
independent groups found that LDL-derived cholesterol rapidly arrives at the PM for

cyclodextrin extraction, surprisingly even in NPC cells (Cruz et al., 2000; Lange et al
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A model was proposed in which the early P M cholesterol is re-internalized to a "cholesterol

sorting compartment," and its subsequent movement back to the PM or to the ER is defe
in NPC cells (Cruz et al., 2000). However, another group found no evidence for early
appearance of LDL-cholesterol at the PM, suggesting the early cyclodextrin-extracted
cholesterol may actually represent an internal pool diverted to the PM by treatment

(Wojtanik and Liscum, 2003). Indeed, one of the original groups recently found this to

the case by using a revised cyclodextrin protocol and other methods (Sugii et al., 200
Based on this recent data, a consensus model for NPC is emerging. LDL-derived

cholesterol esters are hydrolyzed early in the endocytic pathway, since the acid lipa
enzyme was recently localized to an early acidic compartment, rather than to NPC1-

containing late endosomes and lysosomes as previously assumed (Sugii et al., 2003). Fr

cholesterol in this early compartment can be extracted by prolonged cyclodextrin trea

but it is not normally delivered to the PM. Instead, it enters the cyclodextrin-inacc
compartment, likely the multivesicular late endosomes, and egress of free cholesterol

this site is defective in NPC cells. The defect may only be slight, as even a small im

between influx and efflux would result in the observed cholesterol accumulation (Lang
al., 2002). In normal cells, late endosomal cholesterol may be transported directly to
compartments like PM, ER, and mitochondria, or it could first move to the endocytic
recycling compartment (ERC) before subsequent transport (Wojtanik and Liscum, 2003).

Cholesterol transport via the endocytic recycling compartment: The ERC contains prote
and lipids that recycle from sorting endosomes to the plasma membrane. There is no

enyzmatic assay for ERC cholesterol, but compositional data suggest cholesterol enric

in this compartment (Gagescu et al., 2000; Hornick et al., 1997). Recent experiments ha

strongly implicated the ERC in cholesterol transport using the analog dihydroergoster
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(DHE), a naturally fluorescent yeast sterol that can be directly imaged in living cells

(Mukherjee et al., 1998). These DHE studies, confirmed with 3H-cholesterol, show that t

ERC is the major intracellular sterol storage organelle in CHO cells (Hao et al., 2002
Cholesterol is transported from ERC to PM via the same vesicles that carry recycling

proteins (Hao et al., 2002). Consistent with this observation, cells overexpressing Ra

small GTPase that inhibits recycling endosomes, accumulate cholesterol along with rec
markers in enlarged ERC organelles (Holtta-Vuori et al., 2002). However, cholesterol

transport from the PM to the ERC is likely non-vesicular, as it is rapid and ATP-inde

(Hao et al., 2002). DHE studies of polarized HepG2 hepatoma cells gave similar results

showing vesicular and non-vesicular sterol transport and the apical recycling compart
the major storage site (Wustner et al., 2002).
Dissecting the role of the ERC in cholesterol transport is an exiting new field of

research. While the ERC may be involved in NPC disease, current data suggests distinct
pathways. NPC cells are rescued by overexpression of Rab7 or Rab9, GTPases implicated
late endosomal trafficking, but not Rabll, the inhibitor of ERC recycling endosomes
(Choudhury et al., 2002). Notably, NPC 1-deficient cells transfected with NPC1 clear

cholesterol from late endosomes even when cholesterol is trapped in the ERC due to Ra

overexpression (Holtta-Vuori et al., 2002). Rab 11-mediated ERC cholesterol accumulatio

decreases basal ACAT activity -50% but does not affect esterification of PM cholester

delivered via cyclodextrin, suggesting that only some cholesterol transport to the ER

proceeds via the ERC (Holtta-Vuori et al., 2002). Other transport pathways to and from

ERC remain to be described, as well as the mechanism of rapid non-vesicular cholester

transport from the PM to the ERC. Figure 1.7 summarizes endosomal cholesterol transpo
pathways.
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Figure 1.7: Endosomal cholesterol transport pathways.
LDL-derived cholesterol esters (CE) are hydrolyzed by acid lipase, and thefreecholesterol O^C) leaves
endosomes via a pathway involving the N P C proteins and MLN64. This cholesterol is re-esterified by
A C A T in the ER. Endosomal cholesterol reaches the E R via a PM- and Golgi-dependent route or a
direct route. The E R C is a major cholesterol storage compartment, and may serve as an intermediate in
many transfer pathways. Red arrows indicate candidate pathways for non-vesicular transport.

Cholesterol transport to mitochondria: Mitochondria are considered cholesterol-poor
organelles, with the outer mitochondrial membrane containing more cholesterol than the
inner (Cheng et al, 1985). Two important cholesterol-metabolizing P450 enzymes reside on
the matrix side of the inner mitochondrial membrane, sterol 27-hydroxylase (Cyp27) and the
steroidogenic P450scc enzyme. Transport of cholesterol to P450scc is mediated by the
hydrophobic cavity transfer protein StAR, which is described in detail below. P450scc and
StAR are limited to steroidogenic cells, so other related transport proteins may deliver
cholesterol to the widely expressed Cyp27 enzyme.
The source of mitochondrial cholesterol for steroidogenesis is unclear and may vary
in different cells or conditions. In adrenocortical cells, HDL cholesterol taken up via SRB-1
appears to be the predominant substrate (Imachi et al., 1999). In MA-10 Leydig cells,
steroidogenic stimulation causes increased internalization of PM cholesterol to a
compartment resembling late endosomes (Choi and Freeman, 1998). NPC1 mutations or
U18666A inhibit steroidogenic utilization of LDL-derived cholesterol in vitro (Watari et al.,
2000), but NPC1 knockout mice use HDL cholesterol normally for steroidogenesis (Xie et
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al., 2000). This m a y be analogous to the situation in the livers of N P C 1 knockout mice, in
which LDL cholesterol accumulates in a metabolically inactive pool, while cholesterol from
HDL is metabolized normally (Xie et al., 2000). Cytosolic lipid droplets may also provide
cholesterol to mitochondria, as full length StAR interacts with hormone sensitive lipase in
adrenal cells, perhaps stimulating cholesterol ester hydrolysis and mobilization (Shen et al.,
2003). Multiple cholesterol pools can contribute to steroidogenesis, but one compartment
may still be the immediate proximal source for cholesterol that is delivered to mitochondria.

Potential transport by caveolin: Caveolin is an acylated integral membrane protein essential
for the formation of caveolae, a subset of lipid rafts with characteristic flask shapes in
electron micrographs. Caveolin is also soluble in multiple compartments including the
cytosol, and it binds cholesterol and fatty acids (Liu et al., 2002). Pulse chase studies show

that nearly all nascent cholesterol reaching the PM after 10 minutes is in caveolae, while after
60 minutes it is in non-caveolar PM (Smart et al., 1996). Cultured lymphocytes lacking
caveolae exhibit relatively slow initial appearance of nascent cholesterol at the PM, but
transfection of caveolin-1 increases the initial rate ~4-fold (Smart et al., 1996). However,
caveolin is not essential, as similar amounts of nascent cholesterol reach the PM in
transfected and untransfected cells by 1 hour. Further studies have identified a cytosolic
complex containing caveolin, cholesterol, and three immunophilin chaperone proteins:
cyclophilin A, cyclophilin 40, and heat shock protein 56 (Hsp56). Disruption of this
complex with cyclosporin A in NIH 3T3 cells was reported to almost completely block
transfer of nascent cholesterol to PM (Uittenbogaard et al., 1998). This marked inhibition is
surprising given strong evidence for non-caveolin pathways, and another group showed no
effect of cyclosporin A on nascent cholesterol transport in BHK cells under similar
conditions (Heino et al., 2000).
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Treatment of cells expressing the selective uptake receptor SRB-1 with H D L results

in formation of a different cytosolic caveolin complex, containing HDL-derived cholest
esters, caveolin, cyclophilin A, cyclophilin 40, and annexin II rather than Hsp56

(Uittenbogaard et al., 2002). Studies with caveolin mutants showed that acylation at c

133 is required for formation of the annexin II complex (Uittenbogaard et al., 2002), w

acylation at 143 and 156 is required for the Hsp56 complex (Uittenbogaard and Smart, 20

These caveolin-cholesterol-chaperone complexes may represent novel intracellular lipi

particles analogous to plasma lipoproteins (Liu et al., 2002). Indeed, earlier studies

nascent cholesterol transport suggested a lipid-rich low density transport intermedia

(Urbani and Simoni, 1990). In addition, soluble caveolin may coat cytosolic lipid stora

droplets (Pol et al., 2001). Given these important potential functions, it is quite sur

that caveolin-1 knockout mice, which also fail to express caveolin-2 and lack caveolae
non-muscle cells, are viable (Prinz, 2002).

Potential transport by sterol carrier protein-2: The SCP-2 gene has two initiation sit

produce distinct proteins, the 58kD SCP-x and 15kD pro-SCP-2, both of which are cleave

generate 13kD SCP-2. SCP-x cleavage is partial and generates a 45kD fragment, while pr
SCP-2 cleavage is complete and removes a 20 amino acid presequence (Gallegos et al.,

2001). The 45kD N-terminal portion of SCP-x is a thiolase that breaks down straight-ch

and branched chain fatty acyl-CoAs as well as bile acid precursors (Seedorf et al., 20

SCP-x and SCP-2 proteins are found at varying levels in nearly all tissues, and both c

peroxisomal targeting motif. SCP-x and its 45kD fragment appear completely localized i
peroxisomes, while as much as half of SCP-2 is outside of peroxisomes in the cytosol,
mitochondria, and lysosomes (Gallegos et al., 2001).
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S C P - 2 binds m a n y lipids, including fatty acids, fatty acyl-CoAs, phospholipids,
cholesterol, and other sterols (Gallegos et al., 2001). SCP-2 is also called non-specific lipid
transfer protein, as it transfers these lipids between membranes in vitro. The past 20 years
have produced data supporting some role for SCP-2 in nearly every intracellular cholesterol
transport pathway, involving lysosomes, ER, mitochondria, PM, and other compartments
(Gallegos et al., 2001). Recent reports have similarly proposed myriad functions for SCP-2
in the metabolism of phospholipids (Schroeder et al., 2003; Starodub et al., 2000) and fatty
acids (Atshaves et al., 2003; Murphy, 2002). Given so many potential functions, it is
difficult to discern which may be physiological.
Studies of SCP-2 deficient cells may help in this regard. Peroxisome deficiency,
which occurs in Zellweger syndrome, results in near absence of SCP-2. Such cells have
normal trafficking of LDL-derived cholesterol to the ER and PM (Johnson and Reinhart,
1994), indicating that SCP-2 is not essential for the endosomal transport pathway involving
NPC proteins. In contrast, the initial appearance of newly synthesized cholesterol at the PM
after 10 minutes is decreased in cells lacking SCP-2 due to peroxisome-deficiency or SCP-2
antisense treatment (Puglielli et al., 1996). However, analogous to the studies of caveolin,
there is no defect at 20 minutes, indicating that SCP-2 is not essential for this transport.
Furthermore, SCP knockout mice are viable, and all the primary defects can be explained by
absence of the SCP-x peroxisomal thiolase activity (Seedorf et al., 2000). More subtle
defects in hepatic cholesterol metabolism and biliary cholesterol secretion have been
reported, supporting some role for SCP-2 in cholesterol transport (Fuchs et al., 2001).
However, these cholesterol defects may be secondary to major alterations in peroxisome
function and fatty acid metabolism. Definitive proof that SCP-2 functions physiologically in
cholesterol transport has been elusive.
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Potential roles of oxysterol binding proteins: The oxysterol binding protein (OSBP) binds

25-hydroxycholesterol and other oxysterols, and was originally purified as a candidate

transcriptional regulation of cholesterol homeostasis (Taylor and Kandutsch, 1985). The

SREBP-SC AP pathway proved to mediate this regulation, and the function of OSBP remai
uncertain. OSBP has an oxysterol binding domain and a Pleckstrin homology (PH) domain
that mediates membrane association (Lehto and Olkkonen, 2003). OSBP overexpression
slightly decreases ACAT activity and increases cholesterol synthesis, suggesting some

on the ER regulatory pool, and these effects require the PH domain (Lagace et al., 1997

OSBP is normally localized in the cytoplasm, probably on vesicles, but it relocates to

Golgi apparatus upon 25-hydroxycholesterol treatment (Ridgway et al., 1992). OSBP is a

phosphorylated in a Golgi-dependent manner, but this modification does not appear to a

localization or ligand binding (Ridgway et al., 1998a). Other treatments that alter ch

transport affect Golgi localization and/or phosphorylation of OSBP, including choleste

starvation, sphingomyelinase treatment, cyclodextrin extraction of PM cholesterol, and

U18666A or NPC mutations (Mohammadi et al., 2001; Ridgway et al., 1998b; Storey et al.

1998). Since OSBP is clearly sensitive to cholesterol levels and trafficking, it may f

in these pathways. Oxysterols are more hydrophilic than cholesterol and unlikely to re

shuttling proteins, so OSBP is thought to serve a regulatory function in vesicular tra
oxysterol availability, or some other process.
An OSBP-related protein (ORP) family has been described, with 12 members in

humans and 7 in yeast (Lehto and Olkkonen, 2003). All ORP proteins have ligand binding

domains, most have PH domains, and alternative splicing is common (-S designates short

forms and -L long forms). Proteins closely related to OSBP may bind oxysterols, as sho

for the nearest homolog ORP4, while other ligands are likely for more divergent family

members (Lehto and Olkkonen, 2003). Little is known about the function and localizatio
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m a m m a l i a n O R P s , but two have been implicated in cholesterol metabolism.

ORP4-S

associates with vimentin intermediate filaments and decreases esterification of LDL-derived
cholesterol by -40% when overexpressed (Schroeder et al., 2001). Most interestingly,
OSP1-L localizes to the surface of late endosomes, is induced ~ 100-fold upon differentiation
of monocytes to macrophages, and its overexpression enhances LXRa reporter activation
(Johansson et al., 2003).

Intracellular transport of cholesterol metabolites: Cholesterol is metabolized to bile acids
and steroid hormones, and these molecules may also require intracellular transport
mechanisms in specialized cell types. Transmembrane transport proteins for bile acids have
been characterized in the apical and basolateral membranes of hepatocytes and enterocytes,
but less is understood about intracellular bile acid trafficking. The weight of evidence
suggests non-vesicular transport and several cytosolic bile acid binding proteins have been
identified, including 3a-hydroxysteroid dehydrogenase (3a-HSD) and the ileal bile acid
binding protein (IBABP), though transport has not been demonstrated (Agellon and Torchia,
2000). IBABP is transcriptionally activated in enterocytes by bile acids via the FXR nuclear

receptor (Grober et al., 1999), but it is not expressed in liver. Intermediates in either pathwa
of bile acid biosynthesis may also shuttle between compartments in hepatocytes (Agellon and
Torchia, 2000).
Even less is known about intracellular movements of steroid hormones. Since they
typically circulate in plasma bound to proteins, it is possible that they also bind to

intracellular transport proteins in addition to their cognate nuclear receptors. However, there

is only indirect evidence for intracellular steroid transport pathways, such as their transport
across epithelial cells (Fujise et al., 2002) and along neuronal axons (Frolkis and Tanin,
1999).
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T h e S T A R T gene family

Two proteins that function in intracellular cholesterol transport, StAR and MLN64,
belong to the family of StAR-related lipid transfer ( S T A R T ) proteins. S T A R T domains are
- 2 1 0 amino acid lipid binding domains implicated in intracellular lipid transport, lipid
metabolism, and cell signaling events. These domains are found in an extensive protein
family, including S T A R T domain-only and multi-domain proteins, but lipid ligands have
only been identified in a few cases (Ponting and Aravind, 1999; Soccio and Breslow, 2003).
T h e h u m a n and m o u s e genomes each have 15 genes encoding S T A R T domains (Table 1.1),
and phylogenetic analysis divides the family into six subfamilies (Figure 1.8). T h e novel
subfamily of StarD4, StarD5, and StarD6 is the subject of this thesis.

T h e remaining

introduction will address the current state of knowledge about other S T A R T domain proteins.

StarD name
StarDl
StarD2
StarD3
StarD4
StarD5
StarD6
StarD7
StarDS
StarD9
StarDIO
StarDll
StarD12
StaxD13
(StarD14)
(StarD15)

other names
StAR
StAR pseudogene
PCTP
MLN64, es64, CAB1
CRSP
none
none
StarD6 pseudogene
GTT1
KIAA018 9-RhoGAP
KIAA1300
PCTP-like, SDCCAG28, CGI-5
GPBP, COL4A3BP
DLC-1, Arhgap7, pl22-RhoGA
GT650, 4902678-RhoGAP
CACH
THEA, BFIT, KIAA0707

mouse

8, 24 .5
11, 90..7
11, 99..1
18, 33..4
7, 73..3
18, 70..8
10, 56..8
2, 128..3
X, 81..9
2, 121..1
7, 91..1
13, 93..9
8, 35,.5
5, 150,.3
13, 88..9
4, 104..5

human

Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb
Mb

8, 37.4 Mb
13, 59..8 Mb
17, 53..6 Mb
17, 37..3 Mb
5,110.,5 Mb
15, 77., 6Mb
18, 52..0 Mb
2, 94.,7 Mb
X, 64., 1Mb
15, 38..4 Mb
11, 74.,8 Mb
5, 73..5 Mb
8, 12., 7Mb
13, 31..7 Mb
5, 80.,8 Mb
1, 54..8 Mb

Table 1.1: Nomenclature and chromosomal locations of the 15 mammalian S T A R T genes.
The gene names in bold italics are used in the text. All human S T A R T genes except C A C H and T H E A
have been assigned formal names S T A R T domain containing (StarD), but some common names are
widely used. Physical map positions (chromosome, position in megabases) in the mouse and human
genomes are based on the Ensembl database, 2 Dec 2002 revision (www.ensembl.org). Pseudogenes
have been described for human StAR (Sugawara et al., 1995a) and mouse StarD6 (Soccio et al., 2002).
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Figure 1.8: Phylogenetic analysis and domain structure of the S T A R T protein family.
(A) The 15 human S T A R T domains were aligned using ClustalW, and the resulting phylogeneric tree
divides the family into six subfamilies. (B) The domain organization is shown for each protein or
subfamily, with the S T A R T domain in green and other domains in blue Q?H, Pleckstrin homology; Ser,
serine-rich; S A M , sterile alpha motif; RhoGAP, Rho GTPase activating protein; 4TM, four
transmembrane; Pre, mitochondrial presequence; Thio: acyl CoA thioesterase). (C) The S T A R T
proteins from Drosophila melanogaster (fly) and C. elegans (worm) most closely resemble certain
mammalian proteins or protein subfamilies.

The START domain structure: X-ray crystal structures have been solved for the MLN64
START domain (Tsujishita and Hurley, 2000), StarD4 (Romanowski et al., 2002), and
phosphatidylcholine transfer protein (PCTP) (Roderick et al., 2002). All three share the same

helix-grip fold (Iyer et al., 2001), with a-helices at the N- and C-termini separated by nine 0
strands and two shorter a-helices. The curved P-sheet forms a deep pocket with the C-

terminal a-helix acting as a lid, resulting in an internal hydrophobic cavity (Figure 1.9). Th
START structure differs from other hydrophobic cavity lipid binding proteins, such as SCP-2
(Choinowski et al., 2000), SPF (Stocker et al., 2002), phosphatidylinositol transfer protein
(Yoder et al., 2001), and the fatty acid binding protein (FABPs) (Bernlohr et al., 1997). The
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Figure 1.9: The S T A R T domain X-ray
crystal structure.
Like other S T A R T structures, StarD4 has
four a-helices (A-D, blue) and nine (3strands (red) that form a U-shaped sheet.
The C-terminal aD helix may open or
unfold to allow lipid binding in the
internal hydrophobic cavity.

PCTP

structure w a s reported with a phosphatidylcholine (PC) molecule in the cavity

(Roderick et al., 2002), while the M L N 6 4 and StarD4 structures contain cavities large
enough to accommodate a cholesterol ligand (Romanowski et al., 2002).

Lipid entry or

egress would require a major conformational change, most likely opening or unfolding of the
C-terminal a-helix lid. In fact, this helix of P C T P is implicated in m e m b r a n e binding and P C
extraction (Feng et al., 2000).

Furthermore, S t A R can form partially unfolded states

(Christensen et al., 2001) and decreases its helical content upon binding a cholesterol
analogue (Petrescu et al., 2001). Modeling of S t A R using structure-based thermodynamics
shows that an open-lid conformational state can exist at equilibrium, and that cholesterol
binding and lid closure significantly stabilize the complex (Mathieu et al., 2002).

The steroidogenic acute regulatory protein: The rate-limiting step in steroidogenesis is
StAR-mediated delivery of cholesterol to the P450scc enzyme, which resides on the matrix
side of the inner mitochondrial m e m b r a n e ( I M M ) and converts cholesterol to pregnenolone
(Miller and Strauss, 1999; Stocco, 2001). After stimulation by pituitary trophic hormones,
acute steroidogenesis results from phosphorylation of pre-existing S t A R and rapid synthesis
of n e w S t A R (Miller and Strauss, 1999).

W h e n S t A R is mutated in h u m a n s with lipoid
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congenital adrenal hyperplasia ( C A H ) (Bose et al, 1996) or in knockout mice (Caron et al.,

1998), there are marked defects in the synthesis of adrenal and gonadal steroids, as we

cholesterol accumulation in cytosolic lipid droplets of steroidogenic cells. Early stu

not detect StAR mRNA in other steroidogenic organs such as placenta and brain (Sugawar
et al., 1995a), but more sensitive assays have recently shown StAR expression in both

(King et al., 2002; Koh et al., 2002). Increased StAR expression has even been observed
glial brain tumors, perhaps implicating StAR in tumorigenesis (Kim et al., 2003). StAR

fetuses produce normal levels of placental progesterone (Bose et al., 1996), suggesting

existence of alternate steroidogenic mechanisms. StAR-independent steroidogenesis is a

key to the favored two-hit model of lipoid CAH, which explains the clinical manifestat

based on different times of onset for StAR-dependent steroidogenesis in testis (fetal)
gland (postnatal), and ovary (puberty) (Miller, 2002; Miller and Strauss, 1999).
In order for P450scc to act, cholesterol must get to the outer mitochondrial membrane

(OMM), across the intermembranous space, and to the IMM. StAR is synthesized as a 37 kD

protein, but the N-terminal presequence directs mitochondrial import before being clea
the matrix, leaving a 30 kD protein. Despite its final matrix localization, StAR most
acts at the OMM (Bose et al., 2002). In transfection assays and studies with isolated

mitochondria, StAR lacking the presequence (N-62 StAR) has equivalent activity to full

length StAR (Arakane et al., 1998; Arakane et al., 1996). In studies using StAR fusions

mitochondrial proteins, StAR at the OMM facing the cytosol is fully active, while StAR
the intermembranous space or matrix is inactive (Bose et al., 2002). StAR could simply

drop-off cholesterol, or alter the OMM to facilitate cholesterol desorption to the IMM
and Strauss, 1999). An alternate view is that StAR must be imported to act, since data
supporting an OMM site of action rely on non-physiological isolated mitochondria or
transfection of non-steroidogenic cells (Jefcoate, 2002).
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If StAR acts at the O M M , then the purpose of its presequence and mitochondrial

import is unclear. StAR can act as a cholesterol transfer protein in vitro, as N-62 St

selectively transfers sterols from donor liposomes to acceptor mitochondria (Kallen e

1998). However, N-62 StAR lacks target specificity, as other acceptors include trypsin-

treated mitochondria, endoplasmic reticulum (ER), and phospholipid vesicles (Kallen et
1998; Tuckey et al., 2002). Therefore, the presequence may direct cholesterol transfer

mitochondria in preference to other organelles (Miller and Strauss, 1999). In addition,
import may rapidly inactivate StAR (Bose et al., 2002), as StAR undergoes proteolytic
degradation in mitochondria (Granot et al., 2002). Mitochondrial proteins such as the

peripheral-type benzodiazepine receptor (PBR) and PAP7 have also been implicated in S

function (Hauet et al., 2002), and a novel StAR binding protein (SBP) was recently clo

yeast two-hybrid (Sugawara et al., 2003), so future studies of these proteins may shed
additional light on the function of StAR.

The MLN64 protein: MLN64 was cloned as a gene amplified in breast, gastric and
esophageal cancers (Akiyama et al., 1997; Tomasetto et al., 1995). While MLN64 could
play a causative role in tumorigenesis (Moog-Lutz et al., 1997; Watari et al., 1997),

amplification likely reflects close genomic proximity (within 36kB) to the oncogene c

b2 (Her2/neu) (Tomasetto et al., 1995), which is invariantly co-amplified (Watari et al
1997). The N-terminus of MLN64 includes four transmembrane helices, while the C-

terminal START domain is 37% identical to StAR (Moog-Lutz et al., 1997). Like StAR, th

isolated MLN64 START domain binds (Tsujishita and Hurley, 2000) and transfers (Zhang e

al., 2002a) cholesterol in vitro, and stimulates steroidogenesis when co-transfected w
P450scc (Bose et al., 2000; Watari et al., 1997).
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M L N 6 4 expression is detected in all tissues (Watari et al., 1997), and it is a candidate
for StAR-independent steroidogenesis. However, the transmembrane domain of MLN64
localizes it to late endosomes with the START domain facing the cytosol (Alpy et al.,

Zhang et al., 2002a). Given this localization, full-length MLN64 is relatively inactiv

steroidogenesis assays, but proteolysis could release the START domain allowing delive

cholesterol to mitochondria (Watari et al., 1997). Supporting this notion, antibodies a
the MLN64 START domain detect full-length protein and prominent smaller bands in
placenta and transfected cells (Watari et al., 1997).
MLN64 also functions in cholesterol mobilization from endosomes via the Niemann-

Pick C (NPC) pathway. Since MLN64 co-localizes with NPC 1, endosomal cholesterol could

move sequentially from luminal NPC2, through NPC1, to MLN64, and finally to a cytosoli

acceptor (Strauss et al., 2002). MLN64 mutations have not been reported in NPC disease
but overexpression of the MLN64 transmembrane domain with no START domain results in
an NPC phenocopy, with cholesterol accumulation in enlarged endosomes (Zhang et al.,
2002a). A similar phenotype is observed upon overexpression of MENTHO (MLN64 Nterminal domain homologue), an endosomal membrane protein of unknown function, which
is 70% identical to the MLN64 transmembrane domain but lacks a START domain (Alpy et
al., 2002).

The PCTP subfamily: While PCTP, StarD7, StarD 10, and Goodpasture antigen binding
protein (GPBP) form a subfamily based on phylogenetic analysis, the four genes do not

appear as closely related as other subfamilies. Unlike the other subfamilies, the four
subfamily genes do not share a common exonic organization or homology outside the
START domain. In the PCTP structure, 28 residues in the hydrophobic cavity contact PC
(Roderick et al., 2002), and 20 of these are identical or similar in StarD7, including
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11 aromatics. This suggests that StarD7 m a y also bind PC, while StarD 10 and G P B P exhibit

much less similarly at these key residues (only 1 and 3 of the 11 aromatics conserved,
respectively), suggesting different ligands.
PCTP is an extremely specific lipid binding protein, as it promotes intermembrane

transfer of PC but not other phospholipids or sterols (Wirtz, 1991). PCTP is a cytosol

protein, though one report indicates relocation to mitochondria upon clofibrate treatm

This relocation occurs in endothelial cells but not hepatoma cells, and requires a put

phosphorylation site at serine 110 (de Brouwer et al., 2002). PCTP is widely expressed
highest levels in liver (Cohen et al., 1999), and a function has been proposed in the
secretion of PC into bile. However, PCTP knockout mice were reported to have normal

biliary PC levels, but even wild-type adults in this study had very low liver PCTP pro

levels compared to newborn pups (van Helvoort et al., 1999). PCTP may also play a role

cellular lipid efflux via ABCA1, which forms plasma HDL by efflux of phospholipids and

cholesterol to ApoAI (Tall et al., 2002). PCTP overexpression results in a dose depend

acceleration of this efflux, suggesting that PCTP replenishes the cell membrane with P
have been removed by ABCA1 (Baez et al., 2002).
Little is known of StarD7 and StarD 10, which have short extensions of non-START

sequence at their N- and C-termini. There are no StarD7 publications, but -800 express
sequence tag cDNAs (ESTs) indicate abundant and widespread expression. StarD 10 mRNA

is detectable by Northern Blot in testis, liver, kidney, and intestine (Yamanaka et al.

and there are -700 ESTs from many tissues. In testis, StarD 10 mRNA is expressed in ge

but not somatic cells, and the protein localizes to sperm tails (Yamanaka et al., 2000
The widely expressed GPBP has an N-terminal PH domain, two serine-rich domains,
and a C-terminal START domain (Raya et al., 1999). GPBP binds and phosphorylates
Goodpasture (GP) antigen, the C-terminus of human collagen rv a3, which is the target
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autoantibodies in G P syndrome (Raya et al., 1999). P H domains mediate interactions, and

the GPBP PH and first serine-rich domains are sufficient for binding GP antigen (Raya
1999). GPBP lacks a conventional serine/threonine kinase domain, but the START domain
is more likely a regulatory lipid binding domain than a catalytic site. GPBP mRNA is

alternatively spliced and the most abundant form (GPBPA26) lacks the second serine ri

domain (Raya et al., 2000). Antibodies that recognize the rarer full length protein bu

GPBPA26 stain endothelial basement membranes - particularly in renal glomeruli and lu

alveoli, which are affected in GP syndrome - and show markedly increased staining in s

biopsies from patients with dermatologic autoimmune conditions (Raya et al., 2000). GP

is thus implicated in human autoimmune diseases, but other roles are likely as GPBP is

conserved in other mammals lacking the GP antigen, and even in Drosophila and C. elega

The acyl CoA thioesterase subfamily: Cytosolic acetyl CoA hydrolase (CACH) and
thioesterase adipose-associated (THEA) each have two type II acyl CoA thioesterase
domains and a C-terminal START domain. Multiple subcellular compartments contain acyl

CoA thioesterases, which hydrolyze acyl-CoAs to free fatty acids. Several are regulate

PPAR nuclear receptors and nutritional factors, yet their precise roles in lipid metab
remain undefined (Hunt and Alexson, 2002).
CACH has high hydrolase activity for acetyl-CoA (C2), low activity for short chain
acyl-CoAs (C4-C6), but no activity for medium (C12) and long (Ci6) chain acyl-CoAs

(Suematsu et al., 2001). Rat CACH activity is detected only in liver and kidney cytoso

(Matsunaga et al., 1985), and hepatic activity is regulated in several metabolic states
both starvation and a fat-free diet increase activity, suggesting that CACH regulates

CoA levels for fatty acid oxidation and synthesis (Matsunaga et al., 1985). Second, ac

is increased by cholesterol feeding or by cholesterol synthesis inhibitors, both of wh
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decrease cholesterol synthesis and may increase levels of the precursor acetyl C o A (Ebisuno

et al., 1988). Third, activity is elevated in acute streptozotocin-induced diabetes, bu

injection prevents this elevation (Ebisuno et al., 1988). Finally, a PPARa agonist ele

CACH activity 3-fold (Nakanishi et al., 1993), indicating it may be a PPAR target gene
Though the thioesterase domains of THEA and CACH are -60% identical, no acetyl-

CoA hydrolase activity is detectable for recombinant THEA (Suematsu et al., 2001), whi
instead hydrolyzes medium and long chain acyl-CoAs (Adams et al., 2001). Humans
produce two THEA splice variants, which vary in relative abundance among tissues and

encode different C-termini (Adams et al., 2001). THEA-1 and THEA-2 could differ in lip
binding since their START domains have different C-terminal a-helix lids. Only the
THEA-2 C-terminus resembles CACH, and mice express only THEA-2. In mouse brown
adipose tissue, THEA mRNA is induced by cold exposure, suppressed by warmth, and

decreased 2.5-fold in genetically obese (ob/ob) mice compared to lean littermates (Ad
al., 2001). THEA maps to the Dietary obese 1 (Dol) locus on mouse chromosome 4,
syntenic to an obesity locus in the Quebec Family Study on human lp32 (Adams et al.,
2001). THEA may thus play a role in energy metabolism and obesity.

The RhoGAP subfamily: Rho family small GTPases signal in actin cytoskeletal

organization and other cellular processes, and Rho GTPase activating proteins (RhoGAPs
stimulate GTP hydrolysis to inactivate signaling (Ridley, 2001). The human genome
encodes over 50 RhoGAPs, three of which have START domains. Deleted in liver cancer 1

(DLC-1), StarD8, and StarD 13 are -50% identical proteins, each with an N-terminal ster
alpha motif (SAM, a protein interaction domain found in many signaling proteins), a
RhoGAP domain, and a C-terminal START domain. There are no publications on StarD8

and StarD 13, which could share redundant functions with DLC-1 or be expressed in dif
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tissues. There are two potential connections between R h o G A P s and cholesterol metabolism:

Rho proteins have been implicated in regulating the activity of LXRs (Gan et al., 2001
while related Rab proteins regulate vesicular cholesterol transport in the endosomal
compartment as described earlier (Choudhury et al., 2002).
The widely expressed tumor suppressor DLC-1 is often deleted homozygously in

primary hepatocellular carcinomas and breast tumors (Yuan et al., 2003). Deletion or l

expression is found in many tumor cell lines from liver, breast, colon, and prostate (
al., 2003). DLC-1 transfection inhibits growth of DLC-1 negative hepatoma and breast

carcinoma lines, preventing in vivo tumorigenicity of the latter (Ng et al., 2000; Yua

2003). In vitro studies identified two potential signaling functions for rat DLC-1, act
of phospholipase C-51 and RhoGAP activity for RhoA (Homma and Emori, 1995).

Phospholipase C-51 induces Ca2+ release, and cells microinjected with DLC-1 show a rap

rise in intracellular Ca2+ (Sekimata et al., 1999). RhoA affects the cytoskeleton, and
transfected cells round and detach from the plate, changes blocked by dominant active

The SAM and START domains of DLC-1 are dispensable for this cytoskeletal reorganizati

(Sekimata et al., 1999), though they could play roles at physiological expression leve

The high molecular weight StarD9 protein: StarD9 is in sequence databases as a partial
1820 amino acid human coding sequence (Nagase et al., 2000) with a C-terminal START

domain but no defined N-terminus. The 5' exon in the partial cDNA has at least 4000 bp
coding sequence, and upstream genomic sequence shows up to 9995 bp of coding sequence
in this exon. (An exon with -10 kb of coding sequence is atypical, but the mouse gene

shares this feature.) Although additional 5' exons are possible, this large exon and t
exons constitute an ORF of 11,334 bp, encoding a 413 kD protein. In this very large

-42-

predicted protein, only the S T A R T domain exhibits homology to other proteins.

EST

evidence suggests StarD9 is predominantly expressed in the nervous system.

Evolution of the START domain: The distribution of START proteins in completely

sequenced genomes shows the evolutionary history of this domain (Iyer et al., 2001). T
pathogenic bacterium Pseudomonas aeruginosa PA1579 gene is similar to mammalian
PCTP, suggesting horizontal acquisition from hosts since there are no START genes in
prokaryotes (Romanowski et al., 2002). START domains are also absent in the budding
yeast Saccharomyces cerevisiae, a unicellular eukaryote. The slime mold Dictyostelium
discoideum has the CheaterA START protein, indicating the domain was present in the

common ancestor to multicellular eukaryotes (Iyer et al., 2001). CheaterA also include

WD40 and F-box domains, suggesting a role in protein ubiquitination, and CheaterA mut

preferentially form spores rather than stalks (Ennis et al., 2000). The plant Arabidop
thaliana has 20 START genes, 16 of which are fused to homeodomains, suggesting that

ligand binding to these transcription factors may regulate plant development (Ponting

Aravind, 1999). In animals, mammals have 15 START genes, while the fruit fly Drosophila
melanogaster has only four, which most closely resemble mammalian MLN64, GPBP,
PCTP/StarD7, and a RhoGAP. The nematode Caenorhabditis elegans has three additional
START genes - most similar to StAR, StarD 10, and StarD5 - for a total of seven (see
1.9). START genes have also been described in animals without completely sequenced
genomes, including a START protein in the silkworm Bombyx mori that binds carotenoids
(Tabunoki et al., 2002).
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Perspective
By binding lipid ligands, START domains could function in net lipid transfer
between subcellular compartments or in lipid regulation of cellular signaling events. START
proteins likely play significant roles in lipid metabolism, fertility, atherosclerosis,
autoimmune disease, and cancer, making them potential drug targets. There has been
significant recent progress in the study of some START proteins, while others are essentially
uncharacterized and demand further investigation. Given the roles of StAR and MLN64 in
cholesterol metabolism, other related START proteins could also play roles in intracellular
sterol transport. Here we describe the cloning, structure, and regulated expression of the
StarD4 subfamily of three START proteins, and present data that these proteins function in
intracellular cholesterol metabolism.
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C h a p t e r 2: Discovery of the S t a r D 4 subfamily

Dietary cholesterol cDNA microarray experiment: Our initial experiment sought to identify
novel hepatic genes regulated by dietary cholesterol. Most previous studies of cholesterolregulated genes have used cultured cells and genetically modified mice (Horton et al., 2002),
but we used a physiologically relevant model of cholesterol feeding to intact wild type mice.
We assayed gene expression in liver since it is the central organ in cholesterol metabolism
(Dietschy and Turley, 2002). Hepatocytes synthesize a large fraction of whole body

cholesterol, store cholesterol esters in lipid droplets, and convert cholesterol to bile acids,
which are excreted in bile along with free cholesterol. In the metabolism of plasma
lipoproteins, the liver is responsible for uptake of dietary cholesterol in chylomicron
remnants, re-secretion of cholesterol in very low density lipoproteins (VLDL), apolipoprotein
synthesis, and uptake of cholesterol from LDL and HDL.
Known SREBP and LXR target genes do not explain many aspects of cholesterol
metabolism, such as the responsiveness of plasma cholesterol levels to dietary cholesterol.
Therefore, we hypothesized that relevant genes could be identified by their differential
regulation. To identify such genes, we considered PCR-based methods including differential
display (Liang and Pardee, 1992), serial analysis of gene expression (SAGE) (Velculescu et
al., 1995), suppression subtractive hybridization (Diatchenko et al., 1996), selective
amplification via biotin- and restriction-mediated enrichment (SABRE) (Lavery et al., 1997),
and representational differential analysis (Hubank and Schatz, 1999). We attempted some of
these techniques before choosing cDNA microarrays, a relatively novel technique at the time
with many advantages over previous methods (Brown and Botstein, 1999). By collaborating
with the laboratory of Raju Kucherlapati, we obtained glass slide cDNA microarrays
(Cheung et al., 1999) with -9000 mouse ESTs representing -6000 genes.
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Figure 2.1: Liver cholesterol levels increase upon
cholesterol feeding.
Six week-old C57BL/6 male mice were fed a chowbased diet containing 0.02% or 0.50% cholesterol
(wt/wt) for three weeks (n=5 per group). Livers were
extracted and total cholesterol and free cholesterol
fFC) were measured by gas chromatography, while
cholesterol esters (CE) were calculated as the
0.02% 0.50%
Dietary Cholesterol

difference. *P<0.01

O u r experimental comparison w a s C 5 7 B L / 6 male mice fed a c h o w diet low (0.02%)
or high (0.50%) in cholesterol for three weeks. T h e high cholesterol diet raised liver total
cholesterol almost 5-fold, with most of the increase in cholesterol esters but also a significant
increase in free cholesterol (Figure 2.1). R N A w a s extracted from mice on each diet and
used to probe c D N A microarrays (Figure 2.2). A s others have reported (Lee et al., 2000), the
results from a single microarray hybridization are unreliable, so w e performed three

Figure 2.2: Microarray analysis of liver gene expression in response to dietary cholesterol.
R N A was prepared from livers of mice fed chow diets with 0.02% or 0.50% cholesterol. c D N A was
synthesized incorporating Cy3 (red) or Cy5 (green)fluorophores,and the labeled c D N A probes were
competitively hybridized to glass slide c D N A microarrays. (A) A merged image of the red and green
fluorescencefroma representative array.

Unregulated genes appear as yellow spots.

03) A

representative scatter plot of red and greenfluorescenceintensity for each array spot. There was noise at
low signal intensities (<100), but cholesterol-regulated genes were identified above this background.
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independent feeding experiments with duplicate hybridizations for a total of six microarrays.
Among the six genes on the array that were down-regulated more than two-fold by dietary
cholesterol, five were known SREBP-target genes involved in cholesterol or fatty acid
biosynthesis (Horton et al., 2002), thus validating our microarray approach. The sixth gene
was an expressed sequence tag (EST AA239481) representing a novel gene (Table 2.1). A
similar dietary cholesterol microarray experiment was performed by Kara Maxwell using
Affymetrix oligonucleotide arrays, and this study found these six genes and many others that
are down- and up-regulated by cholesterol (Maxwell et al., 2003).

fold
on six arrays
Mean decrease
Fold GenBank
Decrease Accession

Gene Product

la

lb

2a

2b

3a

3b

4.6

AA237469

Isopentyl diphosphate isomerase

3.3

7.6

2.4

3.6

4.9

5.9

2.8
2.6

AA239481
AA268608

novel EST (StarD4)
Squalene epoxidase

3.6
3.2

2.3
2.7

4.8
2.8

1.6
1.3

2.8
2.9

1.9
(44)

2.5

AA061468

HMG CoA synthase

2.6

0.9

5.2

2.0

2.4

2.1

2.0

AA116513

Fatty acid synthase

1.4

1.7

2.0

2.8

2.3

2.0

2.0

AA500330

Farnesyl pyrophosphate synthase

1.2

1.7

2.0

2.8

2.3

2.0

Table 2.1: Six genes down-regulated two-fold or more by dietary cholesterol.
Experiments 1-3 each compared liver gene expression in a pair of individual mice fed different diets
(0.02% versus 0.5% cholesterol). Each experiment was performed on duplicate arrays (a, b) by
reversing the Cy3 and Cy5 probe labeling. Due to variability within and between experiments, the
following criteria were used for regulated genes: expression differed 2-fold or greater on at least 4 of
the 6 arrays with the higher expression level at least 2 5 % over background. For each of the six genes
down-regulated by the high cholesterol diet, the fold regulation on each array is shown, as well the
averagefromall six (the outlying value in parenthesis was eliminated)

Identification of the StarD4 gene and its tissue expression pattern: To identify the n

cholesterol-regulated gene, EST AA239481 was obtained and its 1114 bp insert sequenced.

There were no long protein-coding regions in any reading frame, suggesting the sequence

was 3' untranslated region (3' UTR). BLAST searches placed the EST sequence on a mouse
BAC clone (AC020796), about 3 kb downstream of a 230 bp coding sequence homologous
to START genes. This 230 bp sequence (the coding part of exon 6) was in multiple mouse
ESTs, allowing assembly of a 675 bp open reading frame (ORF) by in silico EST walking.
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T h e m o u s e gene encodes a 224 amino acid protein consisting almost entirely of a S T A R T
domain, so it was named START domain containing 4 (StarD4). The human StarD4
orthologue encodes 205 amino acids, with a shorter N-terminus, 87% identical to the mouse
protein. Both genes have six exons, and they are located on mouse chromosome 18 at 12cM
and the syntenic region of human 5q22.
Mouse and human StarD4 ORFs were RT-PCR amplified from liver, cloned, and
sequence-verified. The sequence of mouse StarD4 from C57BL/6 disagreed with some ESTs
at positions 121 and 152. Since other ESTs agreed with the C57BL/6 sequence, StarD4 was
cloned from a second inbred mouse strain, FVB. Sequencing confirmed that these
nucleotides are polymorphic between strains, and that these single nucleotide polymorphisms
(SNPs) result in amino acid substitutions at positions 41 and 51 (Figure 2.3). Based on the
StarD4 crystal structure described later, side chains at both positions are on the protein
surface and do not contribute to the lipid-binding cavity, so it is uncertain whether they have

aa41 aa51
I
E
E
D
E
W
R
V
A
K
K
A
K
p c 7 R | IC
ATC GAA GAA GAT GAG TGG CGA GTT GCC AAA AAA GCG AAA K-'D' D L / D
I K E D E W R V A K K V K r - - x / D
ATC AAA GAA GAT GAG TGG CGA GTT GCC AAA AAA GTG AAA r V b
nt121
nt152
Figure 2.3: Single nucleotide polymorphisms (SNPs) in the mouse StarD4 coding region.
Multiple independent RT-PCR reactions were performed to amplify the liver StarD4 O R F from two
inbred mouse strains, C57BL/6 and FVB.

cDNAs were sequenced for each strain, revealing SNPs at

nucleotides (nt) 121 and 152. Both SNPs result in amino acid (aa) coding differences.

functional consequences. RT-PCR amplification of human StarD4 gave the expected ORF
(arrowhead) and additional products (Figure 2.4a). Several of these were cloned and
sequenced, revealing mis-spliced StarD4 RNAs that included sequence from intron 5 or
excluded exons (Figure 2.4b). Such products were not amplified from mouse liver and likely
reflect heterogeneous nuclear RNA in the commercial human liver RNA template, rather
than alternative splicing.
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Figure 2.4: Mis-spliced human StarD4
B

H u m a n StarD4 R T - P C R products

RT-PCR products.
RT-PCR primers (arrows) in the human

2000-

StarD4 coding sequence were used to

1500-

amplify this gene by from a commercial
source of human liver RNA.

1000-

(A) The

major RT-PCR product was the expected
•

StarD4 band (arrowhead), but there were

500-

other bands. (B)

These products were

sequenced, revealing mis-spliced m R N A s
which could not encode the StarD4
S T A R T domain.

Northern blots were performed to verify that the array E S T and O R F sequences were
part of the same m R N A (Figure 2.5a). O n a m o u s e multiple tissue northern blot, a StarD4
O R F probe hybridized to a predominant m R N A

at -5.5 kb in all eight tissues with the

highest levels in liver and kidney, in addition to several smaller m R N A s (Figure 2.5b). The
array E S T insert probe also hybridized to this ~5.5 kb m R N A with the same relative tissue

f
c *
^ .= o
tl L Q.

E

.3.2_kb___^
5*40RF>

B
EST

h-3'

5.0 kb

Figure 2.5: Multiple tissue northern blots of
mouse StarD4.
(A) The predicted mouse StarD4 m R N A was at
least 5 kb long with 3.2 kb of 3' U T R between
the O R F and EST AA239481 sequence.
mouse

multiple

tissue

northern

blot

A
was

hybridized with three probes: (B) StarD4 ORF,
(C) EST AA239481 insert, or (D) P-actin loading
control. The major StarD4 m R N A was -5.5 kb,
and smaller transcripts were also detected.
Longer exposures revealed StarD4 expression in
skeletal muscle.
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levels (Figure 2.5c), consistent with the predicted m R N A .

Subsequent E S T cloning and

annotations by the various genome projects have confirmed our descriptions of the mouse
and human StarD4 genes.

StarD4 regulation by dietary cholesterol: To confirm the microarray result that StarD
expression is cholesterol-regulated, w e used other methods to assay gene expression. O n
Northern blots, liver StarD4 expression was decreased ~3-fold upon cholesterol feeding
(Figure 2.6a). W e also designed real-time quantitative R T - P C R (qPCR) primer and probe
sets for mouse StarD4, one set in the O R F spanning exons 1 and 2, and another in the 3'
U T R of exon 6. In multiple cholesterol feeding experiments, a consistent 50-70% decrease
in liver StarD4 expression was observed in both male and female mice using either probe set,
and representative examples are shown in Figure 2.6b. StarD4 expression was not regulated
by dietary cholesterol in non-hepatic tissues such as kidney and heart, though there was
higher expression in the kidney (Figure 2.6c) consistent with the multiple tissue Northern.

A

Liver Northern

B

Liver q P C R

Other tissues

c
10.00%
10.50%

.2 1.40.0% 0.5%
StarD4

(0
a> 1.2-

i

JL

a °-8-

*
p-actin

•

I
©
1
a
Qi

°-6'
0.40.2-

i
0.0J- StarD4 O R F
(males)

4
StarD4 3'UTR
(females)

kidney
heart
(StarD4 O R F , males)

Figure 2.6: Regulation of StarD4 expression by dietary cholesterol.
C57BL/6 mice were fed a semi-synthetic diet with 0.00% or 0.50% cholesterol (wt/wt) for one week
before extraction of tissue R N A . (A) A Northern blot of liver R N A shows a 3-fold decrease in StarD4
relative to loading control p-actin. (B) T w o different quantitative R T - P C R probes for mouse StarD4
showed similar down-regulation by cholesterol feeding in male and female mice (n=5 per group). (C) N o
significant regulation of StarD4 was observed in kidney or heart (n=3 per group).
cyclophin, *P<0.05. NS=not significant
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Normalized to

Expression of the known S R E B P target genes H M G R and squalene expoxidase was also
decreased by cholesterol feeding in liver but not peripheral tissues (data not shown).
In addition, Kara Maxwell performed a time course experiment of feeding a semisynthetic 0.50% cholesterol diet for one week, revealing a difference in regulation of
SREBP-1 versus SREBP-2 target genes (Maxwell et al., 2003). SREBP-2 target genes in
cholesterol metabolism (i.e. H M G R ) are completely down-regulated after only one day of
cholesterol feeding, while SREBP-1 targets in fatty acid metabolism (i.e. F A B P 5 ) take
several days. W h e n StarD4 expression was analyzed in this time course (Figure 2.7), its
expression was decreased after only one day of feeding, consistent with SREBP-2 target
genes and a role in cholesterol metabolism. Further studies in Chapter 3 confirmed that
StarD4 is an SREBP-2 target.

Days of 0.5% cholesterol feeding
ZI0
c
o
W

CZ31
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Figure 2.7:

StarD4 regulation in a

time course of cholesterol feeding.
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StarD4

A subfamily of S T A R T genes including StarD4, StarDS, and StarD6: B L A S T searches
against whole genome and E S T databases identified 15 S T A R T domain-containing genes,
which are described in the introduction. The S T A R T domain protein sequences were aligned
to reveal some highly conserved amino acids across the entire family (Figure 2.8): Trp29,
Trp79, Argl 14, Asp/Glul 15, and Argl47 (based on human StarD4 numbering). Notably, w e
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Figure 2.8: Multiple alignment of human S T A R T domains.

III

The amino acid sequence of 16 human S T A R T domains (15 genes, 2 splice variants of T H E A ) were
aligned using ClustalW. The colored bars above the alignment indicate positions with strong consensus.
Amino acid agreements with StarD4 are boxed, while agreements with consensus are colored yellow.
The black arrows indicate residues that contribute side chain atoms to the lipid binding based on the
mouse StarD4 X-ray crystal structure. The violet arrows indicate positions with charged residues that
form salt bridges in the predominantly hydrophobic cavity.

found two other novel START proteins, subsequently named StarD5 and StarD6, which were
highly similar to StarD4. In a phylogenetic analysis, these three proteins clearly form a
subfamily among START proteins, with the most related subfamily containing the known
cholesterol-binding proteins StAR and MLN64 (Figure 2.9a). Comparing each protein
sequence pairwise, StarD4, StarD5, and StarD6 are -30% identical; they share -20% identity
with StAR and MLN64, and less identity to other START subfamilies (Figure 2.9b).
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GenBank START
Accession Domain
Number Amino
Acids
AF480299 1-205
AF4SO304 1-213AF480305 1-220.
Q14849 230-445
P49675 67-285.
AACO4047 81-298
NP005704 389S25
AF151638 1-214
NP064536 36-258
XP0103B7 808-1023
CAB42562 780-995.
NP0060SS 877-1091
AAL40937 375-607
AAL40938 375394
AB078619 339-555
T43436 58-268.

Figure 2.9: Subfamilies of S T A R T domain containing proteins.
(A) A phylogenetic tree based on the multiple alignment reveals six subfamilies: PCTP-like (orange),
RhoGAP domain-containing (green), the StarD4 subfamily (violet), StAR/MLN64 (blue), acyl CoA
thioesterase domain-containing (pink), and StarD0 (gray). (B) The percent amino acid identity for each
pairwise comparison. Yellow indicates the similarity between the StarD4 and StAR/MLN64 subfamilies.

T h e h u m a n and m o u s e sequences for StarD4, StarD5, and StarD6 were analyzed in
silico using resources available publicly via the National Center for Biotechnology
Information (www.ncbi.nlm.nih.gov) or commercially via Celera Genomics (www.celera.
com). Full-length coding sequences, Unigene clusters, and chromosomal positions were
determined (Table 2.2). The three genes do not reside together in a cluster, but the mouse
and human orthologues for each gene reside in syntenic chromosomal regions. Based on the
Online Mendelian Inheritance in Man (OMIM) database (Hamosh et al., 2002), none of these
genes reside at known disease-associated loci. While there is only one copy per genome

mStarD4
GenBank Accession AF4 80297-S
Unigene cluster Mm.23344
Celera gene mCG21663
Chromosome
18
Genetic Map
12 cM
mRNA length
~5.5 kb
ORF length
675 bp
Protein length
224 aa

mStarD5
hStarD4
hStarD5
AF480302
AF480304
AF480299
Mm.25702
Hs.162205
Hs.172803
mCG8260
hCG27342
hCG37443
7
15q26
5q22
72-77 cM
41 CM
116-121 cM
-5.5,4.5 kb -3.0,1.5 kb -3.0,1.5 kb
618 bp
642 bp
642 bp
205 aa
213 aa
213 aa

mStarP6
AF480303
Mm.83623
mCG9256
18
44 cM
-1.5 kb
702 bp
233 aa

hStarP6
AF480305
Hs.374669
hCG1643548
18q21
71-83 cM
-1.5 kb
663 bp
220 aa

Table 2.2: Gene information for StarD4, StarD5, and StarD6 from mouse and human
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of StarD4 and StarD5, there is a mouse StarD6 gene with introns on chromosome 18 and a

nearly identical intron-less sequence on chromosome 10, likely a processed pseudogene

Mouse StarD6 ORF PCR primers in different exons amplified a strong -700 bp product fr

testis cDNA as well as genomic DNA (Figure 2.10), confirming the presence of this intr
less sequence.

Figure 2.10:

Evidence for a mouse StarD6

a,

tr

^

H „ <& ^ ^
processed pseudogene.
<y
Q
.O
<S^ ** &
Primers that amplify the mouse StarD6 coding
St
i&
O
o *» «£"
sequence detect this sequence in testis cDNA as
^
>s® (S*
well as genomic DNA, but not in a negative control
reaction without template. g£|||

To determine the exonic organization of each gene, c D N A contigs and genomic
sequences were aligned to reveal introns that followed the GT-AG rule. The StarD4
subfamily genes were remarkably similar, with most splice junctions conserved (Figure

2.11). The exonic organization is different for other START genes, supporting a distinc
StarD4 subfamily. Mouse StarD4 has 12 amino acids encoded by exon 1, but this exon is

non-coding in human StarD4 and there are no corresponding sequences in StarD5 or StarD

Upstream in-frame stop codons allowed identification of initiator codons in StarD4 an

StarD6. No upstream stop codons were found in StarD5, but there were no upstream exons

in over 180 mouse and human Unigene ESTs, indicating the first ATG was the start codon
The mouse StarD6 mRNA has a long, multi-exon 5' UTR with multiple initiation codons,
and such upstream AUGs may function as regulators of translation (Morris and Geballe,
2000). While most other START proteins have additional N-terminal domains, StarD4,

StarD5, and StarD6 are 205-233 amino acid proteins consisting almost entirely of START
domains.
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Figure 2.11: Exonic organization of StarD4, StarD5, and StarD6.
Exons for the mouse and human genes, represented as boxes with lengths in nucleotides, were
determined by alignment of c D N A with genomic D N A . Vertical bars show splice junctions that are
conserved among the genes. Coding sequences are white and untranslated regions ( U T R ) are gray. The
5' U T R lengths were based on the longest 5' sequences in each Unigene cluster, while the 3' U T R
lengths were estimated based on Northern blot m R N A sizes (Table 2.2). The symbols are: #, first
upstream in-frame stop codon in 5' U T R ; @ , upstream A U G codon in 5' U T R ; *, poly-A signal
( A A U A A A ) in the 3' U T R . The distance from the stop codon for each poly-A signal is indicated at the
far right. The 5' end of hStarD6 was uncertain based on very little available sequence data.

Tissue expression of StarDS and StarD6

StarD5 and StarD6 O R F s were RT-PCR

amplified a n d cloned f r o m m o u s e liver a n d testis, respectively, a n d used to probe multiple
tissue Northern blots. Like StarD4, StarD5 m R N A w a s m o s t abundant in liver a n d kidney,
but detectable in all tissues tested (Figure 2.12a).

In contrast, S t a r D 6 expression w a s

restricted to testis in both m i c e a n d h u m a n s , a n d expression w a s not detected in the ovary
(Figure 2.12b-c). W h e r e a s the predominant S t a r D 4 transcript w a s -5.5 k b (see Figure 2.5),
there w e r e t w o m a j o r StarD5 transcripts at ~ 3 k b a n d ~ 1 . 5 k B .

S t a r D 6 Northern blots

consistently g a v e a w i d e b a n d at ~1.5 k b , suggesting multiple transcripts around this length.
These m R N A

lengths revealed b y Northern (Table 2.2) are consistent with the positions o f

A A U A A A polyadenylation signals in the 3' U T R s (see Figure 2.11), a n d multiple m e s s a g e s
appear to represent alternative sites o f R N A polyadenylation a n d cleavage.
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Figure 2.12: Multiple tissue Northern blots of StarDS and StarD6.
(A) Mouse blot hybridized with mouse StarD5 O R F probe. (B) Mouse blot hybridized with mouse
=small
StarD6 O R F probe. (C) Human blot hybridized with mouse StarD6 O R F probe (sm. int.
intestine, PBL=peripheral blood leukocyte).
Since StarD5

showed

similar tissue distribution to StarD4, w e

measured its

expression by q P C R in control and cholesterol-fed m o u s e livers. In this experiment, w e also
assayed M L N 6 4 , a widely expressed cholesterol-binding S T A R T protein, but not S t A R and
StarD6, which are not expressed in liver.

Neither StarD5 nor M L N 6 4 expression w a s

regulated in m o u s e liver upon cholesterol feeding, while StarD4 w a s decreased as expected
(Figure 2.13).

10.0% cholesterol
Figure 2.13: Dietary cholesterol does not affect
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liver StarD5 or M L N 6 4 expression.
C57BL/6 mice were fed a semisynthetic diet with
0.00% or 0.50% cholesterol (w/w) for one week
before extraction of liver R N A (n=5 per group).
Expression of StarD4, StarD5, and M L N 6 4 was
assayed by quantitative RT-PCR and normalized to
cyclophin A.

*P<0.05, NS=not significant vs.

0.0% cholesterol.
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56

Purification and crystallization of recombinant mouse StarD4 protein: In collaboration
with Michael Romanowski and Stephen Burley at Rockefeller University, we sought to

express recombinant StarD4 in bacteria and solve its X-ray crystal structure. We clon
sequence-verified the mouse (C57BL/6 strain) StarD4 ORF as an in-frame fusion with

glutathione S-transferase (GST) in a lac-inducible bacterial expression plasmid. When
bacteria were transformed and induced with IPTG, a -55 kD protein was expressed,

consistent with the predicted molecular weight of the GST-StarD4 fusion protein (Figu
2.14a, arrow).
A summary of the subsequent purification of StarD4 is shown in Figure 2.14b. When

bacteria were lysed (lane 1), most GST-StarD4 was soluble in the supernatant (lane 2)

performance liquid chromatography (FPLC) was performed against a glutathione affinity

column, and most proteins flowed through (lane 3) while the ~55 kD GST-StarD4 bound th
column and was eluted (lane 4). Next, the GST moiety (-30 kD) was cleaved from StarD4

(-26 kD) to give two bands (lane 5). To separate GST, a second FPLC was performed with

glutathione affinity column, and StarD4 flowed through (lane 6). After dialysis, an in
pellet formed that contained some StarD4 as well as contaminating proteins that were

previously apparent (lane 7). The supernatant of this dialysis contained StarD4 and a
molecular weight contaminant (lane 8), so preparative high performance liquid
chromatography (HPLC) was performed against an anion exchange column (lanes 9).

StarD4 eluted as a compact peak (Figure 2.14c) that was isolated as the -26 kD purifie

protein (lane 10), smaller than -30 kD GST as predicted (lane 11). By matrix-associat
laser desorption mass spectrometry (MALDI-MS), the purified protein was 25957 Da,

compared to the predicted 25891 Da. This difference of 66 Da was likely within the er
the measurement, so further MS analysis was not pursued.

57

*

j° ^

0° ^

1

2

3

4

5

6

7

J

/

8

9

J

*

10 11

^PB#»- ***

50mM |

1M

Figure 2.14: Expression and purification of recombinant mouse StarD4 protein.
(A) Bacteria were transformed with an inducible expression plasmid for GST-fused StarD4. Whole cell
lysates were run on SDS-PAGE and stain with Coomassie blue. Induced cells show a ~55kD protein
(arrow) consistent with GST-StarD4. (B) Coomassie gel summarizing the purification of recombinant
mouse StarD4, see text for details. (C) On sepharose Q anion exchange HPLC, a sharp StarD4 peak
eluted between 230-297mM KC1.
To determine whether StarD4 is a monomer or a multimer in solution, we performed
gel filtration of the purified protein. Relative to monomeric standards of 25, 43, and 67 kD
(Figure 2.15a), the peak for StarD4 elution was at 56.4 mL near the 25kD marker (Figure
2.15b-c). Based on the standard curve (Figure 2.15d) StarD4 had an apparent M.W. of 26.8
kD, consistent with the predicted monomeric M.W. of 26.0 kD. The StarD4 peak did show a
slight shoulder to the left, indicating some higher order structures like dimers and trimers,
such as the faint band visible at 49 mL elution volume (Figure 2.13b-c), but these accounted
for quantitatively very little of the total StarD4. Therefore, StarD4 behaves predominantly
like a monomer in solution.
To obtain crystals of StarD4 protein, we subjected it to a standard screen of
crystallization solutions. In one condition, disordered crystals formed within an hour (Figure
2.14a). To obtain more suitable crystal morphology, we optimized the temperature (4°C was
better than room temperature), pH (0.1 M sodium cacodylate pH 6.5 gave crystals, but pH
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Figure 2.15: Gel filtration of recombinant mouse StarD4.
(A) Tracing of absorbance at 280 n m (A280) for three monomeric standards (67, 43, 25 kD) run over a
GF75 size exclusion chromatography column. (B) A280 elution profile of recombinant StarD4, with the
peak at 56.6 mL. (C) SDS-PAGE gel offractionscollected each 3 mL. (D) Based on this standard
curve, StarD4 had a molecular weight of 26.8 kD, consistent with the predicted monomer of 26.0 kD.

5.6 or 7.5 did not), salt (0.2 M magnesium acetate but not 0.0 or 0.3 M), polyethylene glycol
8000 ( 1 1 % w a s best), glycerol ( 2 2 % w a s best, Figure 2.14b-d), and time of growth (2 days
w a s best). T h e final crystals were hexagonal rods with excellent morphology (Figure 2.16e).
W h e n crystallization w a s attempted in the same conditions with 1 ug/ml cholesterol in 0 . 1 %
ethanol, the morpholgy

deteriorated to crystals with splintered ends (Figure 2.16f).

B
*
w
20%

22%

25%

Figure 2.16: Optimization of m o u s e StarD4 crystallization conditions.
(A) Purified mStarD4 formed disordered crystals in one condition of a standard crystal screen.
Crystallization conditions were subsequently optimized. (B-D) Optimization of glycerol concentration,
in which 2 2 % gave the most ordered crystals. (E) Higher magnification image of a StarD4 crystal in
the optimal crystallization solution.

(F) W h e n

1 ug/ml cholesterol in 0 . 1 % ethanol (final

concentrations) w a s added to this solution, crystal morphology deteriorated.
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Subsequent studies of P C T P by others showed that lipid vesicles were necessary to load a
recombinant S T A R T protein with lipid ligand before crystallalization (Roderick et al., 2002).

T h e StarD4 X-ray crystal structure: Michael R o m a n o w s k i collected diffraction data from
optimized seleno-methionine StarD4 crystals and solved the X-ray crystal structure of StarD4
at 2.2 A resolution (Romanowski et al., 2002).

T h e StarD4 secondary structure (Figure

2.17a, 2.18a) consists of an N-terminal a-helix (aA, dark blue), 3 P-strands (J31-3, light blue),
2 shorter a -helixes (aB and a C , cyan), seven p-strands (J34-10, green, yellow, and orange),
and a long C-terminal a-helix (aD, red). T h e ten P-strands form an antiparallel twisted Psheet, making a U-shaped cavity with the C-terminal a-helix acting as a lid (Figure 2.17b).
T h e N-terminal 23 amino acids of m o u s e StarD4, 17 of which are absent in h u m a n StarD4
(see above), were disordered and not part of the crystal structure.

A m i n o acids highly

conserved a m o n g the whole S T A R T protein family (see Figure 2.8) tended to occur at
junctions in the secondary structure: Trp45 right before pi, Trp95 at the end of a C , and
Argl30 at the start of P6. T h e StarD4 structure is very similar to that solved for M L N 6 4
(Figure 2.17c, 2.18).

T h e root m e a n squared deviation ( R M S D ) for the two a-carbon

Figure 2.17: Overview the StarD4 X-ray crystal structure
(A-B) Ribbon diagrams of the StarD4 structure in two orientations, with the N-terminus blue and the
C-terminus red. (C) Backbone tracing of the previously solved M L N 6 4 S T A R T domain structure
(blue) (Tsujishita and Hurley, 2000) superimposed with StarD4 (yellow).
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•N
StarD4

MLN64-START

Figure 2.18: StarD4 and MLN64 have similar START structures
Despite sharing only 2 1 % amino acid identity, mouse StarD4 and the human M L N 6 4 S T A R T domain
have the same secondary structure elements and protein fold.

backbones was 1.7 A. The compact globular START domain fold has been classified as a
helix-grip fold, since the C-terminal a-helix is "gripped" by the folded P-sheet.
The key feature of the START structure is the cavity lined by predominantly
hydrophobic residues (Figure 2.19a), also called the lipid-binding tunnel since there are two
small openings accessible to the outside. Hydrophobic lipids bind in this cavity, as
phosphatidylcholine was co-crystallized with PCTP (Roderick et al., 2002). The volume of
the MLN64 cavity was previously reported as -1900 A3, but Michael Romanowski showed
that this calculation was in error and measured the correct cavity volumes for StarD4 and
MLN64 as 847 +/- 106 A3 and 848+/- 107 A3, respectively. This volume is consistent with
the binding of one cholesterol molecule, which is reported to occupy 741 A3 (Schroeder et
al., 1993). The cavities of StarD4 and MLN64 were similar overall in size and shape (Figure
2.19b), and cholesterol could be modeled into either cavity in two orientations (Figure
2.19c).
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Figure 2.19:

S8r33°

The StarD4 lipid binding cavity.

(A) Cavity volume plots for StarD4 (red)

and the M L N 6 4 S T A R T domain (blue), with cavity-lining

amino acid residues shown. (B) Superposition of the

StarD4 and M L N 6 4 cavities. (C) Cholesterol

(yellow) can be modeled in two orientations into the StarD4 cavity.

The residues lining the cavity are predominantly hydrophobic, though there are some
polar and even charged side chains. For example, at the C-terminus of StarD4 both p9 and
aD contribute side chains to the cavity, and these residues are more hydrophobic than those
that face the surface (Figure 2.20a-b). Indeed, the C-terminal aD appears to be an
amphipathic helix with a polar face and a non-polar face (Figure 2.20c), and amphipathic
helices in apolipoproteins have been strongly implicated in membrane binding and lipid

extraction (Saito et al., 2003). It is thought that ligand specificity arises from the amino acid
side chains that contribute atoms to the cavity lining. In this regard, we attempted

Figure 2.20:

Examples of hydrophobic amino acids lining the StarD4 lipid-binding cavity.

On p-sheet 8 (A) and a-helix D (B) of StarD4, the residues facing the cavity are generally more
hydrophobic than those facing the surface. (C) a-helix D appears to be an amphipathic helix with polar
and non-polar faces.
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comparisons of the cavity-lining residues in the structures of StarD4, M L N 6 4 , and P C T P
StarD4 agreed with the cholesterol-binding MLN64 at some positions, but with PCTP at
others, and many positions were divergent among the three. When these comparisons were
extended to other START domains with unknown ligands, the analysis was further
complicated (see arrows in Figure 2.8). No patterns were apparent in the conservation
cavity residues, except for four positions involving charged amino acid residues that
salt bridges.
In the short aC helix of StarD4, the charged side chains of Arg92 and Asp96 are

within 2.9A of each other and form a salt bridge (Figure 2.21a), while the correspondin
positions in MLN64 are uncharged side chains, Met307 and Asn311. On the START protein
multiple alignment, only StAR and MLN64 proteins have Met-Asn at this position, while

most others have the Arg-Asp salt bridge (Figure 2.21b). Therefore, these positions we
previously proposed as "likely lipid specificity determinants," with the Met-Asn pair

determining cholesterol binding while the Arg-Asp salt bridge could help bind other li

(Tsujishita and Hurley, 2000). We disagree with this prosposal, which predicts that the

StarD4 subfamily would not bind sterols. (Chapter 4 presents data that strongly implic

StarD4 and StarD5 in intracellular cholesterol metabolism.) The second difference is t
bridge in MLN64 between P5 and P6, Asp332 and Arg351. StAR has a corresponding Glu-

Arg salt bridge, while no other START domains have this charge pair (Figure 2.21b). Fiv

START domains have only the Arg, perhaps resulting in an unbalanced positive charge in
lipid binding pocket. In summary, StAR and MLN4 are the only START domains with a salt

bridge between P5 and p6, while most other START domains including the StarD4 subfamil

have a salt bridge in aC that is absent in StAR/MLN64. We describe experiments in Chap
4 that test the functional relevance of these salt bridges.
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aC
B

92
StarD4 Arg
StarD5 Arg
StarD6 Arg
StAR
Met
MLN64 Met
PCTP
Arg
StarD7 Arg
StarDIO Arg
GPBP
Arg
DLC-1 Gin
StarD8 Arg
StarD13 Arg
THEA
Arg
CACH
Arg
StarD9 Trp

96
Asp
Asp
Asp
Asn
Asn
Asp
Asp
Asp
Glu
Asp
Asp
Asp
Asp
Asp
Tyr

05
117
Tyr
Thr
Thr
Glu
Asp
Trp
Trp
Tyr
Gin
Tyr
Tyr
Tyr
His
His
Leu

P6
136
Ser
Val
Val
Arg
Arg
Arg
Arg
Arg
Ser
Arg
Arg
Arg
Ala
Val
Cys

Figure 2.21: Salt bridges in S T A R T domain lipid binding cavities.
(A) The StarD4 structure shows a salt bridge between two charged side chains on a-helix C. (B)
M L N 6 4 lacks charged residues these positions (corresponding to amino acids 92 and 96 in mouse
StarD4), but has a different salt between charged residues on p-sheets 5 and 6 (corresponding to
StarD4 117 and 136). These salt bridge positions were compared for all 15 S T A R T domains. Positive
residues are blue, negative are red, and neutral are black.

T h e C. elegans gene K 0 2 D 3 . 2 :

In our analysis of the S T A R T gene family in non-

m a m m a l i a n genomes (see Figure 1.8), w e noted one putative StarD4 subfamily m e m b e r ,
n a m e d K 0 2 D 3 . 2 , in the nematode w o r m C. elegans. A s annotated in W o r m B a s e (Harris et
al., 2003) by computer algorithms, the predicted K 0 2 D 3 . 2 protein had 60 extra amino acids
(positions 40-100) that failed to align with other S T A R T domains. This excess sequence w a s
encoded by predicted exon 2 and the start of exon 3. Since there were no c D N A sequences
for K 0 2 D 3 . 2 described in E S T databases, w e hypothesized that the splice junctions m a y have
been mis-annotated. P C R primers in exons 1,3,6, and 8 of the predicted gene (Figure 2.21a)
were used to amplify K 0 2 D 3 . 2 from a C. elegans c D N A library. T h e forward primer at the
end of predicted exon 3 gave the expected P C R products, but P C R products from the exon 1
forward primer were - 2 0 0 bp shorter than predicted (Figure 2.21b). Cloning and sequencing
of these P C R products confirmed that the annotated second and third exons were incorrect,
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A

C. elegans K02D3.2 S T A R T gene
Predicted
891 bp
Actual
711 bp

^
^
EE-EjB-iE3ZZHl>-i3Hi3-EHi]
•4-4R2
R1
m
FlHiMiHIr-SD-Q]

StarD4

18%

StarD5

23%

StarD6

17%

StAR

12%

MLN64

4%

PCR primers F/R
B

1/1

PCTP

14%

StarD7

15%

StarDIO

12%

GPBP

9%

DLC-1

10%

1/2 2/1 2/2

1000
500

Predicted: 891 688 529 326
Actual: -700 -500 ~550 -350

StarD8

8%

StarD13

11%

THEA2

9%

CACH

5%

StarD9

10%

Exonl->
intronl
<-exon2
CCGAAAAGgttagagg
tgtttcagAAAACCGG

Figure 2.22: c D N A cloning of the C. elegans StarD4 subfamily member K02D3.2.
(A) K02D3.2 was annotated as an 8 exon gene with an 891 bp ORF, but the encoded S T A R T domain
would be interrupted by non-START amino acid sequence. Forward (Fl and F2) and reverse (RI and
R2) P C R primers were used to clone the K02D3.2 cDNA. The actual gene encodes a typical S T A R T
domain via 7 exons and a 711 bp ORF. (B) RT-PCR results. (C) The correct splice junction between
exons 1 and 2 of K02D3.2. (D) K02D3.2 protein sequence was aligned with the 15 human S T A R T
domains, and the percent identity for each pairwise comparison is shown.

with 180 extra nucleotides not present in the actual m R N A . T h e correct exonic organization
and the exon 1 to exon 2 splice junction are s h o w n (Figure 2.21a, c).
K 0 2 D 3 . 2 appears to encode a 236 amino acid protein consisting entirely of a S T A R T
domain.

While additional exons upstream of the predictedfirstexon cannot be ruled out,

there is an in-frame stop codon at -42 from the A T G in genomic sequence. Since the forward
primer starting at +1 in the O R F amplified P C R products with either reverse primer, w e
attempted P C R s with two additional forward primers. O n e w a s at -68 to -44 from the A T G ,
and the other w a s splice leader 1 (SL1), a 22 nucleotide sequence that is trans-spliced to the
5' ends of 6 0 % of w o r m m R N A s (Ferguson et al., 1996). Both of these primers failed to
amplify K 0 2 D 3 . 2 product (data not shown), suggesting that its 5' U T R does not extend to
-68 from the A T G and is not modified with S L 1 .
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T h e predicted K 0 2 D 3 . 2 protein w a s

compared to the 15 mammalian S T A R T domains by multiple alignment, and it showed 2 3 %

identity to StarD5, 18% to StarD4, 17% to StarD6, and less identity to other START dom
(Figure 2.2 Id).

Expression of a K02D3.2 GFP reporter in C. elegans: Since worms have only one member
of the StarD4 subfamily, K02D3.2 may be functionally orthologous to one of the three
mammalian genes. K02D3.2 could thus show similar regulated gene expression to StarD4

(cholesterol-regulated), StarD5 (ER stress-regulated as described in Chapter 3), or St

(sperm-specific as described in Chapter 5). To test this hypothesis, we generated repo
worms expressing GFP under control of the K02D3.2 regulatory elements.
A 2.8 kB fragment of K02D3.2, spanning from the 5' flanking region (-2700 from the
ATG, just downstream of the preceding gene, tRNA KllE4.tl) into the first exon, was
cloned by PCR from genomic DNA. This fragment was subcloned as a GFP reporter, such

that a fusion protein between the first 38 amino acids of K02D3.2 and GFP was expresse

In collaboration with Elliot Perens and Shai Shaham, we microinjected this construct i
worms and generated lines carrying the reporter as an extrachromosomal array. The GFP

reporter showed strong expression in the hypodermal seam cells in embryos (starting at
fold stage, Figure 2.23c), early and late larvae (Figure 2.22a-b), but not adult worms

shown). Seam cells are present in pairs bilaterally along the sides and secrete cuticl
coats the worm. No other cell types showed detectable reporter expression.
We grew K02D3.2 reporter worms on media lacking cholesterol, which would induce

expression of a sterol-regulated gene like mammalian StarD4, or containing tunicamycin
which would induce expression of an ER-stress regulated gene like mammalian StarD5.
However, these treatments had no effect on reporter expression, which remained strong

embryonic and larval seam cells but absent in adults (data not shown). Since the K02D3
-66-

reporter was not expressed in male germ cells like StarD6, nor regulated like StarD4 or
StarD5, it does not appear to be a clear orthologue for any of the three mammalian genes.

DIC

G F P

Merge

B

Figure 2.23: Expression of a K02D3.2 promoter G F P reporter in C. elegans.
A G F P reporter driven by the K02D3.2 5' flanking region was microinjected into C. elegans and
maintained as an extrachromosomal array. W o r m s were imaged by differential interference contrast
(DIC) and fluorescence compound (GFP) microscopy. Adult worms showed no reporter expression.
(A) A n L1/L2 larva shows reporter expression along its lateral side in a string of about ten cells,
identified as seam cells based on morphology and location. Paired GFP-expressing seam cells were
present on the opposite side. (B) A close-up image of an L3/L4 larva, showing pairs of seam cells that
recently divided. (C) Seam cell reporter expression in an embryo at the three-fold stage.
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Chapter summary: This chapter describes the initial discovery of StarD4 using microarrays,

as StarD4 expression in mouse liver was down-regulated by cholesterol feeding. The X-

crystal structure of StarD4 was solved, showing a predominantly hydrophobic lipid-bind
cavity like other START domain structures. Analysis of genomic and cDNA sequence

databases identified the entire mammalian START gene family, including two close StarD
homologues, StarD5 and StarD6. StarD4 and StarD5 were widely expressed with highest

levels in the liver, but StarD5 was not cholesterol-regulated like StarD4. StarD6 expr

was limited to the testis. C. elegans has one StarD4 subfamily gene, but a K02D3.2 GFP

reporter did not show regulated expression like any of the three mammalian genes. Inst
this gene appeared specifically expressed in embryonic and larval seam cells

-68-

C h a p t e r 3: Regulation of S t a r D 4 a n d S t a r D 5 Expression

StarD4 and StarDS are not highly regulated during steroidogenesis: In steroidogenic ce
pituitary trophic hormones signal via c A M P and induce StAR expression to high levels
(Stocco, 2001). W h e n steroidogenesis was activated in M A - 1 0 mouse Leydig tumor cells by
a c A M P analog, StAR m R N A expression increased 45-fold as expected, while expression of
M L N 6 4 was unchanged (Figure 3.1). StarD4 was induced almost 3-fold, as was the S R E B P
target gene H M G R .

The StarD4 induction by c A M P was similar to the induction in these

cells by serum-free media (data not shown), a treatment well known to activate SREBPs.
Activation of S R E B P target genes in steroidogenesis likely reflects increased demand for de
novo cholesterol synthesis, since cholesterol is the substrate for steroid production. StarD5
expression was unchanged upon steroidogenic stimulation, while StarD6 expression was
undetectable in M A - 1 0 cells (see Figure 5.1). Therefore, StAR is highly regulated by
steroidogenic stimuli, but the StarD4 subfamily did not show similar regulation.

control
Figure 3.1:

+cAMP

START domain gene

regulation in steroidogenesis.
Mouse M A - 1 0 Leydig tumor cells were
cultured in control media or 8-bromocAMP

(n=3 wells each) to stimulate

steroid hormone production.

After 20

hours, R N A was extracted and analyzed
for gene expression by q P C R normalized
to cyclophilin. *P<0.05 vs.control.

Regulation of StarD4 expression by sterols: StarD4 and StarD5 are also widely expressed
in non-steroidogenic tissues, so w e decided to study their regulation in the mouse N I H 3T3
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fibroblasts.

When

these cells were cultured in 25-hydroxycholesterol and cholesterol

(sterols) to repress SREBP activation, StarD4 expression decreased 4.3-fold compared to the
control media (Figure 2.2a). 3T3 cells were also cultured in the drug mevinolin/lovastatin
(statin) to inhibit cholesterol synthesis, deplete cellular cholesterol, and activate SREBPs.
Statin treatment increased StarD4 expression 3.4-fold relative to control media and almost
15-fold relative to sterol-containing media. A similar pattern of gene regulation was
observed for several known SREBP-target genes such as HMGR (Figure 3.2b). This is
consistent with SREBP regulation of StarD4, while StarD5 and MLN64 showed no sterol
regulation in NIH 3T3 cells (Figure 3.2c). Since the initial microarray experiment revealed
StarD4 down-regulation by dietary cholesterol in mouse liver, we performed the same
treatments in mouse Hepa-1 hepatoma cells. Again, StarD4 and HMGR mRNA levels were
decreased by sterols and increased by statin, while StarD5 expression was not regulated
(Figure 3.3).
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ACLY

StarTM StarD5 MLN64

Figure 3.2: StarD4 is sterol-regulated in cultured 3T3 fibroblasts.

NIH 3T3 cells were cultured for 18-20 hours in three different media (n=4 wells each): contr
(DMEM with 10% lipoprotein-depleted serum), sterols (plus lug/mL 25-hydroxycholesterol and

lOug/mL cholesterol), or statin (plus lug/mL mevinolin/ lovastatin). RNA was extracted an an

for gene expression by qPCR normalized to cyclophilin. (A) Sterol-regulated expression of S
(B) Sterol-regulated expression of other SREBP-target genes HMG CoA reductase (HMGR) and
synthase (HMGS), the LDL receptor (LDLR), and ATP citrate lyase (ACLY). (C) Lack of sterol
regulation for StarD5 and MLN64. *P<0.05 vs. control.
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Figure 3.3: StarD4 is sterol-regulated in

• • sterols
cultured Hepa-1 hepatoma cells.
••••••••• • statin
*
X

Hepa-1 cells were cultured for 18-20 hours in the
three media described above (n=3 wells each).
RNA

was extracted and analyzed for gene

expression by q P C R normalized to cyclophilin.

|

0.5H

*P<0.05 vs. control.
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StarD4 is induced in n S R E B P transgenic mice: To confirm that StarD4 is a target for
S R E B P transactivation, w e used transgenic mice overexpressing active truncated nuclear
S R E B P s (nSREBPs). These mice show constitutive activation of target genes: SREBP-la
preferentially activates genes involved in fatty acid synthesis and metabolism, while SREBP2 preferentially activates genes involved in cholesterol metabolism (Horton et al., 2002). The
SREBP-1 target fatty acid binding protein 5 (FABP5) (Maxwell et al., 2003) was strongly
induced by nSREBP-la and only weakly induced by nSREBP-2. The control SREBP-2
target H M G C o A synthase ( H M G S ) was strongly induced by SREBP-2 and also induced by
SREBP-la. Additional control SREBP-1 and SREBP-2 targets also showed this expected
pattern of regulation (data not shown). Others have shown the same results by Northern blot
for panels of S R E B P targets, with cholesterol-related genes strongly upregulated by SREBP2 and SREBP-la, but lipogenesis-related genes only regulated by SREBP-la (AmemiyaKudo et al., 2002).

StarD4 expression was inducedfive-foldin nSREBP-2 transgenics

(PO.01) but only two-fold in nSREBP-la transgenics (P=NS) (Figure 3.4). This pattern of
regulation is consistent with SREBP-2 regulation, so StarD4 is an SREBP-2 target likely to
function in cholesterol metabolism.

71

FABP5

HMGS

StarD4

Figure 3.4: StarD4 expression is activated in nSREBP-2 transgenic mouse liver.
Expression of StarD4 and control genes was analyzed by qPCR in the livers nSREBP-la and nSREBP-2
transgenic male mice (Tg) (n=5 per group) and compared to non-transgenic littermate controls (cont).
Expression is normalized to (3-actin, and expression in the wild type littermate controls was set equal to
one for each gene. *P<0.05 vs. control, NS=not significant

Affinity-purified rabbit polyclonal antibodies against m o u s e StarD4 peptides were
also generated. O n e antibody w a s against amino acids 52-67, including P2 and the loops that
precede and follow it (Figure 3.5b), and this epitope w a s not conserved in StarD5, StarD6, or
other S T A R T domains. In a Western blot from lysates of h u m a n embryonic kidney ( H E K
293) cells, this antibody detected high molecular weight background bands but not a -25 k D
band representing StarD4. This probably indicates relatively low StarD4 expression in these
cells, since the epitope w a s 1 0 0 % conserved between m o u s e and h u m a n StarD4. W h e n the
cells were transfected with an expression plasmid for FLAG-tagged m o u s e StarD4, but not
for other S T A R T proteins like P C T P , a band w a s detected at the predicted size (Figure 3.5a).
A ~25 k D band w a s also detected in m o u s e liver extracts, and this band w a s clearly induced
in the livers of n S R E B P - 2 transgenic mice (Figure 3.5c). Therefore, S R E B P - 2 activation in
m o u s e liver results in increased StarD4 m R N A and protein.

-72-

Figure 3.5: Anti-StarD4 antibody shows
fffi

increased expression of the endogenous
protein in n S R E B P - 2 transgenic liver.

177114- I I
8164- = S _ 5037-

(A) The polyclonal anti-StarD4 antibody was
tested by Western blot on lysates from H E K
293 cells untransfected (control) or transfected
with StarD4 or P C T P expression plasmids.

26- —

Littermate
controls

20-

nSREBP-2
Transgenic

26.0.

(B) The location of the 52-67 antigenic peptide
(green) in P-sheet 2 of the StarD4 structure.
(C) Anti-StarD4 Western blot of liver protein
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T h e S t a r D 4 promoter:

from

control

and

nSREBP-2

transgenic mice.

StarD4 m R N A

expression is sterol-regulated like SREBP-target

genes, a n effect likely mediated b y a promoter S R E .

T o locate the StarD4 promoter b y

defining the 5' m R N A end, w e performed 5' R N A ligase-mediated rapid amplification o f
c D N A ends (5' R L M - R A C E ) on mouse liver R N A (Figure 3.6). Sequencing 25 R A C E
products revealed 8 initiation sites 104-149 bp upstream of the A T G codon, with the most
c o m m o n being -137A (10/25) and -107A (8/25). -137A was defined as the +1 site for
numbering the mouse promoter (Figure 3.7). 5' R L M - R A C E analysis of human liver StarD4

Figure 3.6: Analysis of mouse StarD4 by 5'
A
H
outer inner

M
^
5'^

.??•?• bp.
128 bp.

+
*

+

Rapid Amplification of c D N A ends ( R A C E ) .
(A) Design of RNA-ligase mediated 5' R A C E . A n

adapter I ??? I known S

5' I
inner outer

adaptor sequence was ligated to the 5' end of
decapped m R N A

and c D N A

was synthesized.

Primers in the adaptor and in the known StarD4
3

O/O

I/I 5/1 5/0

500 **
400
300
200

sequence were used for nested PCR. (B) Agarose gel
*fiB&
tfKSK*

of P C R products with forward/reverse primer
combinations (I=inner, 0=outer, 5=StarD4 5')- The

r-W;

outer (O/O) P C R was used as template for the
subsequent P C R reactions. The inner (I/I) R A C E

100
P C R products (arrow) were cloned and sequenced.
The control 5' primer gave the expected bands
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also revealed multiple initiation sites, with the most c o m m o n being -13IG from the end of
exon 1 (8/12 clones) (Figure 3.7). A s predicted, the human StarD4 gene differed from the
mouse gene, with its A T G start codon located in the second exon resulting in a protein 16
amino acids shorter at the N-terminus. There is no consensus T A T A box in either StarD4
promoter, consistent with multiple initiation sites in TATA-less genes (Ince and Scotto,
1995). Several other SREBP-target genes have TATA-less promoters and multiple intitiation
sites, including H M G R (Reynolds et al., 1984) and 7 D H C R (Kim et al., 2001).
Mouse sequence from -350 to -100 is 6 8 % identical to sequence from -281 to -10 in
the human promoter (Figure 3.7). This high sequence identity for non-coding D N A indicates
AC SF*E-^
mouse -350 GGATCCAATUCCTAC
AAACCCTTACGCTTAGGGAACTCTGTC-TGGCTCCGGJCCAGCCCAqACGC
* ******p# *
human
** *** * *
*********** ****** *|* ******* *|* *
GG
-281 CCAA CCAAT CCAAACCTGCAGGCAACCCCAGACATCCAGGGAACCCTGGCGCGGCTCGGGlCCAGCCCACjACCC
SRE-C TG GG
SRE-B GG
TG
mouse-287 ACGCGGAATCGGTCCA1CC-TCGGAGGCCAAT CGGCTCCCTTCACGCT G AGGCACCAGJCCAATC C C A G C G A A C
* * * * * *
********** *****
****
***** ** * * ******
* * * * G******
*
human
CC
CAATC C G A A C A A G C
TG sir
-208 ACGCGGAATCATTCCA JTTATCGGCCafc C AAT|CAGC CCTCCAC ACGC CCCGCGCCA
T
GC box
GGA
GTG
mouse
GGGCGGGGC
**
***
******
* * * * * SRE-D* * T G
human -135 G C A C G T T G T T C C G G C C A C C T C C T C T C A G C C C C C C C T C C C C G G A G C C C C C G G G A T C G G G C C A G G | *********
GGGCGGGGC
-215 acacgttactcccgcta|acaccccac1ggaagttcccctccgaggattcgggcaSRE-E ATC

mouse-152 G A A G G G C G T T G C T C G C C T T C A I C C A A G G C A G J C C T T C T G C C T T C T G A T T G G C T G T G G C T G G A A G G C G T C C C G C G
* ****
** ****** * *
* **
*******
********
r
human
-62 G G - G G G C T C G G C C C G C C T T G C C C T G A G G C G C T G G G T G C C T T C C A G T T G G C T G C G A

mouse -80 CCCATTGGCTGCTGCCAGCCGCGCTGGGCGGGCTGGAAAATATCTTGCTGAAACGCGCGGGGTTGCAG|G|A|GT
human -8
mouse
human

(io]]
c G G T A C G G G A C A *. A A G G A G G G C G G T C 3
5g|a|\ G T T G T T G A C C G C CD G A\ jajr qcjrCT
|g|gcga|g}
C TlAlj C T T T T C C T
CCAGCGC
sgSCTf]c A A G T T G G C T G C T

mouse + 65 G C C G A G T G G G G T C C A G C G G G G C C A A G G C G A A G C T G A G C A T C T C C T G G A C C T G C C C C C T G T A G A G G G G A G A G A G
human +20 G T C G C C T G C G C A T C G G C G G G C C G G G A G G C T G A G C A G T A C T G T T G A G A G C G G T C T G A G G T G C T T G G T A G C G C G C

R(int1) K
mouse +138 IatgIgc TGA CCC T G A G A G C C C G TGG t c a c a g a t t g g c a g . . G A A G A T C A A A C T G G A A G G A C T G T C T G A T G T T >
******* ************

human +93 cgtagctgcttccacgtccttgcttcacctcaggtaaag . . . agagaagta\atg\gaaggcctgtctgatgtt>
(jnt 1)

M

E

G

L

S

D

V

Figure 3.7: Alignment of m o u s e a n d h u m a n S t a r D 4 proximal promoter sequences.
Nucleotides conserved between the species are indicated b y (*). Promoter sequence is black, 5'
untranslated region is green, and StarD4 coding sequence in exons 1 and 2 is blue (interrupted by intron
1). Transcription start sites identified by 5 ' R A C E are s h o w n in boxes with the n u m b e r of R A C E clones
indicated (total n = 2 5 for m o u s e , n = 1 2 for h u m a n ) . T h e most c o m m o n start sites (red) were designated
+1 for promoter numbering.

Potential promoter elements are indicated: sterol regulatory elements

( S R E s ) and C C A A T and G C boxes. Sequences of the StarD4 reporter constructs (mouse -350/+34 and
h u m a n -291/-9) are between the (<) and (>) symbols. Site-directed mutations are indicated in violet.
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the presence of conserved gene regulatory elements. There are three conserved C C A A T
boxes and two GC boxes, potential binding sites for NF-Y and Spl, respectively. There

also three conserved sequences resembling SREs (called A, B, and C) at -300, -279, an
in the mouse promoter. Two additional potential SREs (D and E) at mouse -199 and -132
not conserved in the human promoter.
In addition to the StarD4 proximal promoter, a more distal region was also conserved
at -1.1 kB in mouse and -1.8 kb in human StarD4. In this stretch of ~100bp, there was

80% interspecies nucleotide identity (Figure 3.8). No SREs were apparent by inspectio

though TRANSFAC analysis (Matys et al., 2003) yielded approximately 100 other potenti

factor-binding sites. This conserved upstream sequence may represent an enhancer eleme

-1221 TTGCT-TTAGTGACATTCCACCTCGACAGAGAGAGTGGTTTCCAATGACCCTAACTTCAT mouse
..j 398 [rTGClJGJTTAGTJA^CATTCCACJTJll^^T^GAGl
fTGG^TCCAAT|^CCC|AkACTTCAT| human
TCTAACTAAGAAACCACAGGGCAAAAGATGAAGAACAGAGGGGAAAGAAAGAA -1110
TCTAACfcJAAGAA^A
iffil]GGCAj^GATGAAGAACft(A^A^^
-1793

mouse
human

Figure 3.8: A potential enhancer region conserved between mouse and human StarD4.
This 5' non-coding sequence was conserved upstream of mouse and human StarD4, but not present
elsewhere in the genome.

Identification of the StarD4 promoter S R E by reporter transfection studies: To identify a
functional SRE, luciferase reporters driven by the StarD4 promoter were cloned and

transfected into NIH 3T3 cells. Mouse StarD4 -350/+34 reporter activity decreased 9-f
upon culture in cholesterol and 25-hydroxycholesterol (sterols) and increased 3-fold

culture in statin (Figure 3.9a). The positive control SREx3 reporter was similarly reg
while the pGL3 empty vector was unregulated. Furthermore, the mouse StarD4 reporter

showed dose dependent activity in response to both oxysterol (Figure 3.9b) and statin

3.9c). The -350/+34 mouse reporter contains all elements necessary for sterol regulati

it showed similar activity and sterol regulation to longer reporter constructs (Figure
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Figure 3.9: Regulation of the m o u s e S t a r D 4 luciferase reporter b y sterol a n d statin treatment.
T h e m o u s e StarD4 -350/+34 luciferase reporter w a s transfected in N I H 3 T 3 cells, w h i c h w e r e then
cultured in lipoprotein-deficient m e d i a with sterols or statin as described a b o v e for 18-20 hours. ( A )
T h e m o u s e StarD4 reporter w a s regulated like the positive control SRE-regulated reporter ( S R E x 3 ) ,
while the e m p t y luciferase vector ( p G L 3 ) w a s unregulated.

T h e m o u s e S t a r D 4 reporter activity

s h o w e d dose dependent repression b y oxysterol ( B ) a n d activation b y statin ( C ) . Luciferase values
w e r e normalized to p-galactosidase and control values were set equal to one. * P < 0 . 0 5 vs. control.

The two constructs that spanned to -1335 included the putative enhancer element, but

to show higher activity than shorter -350 constructs with only the proximal promoter.
human StarD4 reporter was regulated similarly to the mouse reporter, though its fold

regulation was consistently less (only ~10-fold rather than ~20-fold comparing sterol
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Figure 3.10: S t a r D 4 luciferase reporters with longer p r o m o t e r s s h o w similar regulation.
T h e indicated lengths o f m o u s e StarD4 promoter w e r e used to generate luciferase reporters. All five,
including the minimal -350/+34 reporter, s h o w e d significant activity differences in sterol- versus statintreated N I H 3 T 3 cells. Luciferase activity w a s normalized to P-gal. * P < 0 . 0 5 , statin vs. sterols.
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statin, see Figure 3.11a-b). T w o different length of human promoter (-521/-8 and -282/-8)
reporters also showed no differences in activity or regulation (data not shown).
W e used site-directed mutagenesis to introduce point mutations into the potential
S R E s of the mouse and human StarD4 reporters (see Figure 3.7).

S R E - A or SRE-C

mutations had little effect on fold sterol regulation, while SRE-B mutations markedly
decreased sterol regulation in both species (Figure 3.1 la-b). In separate experiments with the
mouse StarD4 reporter, overall regulation was less than typically observed, but mutations in
potential S R E - D or SRE-E also did not affect sterol regulation (Figure 3.11c).
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i
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for each reporter was set equal to one. *P<0.05,
mutant vs. wild type (statin-treated).

Since S R E - B

appears to b e the functional element, w e studied S R E - B

mutant

reporters in m o r e detail. W h e n S R E B P cleavage w a s repressed b y sterols, wild type a n d
S R E - B m u t a n t reporters h a d the s a m e absolute activities (Figure 3.12a-b). H o w e v e r , w h e n
cells w e r e cultured in the control m e d i a or in statin, the wild type reporters w e r e strongly
activated while the S R E - B mutant reporters w e r e only w e a k l y activated. B o t h the m o u s e a n d
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h u m a n S R E - B mutant reporters showed residual regulation, with activity 4- to 5-fold higher
in statin compared to sterols. However, in other experiments that compared sterol-containing
to control media, there was no activation of SRE-B mutant reporters in the absence of sterols
(Figure 3.12c).
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Figure 3.12: StarD4 S R E - B mutant reporters show defective sterol-regulation.
Mouse and human wild type or SRE-B mutant luciferase reporters were transfected into NIH 3T3 cells.
(A, B) Cells were cultured in control medium, sterols, or statin as before. Luciferase activity was
normalized to p-gal, and fold activation compared to sterol-treated cells is indicated. (C) In another
experiment, cells were cultured in control medium or sterols. Luciferase activity was normalized to Pgal, and wild type activity in sterols was set equal to one. *P<0.05 vs. sterol-treated.

There were three possibilities for the residual activation SRE-B mutant reporters by
statin treatment: (1) the SRE-B mutation may not have completely eliminated SREBP
binding, (2) sequences in the pGL3 reporter vector may be SREBP-regulated, and (3) other
potential StarD4 SREs may function in the absence of SRE-B. Consistent with the second
possibility, it was reported that the pGL3 vector contains an E-box in its cloning polylinker
that is SREBP-regulated in HepG2 cells (Annicotte et al., 2001). This E-box is unlikely to
function in NIH 3T3 cells, as the empty pGL3 vector was not sterol-regulated (see Figure
3.8a). To rule out this artifact, we re-cloned the mouse wild type and SRE-B reporters using
different restriction sites, thus eliminating the vector E-box. This modification did not affect
regulation, as the wild type modified reporter was regulated 21-fold (statin compared to
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sterols) and the SRE-B mutant was still regulated 4-fold (Figure 3.13).

To test the third

possibility that other S R E s function in the absence of SRE-B, w e generated double mutants
of the modified mouse StarD4 reporter, each with mutations in SRE-B and a second potential
SRE. Upon transfection, all the double mutants showed less regulation (1.3- to 2.4-fold) than
the SRE-B alone mutant (4.4-fold, Figure 3.13). This result is difficult to interpret, but it
implies that other SREs may have low levels of function. Nonetheless, most of the sterol
regulation of mouse and human StarD4 is mediated by SRE-B.
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Figure 3.13: Additional mutagenesis studies of the mouse StarD4 promoter.
Mouse StarD4 -350/+34 was re-cloned into the Sad and Hindlll sites of the pGL3 reporter, thus
eliminating the putative SREBP-binding E-box in the vector polylinker. This reporter showed similar
activity and sterol-regulation to the previous BamHl/Hindlll reporter. Mutations were generated in
various elements of the SacIIHindlll reporter as indicated. Transfected cells were cultured in sterols or
statin as before, and luciferase activity was normalized to P-gal. *P<0.05 sterols vs. statin.

We also generated mutations in two CCAAT boxes near SRE-B (see Figure 3.7),
since these elements bind NF-Y and cooperate with SREBPs to activate transcription
(Edwards et al., 2000). When the CCAAT box located 9 bp downstream of SRE-B was
mutated, the reporter was virtually unregulated, with low activity even in the absence of
sterols (Figure 3.13). Mutations in another CCAAT box after SRE-C, 40 bp from SRE-B,
also blunted sterol regulation. Similar results were obtained with both CCAAT box
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mutations in the human StarD4 reporter (data not shown).

It appears that these C C A A T

boxes, in addition to SRE-B, are necessary for maximally activated transcription from the
StarD4 promoter.

StarD4 and StarDS are not LXR target genes: Cholesterol can regulate gene expression v
the S R E B P and L X R transcription factors, so w e also assayed for L X R regulation of StarD4
and StarD5.

W h e n mice were treated with the synthetic L X R agonist T0901317, liver

expression of the known LXR-target gene A B C G 5 was induced almost 3-fold, while StarD4
and StarD5 m R N A levels were unchanged (Figure 3.14a). By visual inspection, these mice
developed the expected hepatic steatosis, indicating L X R activation of SREBP-lc and fatty
acid synthesis (Lund et al., 2003). Since StarD4 was not induced, it appears to be a poor
target for SREBP-1 in mouse liver, consistent with data from the SREBP-la transgenic mice
(see Figure 3.4).
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Figure 3.14: StarD4 and StarDS are not L X R target genes.
(A) Mice were treated by gavage with the synthetic L X R agonist T0901317 or vehicle control (n=5 per
group) for two days, and liver R N A was extracted. (B) R A W cells were treated for 18-20 hours with
either 25-hydroxycholesterol or T090131 (n=3 per group) before R N A extraction. Gene expression was
assayed by qPCR normalized to cyclophilin. A B C G 5 and A B C A 1 were control L X R targets, while
H M G CoA synthase ( H M G S ) was a control SREBP-2 target. *P<0.05 vs. control.
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W e also treated the R A W

mouse macrophage cell line with L X R ligands.

As

expected, ABCA1 mRNA levels were highly regulated (Costet et al., 2000), 6-fold by the
weak LXR agonist 25-hydroxycholesterol and 30-fold by the strong agonist T0901317

(Figure 3.14b). It is also notable that PCTP expression was not activated by LXR agoni

these cells (data not shown), since this gene has been proposed to facilitate ABCA1-me
lipid efflux (Baez et al., 2002). Expression of StarD4 was decreased four-fold by 25hydroxycholesterol, consistent with its sterol regulation in NIH 3T3 and Hepa-1 cells

Figures 3.2, 3.3). LXR agonist caused a two-fold increase in StarD4, but this regulati
also observed for another SREBP-2 target, HMGS. Conversely, StarD5 was unregulated by

oxysterol or synthetic LXR ligands in RAW cells. Similar results were observed in Hepa

cells (data not shown). Therefore, StarD5 is not an LXR target gene, while there may b
weak LXR activation of StarD4 consistent with SREBP-mediated effects.

StarDS activation in cholesterol-loaded macrophages under ER stress: In addition to

SREBPs and LXRs, a third transcriptional pathway can be activated by cholesterol. Taba
and coworkers recently demonstrated induction of various components of the ER stress

response in free cholesterol-loaded macrophages (Feng et al., 2003a). To confirm these
findings, we used a previously described RT-PCR assay for splicing of the Xbpl mRNA

(Calfon et al., 2002), an effect mediated by IRE-1 in response to ER stress (Yoshida et

2001a). As a control, treatment of NIH-3T3 cells with the ER stressor tunicamycin trig
Xbpl processing (Figure 3.15a-b). In cDNA provided by Ira Tabas, processed Xbpl

appeared in free cholesterol-loaded macrophage, but not control or cholesterol-ester l
macrophages, confirming ER stress activation (Figure 3.15c).
This macrophage cDNA was also assayed for expression of StarD4, StarD5, and the
control ER-stress induced genes CHOP and BiP. Free cholesterol-loading activated
-81-
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Figure 3.15: A n X b p l splicing assay shows E R stress in free cholesterol-loaded macrophages.
( A ) N I H 3 T 3 cells were cultured for 18 hours in control media or 2.5 ug/ml tunicamycin to induce E R
stress. X b p l was R T - P C R amplified from these cells, giving a 601bp product in control cells but a
smaller 575 bp product after E R stress-induced splicing of a non-traditional 26 bp intron. (B) PstI digest
of these P C R products cleaves the unprocessed form (Xbplun) into smaller 312 and 289 bp fragments,
while the processed (Xbplpr) form lacks the PstI site. (C) c D N A from control, cholesterol ester ( C E )
loaded, and free cholesterol (FC) loaded macrophage w a s likewise assayed for X b p l splicing by P C R
and PstI digest.

expression of CHOP 50-fold and BiP 4.6-fold, while there was no significant effect of

cholesterol ester-loading (Figure 3.16). The difference in fold regulation likely refl

high baseline expression of BiP, which has a housekeeping role in ER protein folding,
the pro-apoptotic transcription factor CHOP is not expressed in unstressed cells (Ma

2002). StarD4 expression was decreased 3-fold in response to loading of free cholester
esters, consistent with sterol regulation via SREBPs. StarD5 expression, however, was

regulated similarly to BiP, with an almost 4-fold increase in free cholesterol-loaded
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for each gene. *P<0.05 vs. control.

macrophages.

Since StarD5 was not activated by L X R agonists (see Figure 3.14), this

suggests activation by the ER stress response.

StarDS activation in ER stressed NIH-3T3 cells: To test whether StarD5 expression is
indeed activated by E R stress, w e treated N I H 3T3 cells with tunicamycin to induce the UPR.
Tunicamycin activated C H O P (28-fold) and BiP (10-fold) as expected, while StarD5 was
activated 8-fold and the negative control M L N 6 4 was not regulated (Figure 3.17a). Northern
blots of these samples showed both StarD5 m R N A s were activated by tunicamycin (Figure
3.17b). W e also tested three additional agents that stress the E R by different mechanisms, as

Cont

NIH-3T3 cells
control
tunicamycin

Tuni

28S-

18S -

at Jis
CHOP

BiP

(3-actin

StarD5 M L N 6 4

Figure 3.17: StarD5 expression is increased in NIH 3T3 cells by tunicamycin treatment.
NIH 3T3 cells were cultured 18-20 hours in control media or 2.5 ng/ml tunicamycin (n=3 wells each) to
induce ER stress, and R N A was extracted. (A) qPCR analysis of gene expression, normalized to
cyclophilin. *P<0.05 vs. control. (B) Northern blot probed for StarD5 or p-actin control.

described in the introduction. All four agents activated expression of BiP (9- to 17-fold) and
StarD5 (~6-fold), confirming that ER stress activates StarD5 expression (Figure 3.18a).
StarD4 expression showed small and inconsistent changes in response to ER stressors (only
-50% differences), perhaps due to effects on SREBP trafficking from the ER. To show that
StarD5 expression was specific for ER stress as opposed to other stresses, cells were heat
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shocked at 42°C.

Heat shock protein 70 (Hsp70) w a s activated as expected, while BiP,

StarD5, and StarD4 were not activated. Heat shock actually caused a 3-fold decrease in
expression of StarD5 and BiP, again showing coordinate regulation of these genes. These
results indicate that StarD5 expression is specifically induced by the ER stress response.
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Figure 3.18: StarD5 is induced by E R stressors but not heat shock.

(A) NIH 3T3 cells were cultured in control media or ER stressed with 2.5ug/ml tunicamycin,

thasigargin, lOug/ml brefeldinA, or 2mM DTT (n=3 wells each). (B) NIH 3T3 cells were cultur

or 42°C to induce heat shock. Gene expressrision was assayed by qPCR and normalized to cyc
*P<0.05 vs. control, NS=not significant.

StarDS promoter reporter studies: T h e StarD5 promoter sequence from m o u s e and h u m a n
was compared. Regions 400 bp upstream of the ATG translation start codon were conserved
-50% between species (Figure 3.19). A 100 bp region between -153 and -54 in mouse was
66% identical (between arrows), and contained three conserved promoter elements: two
CCAAT boxes and one GC box. ER stress response elements (ERSE) have been identified
in the promoters of BiP and other ER stress regulated genes (Roy and Lee, 1999), but there
were no consensus ERSEs in the StarD5 proximal promoter.
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Figure 3.19: The StarD5 proximal promoter lacks a consensus ER stress response element.
Alignment of mouse and human StarD5 sequence around the A T G translation start codon (+1). The
overall identity of upstream non-coding sequence was - 5 0 % between the species. The sequence between
the two arrows was - 6 6 % identical. While upstream D N A included conserved C C A A T and G C boxes,
there was no consensus ERSE.

Despite the absence of a consensus E R S E , the StarD5 proximal promoter could
contain novel elements responsive to ER stress. We cloned a luciferase reporter driven by
mouse StarD5 sequence from -400 to -1 from the ATG. For comparison, we also transfected
two ER stress activated reporters, one driven by the BiP promoter and the other with five
synthetic ATF6 consensus sites (5xATF6) (Lee et al., 2002). Upon treatment of cells with
tunicamycin, the positive control reporters were activated, 5xATF6 by 16-fold and BiP by
2.5-fold, while the StarD5 reporter was actually repressed -30% (Figure 3.20). The mouse
StarD4 -350/+34 promoter was also slightly repressed by tunicamycin, as was a shorter
StarD5 promoter -200/-1 reporter (data not shown). The failure of tunicamycin to activate
these StarD5 promoter reporters, despite robust activation of the endogenous StarD5 gene in
the same cell type (see Figure 3.16), suggests that the elements responsible for ER stress
activation do not lie in the proximal 400 bp upstream of the ATG. The ER stress responsive
elements in the StarD5 gene remain to be identified.
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luciferase reporter is not activated by E R stress.
NIH 3T3 cells were transfected with luciferase (Luc)
reporters driven by synthetic ATF6 sites (5xATF6),
the BiP promoter, or the StarD5 promoter. After
transfection, cells were cultured in control media or
ER stressed with l.Opg/ml tunicamycin. Luciferase
activity was normalized to P-gal, and control was set
equal to one for each reporter. *P<0.05 vs. control.

Chapter S u m m a r y : This chapter presents data that the widely expressed StarD4 and StarD5
genes are not regulated by steroidogenic stimulation like StAR, nor by LXRs which stimulate
reverse cholesterol transport. StarD4 was shown to be sterol-regulated via SREBP-2, and a
functional SRE was identified in the StarD4 promoter. StarD5 was not sterol-regulated, but
it was activated by mutliple ER stressors, including free cholesterol-loading in macrophages,
though the responsible promoter elements were not identified.
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C h a p t e r 4: S t a r D 4 a n d S t a r D S in Intracellular Cholesterol M e t a b o l i s m

Localization of StarD4 and StarDS throughout cells: If StarD4 subfamily proteins play
roles in intracellular sterol transport, then subcellular localization may provide clues to
function. StarD4, StarD5, and StarD6 consist entirely of S T A R T domains and lack other
domains that could mediate localization. Since the isolated S T A R T domains N-62 StAR
(Arakane et al., 1996), M L N 6 4 - S T A R T (Zhang et al., 2002b), and full length P C T P (de
Brouwer et al., 2002) are found throughout the cell cytosol and nucleus, w e hypothesized that
StarD4 subfamily members would share this distribution. P R O S I T E (Falquet et al., 2002)
and other protein sequence searches failed to identify any consensus localization signals in
the StarD4 subfamily.
Mouse StarD4 was cloned as a fusion with enhanced green fluorescent protein
(EGFP), such that the E G F P moiety was at the StarD4 N-terminus (rather than at the Cterminal a-helix lid). In transiently transfected H E K 293 or N I H 3T3 cells, the distribution
of EGFP-mStarD4 was throughout the cytosol and nucleus, indistinguishable from E G F P
alone (Figure 4.1).

Some lipid binding proteins change their subcellular localization in

E G F P alone

EGFP-StarD4

Figure 4.1: A GFP-StarD4 fusion
protein localizes throughout cells.
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cloned. U p o n transient transfection of
H E K 293 (B) or N I H 3T3 cells (D), the
EGFP-StarD4

fusion

protein

was

NIH
distributed evenly throughout the cell.

3T3
The same distribution was observed for
E G F P alone in these cells (A,C).
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response to specific stimuli, as described in the introduction for P C T P and O S B P (de
Brouwer et al., 2002; Lehto and Olkkonen, 2003). However, treatment of transfected cells
with 25-hydroxycholesterol, lovastatin, or tunicamycin did not change the distribution of
EGFP-StarD4 (data not shown).
F L A G epitope-tagged expression plasmids were cloned for six mouse

START

domains: the isolated S T A R T domains of StAR and M L N 6 4 , and the full-length proteins for
PCTP, StarD4, StarD5, and StarD6. Upon transient transfection in H E K 293 cells and antiF L A G immunofluorescence, StarD6 protein was barely detectable but the otherfiveF L A G S T A R T proteins showed similar localization. All were found throughout the cytosol and
nucleus, and there was no punctuate staining to suggest a specific subcellular compartment.
More detailed microscopy, and the response of these proteins to various treatments, has not
been performed. However, the patterns observed were consistent with the prediction that
isolated S T A R T domains distribute throughout the cell.

StAR

PCTP

MLN64

StarD4

StarD5

StarD6

Figure 4.2: FLAG-tagged StarD4 and StarD5 proteins localize throughout cells
H E K 293 cells were transfected with N-terminal FLAG-tagged expression constructs for the six
indicated mouse S T A R T domains. StAR and M L N 6 4 were truncated proteins lacking the N-terminal
domains that mediate localization of the full-length proteins. B y anti-FLAG immunofluorescence,
very little FLAG-StarD6 was detected, but the other five were similarly distributed throughout cells.
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Cell culture assay for StAR-like steroidogenic activity:

Several studies of StAR and

MLN64 have used a cell culture steroidogenesis assay, in which non-steroidogenic COS-1

cells are transfected with an expression plasmid for the P450scc enzyme and its cofact

(Huang and Miller, 2001). The mitochondrial P450scc enzyme converts cholesterol into th

first steroid pregnenolone, which can be assayed in the cell culture media (Sugawara e

1995a). However, it is more convenient to assay for progesterone, which is generated fr
pregnenolone by 3p-hydroxysteroid dehydrogenase (3P-HSD), so an expression plasmid for
this enzyme is often co-transfected (Zhang et al., 2002b). Compared to the basal
steroidogenesis by the two transfected enzymes, co-transfection of StAR increases

progesterone production, presumably by delivering the substrate cholesterol to P450scc
(Sugawara et al., 1995a). The isolated START domains of StAR and MLN64 are similarly

active in this assay (Bose et al., 2000). Addition of the oxysterol 22(R)-hydroxycholes
gives high levels of steroidogenesis even in the absence of StAR, apparently reaching
P450scc without need for an intracellular transport protein.
The FLAG-START expression constructs described earlier were tested in this

steroidogenesis assay. 22(R)-hydroxycholesterol caused a 13-fold increase in progester

production, while co-transfection of StAR in the absence of oxysterol resulted in an 1

increase. StarD4 showed StAR-like activity, increasing progesterone production 4-fold
(Figure 4.3a). Further experiments tested all six FLAG-STARTs. As expected, the StAR
and MLN64 START domains stimulated steroidogenesis, and PCTP was an inactive negative

control. StarD4 and StarD5 both increased steroidogenesis 2- to 3-fold, but not to th

extent as StAR and MLN64, which gave 5- to 7-fold increases (Figure 4.3b). In repeated

experiments, StarD4 and StarD5 consistently showed activity approximately one third of

StAR activity. This disparity may reflect different protein expression levels, even th
equal amounts of DNA were transfected. On anti-FLAG Western blots, transfected StAR,
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P C T P , M L N 6 4 , and StarD5 were expressed to similar levels, while StarD4 showed m u c h less
expression (Figure 4.3c). Consistent with the immunofluorescence (see Figure 4.2), StarD6
protein expression w a s undetectable by Western, so its steroidogenic activity could not be
determined. L o w e r StarD4 protein expression m a y account for its lower activity, but further
dose response studies are necessary to address the relationship between protein expression
levels and activity. Preliminary studies showed that decreasing the amount of transfected
S t A R by 5-fold did not affect its level of activity (data not shown).

While specific

conclusions regarding their relative activities cannot be reached, it is clear that StAR,
M L N 6 4 , StarD4, and StarD5 S T A R T domains stimulated steroidogenesis in this assay.
Therefore, StarD4 and StarD5 can function in intracellular cholesterol metabolism.
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Figure 4.3: StarD4 and StarD5 have StAR-like activity in the cell culture steroidogenesis assay
(A) C O S - 1 cells were co-transfected with expression plasmids for two steroidogenic enzymes, P450scc
and 3 P - H S D , and the indicated FLAG-tagged S T A R T domain (n=3 wells each). Control cells were
transfected with empty F L A G expression vector rather than S T A R T domains. After 48 hours, media
progesterone levels were measured by enzyme linked immunosorbent assay (ELISA). Both S t A R and
StarD4 significantly stimulated progesterone production over control levels. The positive control was
treatment of F L A G vector transfected cells with lug/ul 22(R)-hydroxycholesterol ( 2 2 R H C ) , a StARindependent substrate for steroidogenesis. (B) The same assay performed with additional S T A R T
domains. Progesterone production in control F L A G vector transfected cells was set equal to one.
*P<0.05 vs. control. (C) Anti-FLAG Western blot of F L A G - S T A R T transfected C O S - 1 cells.
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Site-directed mutations in cavity salt bridges o f StarD4 a n d M L N 6 4 : A s described earlier,
S t A R and M L N 6 4 have a unique salt bridge between charged amino acids in 05 and 06,
rather than one in a C

like the StarD4 subfamily and other S T A R T

domains.

These

differences were proposed as lipid specificity determinants (Tsujishita and Hurley, 2000), so
w e performed site-directed mutagenesis of the F L A G - M L N 6 4 and F L A G - S t a r D 4 expression
plasmids.

W h e n two charged residues in M L N 6 4 were mutated to the corresponding

uncharged residues in StarD4 (Asp332Tyr and Arg351Ser), the B5/p6 salt bridge was
eliminated, yet this protein with neither salt bridge (none) had wild type steroidogenic
activity (Figure 4.4a).

W h e n two more residues were mutated to agree with StarD4

(Met307Arg and Gln311Asp), such that the a C salt bridge w a s present (switch), activity
decreased 2 5 % but this difference w a s not significant.

However, activity w a s decreased

- 5 0 % in M L N 6 4 mutants with both salt bridges present (both) or with other combinations of
substitutions (A-D, not significant for mutant B ) . Wild type M L N 6 4 protein and its various
mutants were expressed to similar levels based on an anti-FLAG Western blot (Figure 4.4b).

StarD4

wt swtich none both A
B
C D
a3/a3: 0/0 +/- 0/0 +/- 0/0 0/0 +/- +/P5/p6: -/+ 0/0 0/0 -/+ -/0 0/+ -/0 0/+

B

wt switch none both A
B C D
a3/a3: +/- 0/0 0/0 +/- 0/0 0/0 +/- +/PS/06: 0/0 -/+ 0/0 -/+ -/0 0/+ -/0 0/+

Figure 4.4: Steroidogenic activities of StarD4 and M L N 6 4 salt bridge mutant proteins
The COS-1 steroidogenesis assay was performed as before, by co-transfecting expression plasmids for
P450scc, 3P-HSD, and a FLAG-tagged S T A R T domain (n=2 wells each), then assaying for media
progesterone after 48 hours.

M L N 6 4 and StarD4 mutants were generated with amino acid

substitutions affecting the charged amino acids (+/-) that form salt bridges in a-helix 3 or between Pstrands 5 and 6.

(A) Progesterone production by wild type M L N 6 4 and seven mutants. (B) Anti-

F L A G Western blot showing similar expression levels for these M L N 6 4 proteins. (C) Progesterone
production by the corresponding StarD4 wild type and mutant proteins. *P<0.05 vs. wild type.
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The corresponding set of StarD4 mutants was also generated: Arg92Met and
Asp96Gln eliminated the aC salt bridge, while Tyrll7Asp and Serl36Arg added the 05/06

salt bridge. As with MLN64, the mutant with neither salt bridge (none) was fully active
while the mutant with both was only 50% active relative to wild type (Figure 4.5c).

However, StarD4 with the 05/06 salt bridge alone (switch) was also only 50% active, wh
mutant B with an unbalanced positive charge on 06 was fully active. Since the baseline

progesterone production in the absence of START domains was typically 10-20 ng/ml, som
of the StarD4 mutants were essentially inactive.
Several conclusions can be drawn based on the behavior of these StarD4 and MLN64

mutants. The salt bridges are not essential for function, since mutants with neither s
(none) have the same steroidogenic activities as wild type proteins. The MLN64 mutant

lacking the 05/06 salt bridge but with the StarD4 aC salt bridge (switch) retained high

activity, inconsistent with the hypothesis that the salt bridges determine differentia

binding. The presence of both salt bridges in the same protein (both) reduced activity

perhaps due to excess charge in the predominantly hydrophobic cavity or altered protei
folding. The unbalanced negative change on 05 in mutants A and C likewise decreased

activity. However, an unbalanced positive change on 06 did not significantly affect ac

in the absence of the aC salt bridge (mutant B), while activity was decreased in the p
of this salt bridge (mutant D). Notably, five START domains (PCTP, StarD7, StarD8,

StarD 10, and StarD 13) have the salt bridge configuration of mutant D (see Figure 2.21
this unbalanced positive charge can apparently be tolerated by the START structure.

Tom20 fusion proteins localizing START proteins to mitochondria: Miller and coworkers
localized StAR to different parts of the mitochondria (OMM, IMM, intermembrane space,

and matrix) by making fusions to various mitochondrial proteins (Bose et al., 2002). On
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the fusion to the C-terminus of T o m 2 0 , which places S t A R on the cytosolic side of the outer
mitochondrial m e m b r a n e , w a s functional in steroidogenesis. Furthermore, T o m - S t A R gave
similar steroidogenesis to 22(R)-hydroxycholesterol, with twice the activity of full-length or
N - 6 2 StAR. They conclude that S t A R functions at the outer mitochondrial m e m b r a n e , and
that artificial localization of the protein there results in m a x i m u m activity.
We

generated F L A G - T o m - S T A R T

chimeras by cloning m o u s e T o m 2 0 into the

F L A G - S T A R T expression plasmids for StAR, M L N 6 4 , StarD4, StarD5, and P C T P . F L A G T o m - S t A R w a s active as expected, though it w a s less active than F L A G - S t A R (Figure 4.5a).
This difference from the previous report m a y be due to the F L A G epitope tag or different
protein expression levels.

Indeed, anti-FLAG Western blots showed that T o m - S T A R T

chimeras were expressed at m u c h lower levels than S T A R T alone proteins, while expression
w a s similar a m o n g the various T o m - S T A R T chimeras (Figure 4.5b).

T o m - P C T P did not

have significant steroidogenic activity, while the T o m fusions of StAR, M L N 6 4 , StarD4, and
StarD5 all increased steroidogenesis 3.4- to 4.0-fold relative to T o m 2 0 alone (Figure 4.5a).

Figure 4.5: Steroidogenic activities of
Tom20-START fusion proteins.
FLAG-tagged

fusions

of

the

mitochondrial outer membrane protein
Tom20

and

START

domains

were

generated. (A) These were tested in the
COS-1 steroidogenesis assay as before.
The F L A G empty and StAR plasmids
were controls. The fold difference from
the Tom alone control is indicated for
each Tom-START.
alone.

(B)

*P<0.05 vs Tom

Anti-FLAG Western blot

shows similar expression levels for the
five Tom-STARTs, but lower expression
37.4-

than S T A R T alone proteins like StAR.

kD
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Therefore, in contrast to the F L A G - S T A R T results, in which S t A R and M L N 6 4 appeared
more active than StarD4 and StarD5, these four FLAG-Tom-START fusions had nearly the
same steroidogenic activities.

Effects of START domain overexpression on SREBP activity: The steroidogenesis assay is
thought to measure cholesterol transfer to mitochondria, so we also sought to assay
cholesterol transfer to the ER. SREBP processing is regulated by changes in ER cholesterol,
so we used a luciferase reporter driven by three consensus SREs (SREx3) as an indirect
measure. Activity of the SREx3 reporter in HEK 293 cells was decreased -70% by cotransfection of the StAR or MLN64 START domains, compared to empty FLAG vector
(Figure 4.6a). This repression of SRE activity was significant and similar to the effect of
exogenous 25-hydroxycholesterol. StarD4 and StarD5 decreased SRE activity -50%, while
PCTP did not change activity. Repeat experiments confirmed that PCTP had no effect, while
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Figure 4.6: S T A R T proteins including StarD4 and StarD5 repress S R E reporter activity.
(A) HEK 293 cells were co-transfected with an SREBP-regulated luciferase reporter (SREx3 Luc) and
the indicated FLAG-tagged START expression plasmid. Luciferase activity was normalized to P-gal,
and activity with the control empty FLAG vector was set equal to 100%. As a positive control, adding
25-hydroxycholesterol (25HC) repressed SREBP activity as expected. Activity was also repressed by
four START domains, but not PCTP. (B) A repeat experiment, also in HEK 293 cells, showed that StAR
and StarD4 repress reporter activity, but PCTP had no effect. *P<0.05 vs. empty vector.
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the other S T A R T domains repressed S R E reporter activity (Figure 4.6b and data not shown).
Such a decrease suggests less S R E B P processing, though this w a s not directly shown.

These

S T A R T proteins could either deliver cholesterol delivery directly to the E R or facilitate the
conversion of cholesterol to oxysterols, which then feed back to the E R regulatory pool.

Effects of START domain overexpression on LXR activity: Since the START domains of
S t A R , M L N 6 4 , StarD4, and StarD5 affected S R E B P activity, w e also assayed for effects on
L X R activity. C O S - 1 cells were transfected with an L X R E luciferase reporter, expression
plasmids for h u m a n L X R a and R X R a , and the F L A G - S T A R T s .

The S t A R and M L N 6 4

S T A R T domains both stimulated L X R E activity 5.5-fold, similar to effects of the synthetic
LXR

ligand T 0 9 0 7 3 1 7 (Figure 4.7a).

StarD4 and StarD5 likewise activated the L X R E

reporter 3- to 4-fold, while P C T P had no effect. These S T A R T domains could activate

Figure 4.7: S T A R T proteins including StarD4 and StarD5 stimulate L X R E reporter activity.
(A) COS-1 cells were co-transfected with an LXR-regulated luciferase reporter (LXRE Luc) and
expression plasmids for L X R a and RXRa, as well as the indicated FLAG-tagged S T A R T expression
plasmid. Luciferase activity was normalized to P-gal, and activity of the control empty F L A G vector was
set equal to one. As a positive control, adding the synthetic L X R agonist T0907317 (agonist) activated
L X R activity as expected. Activity was also stimulated by four S T A R T domains, but not PCTP
(B) Direct comparison between S T A R T domain activation of the L X R E reporter and steroidogenesis.
One plate of COS-1 cells was transfected at the same time with the respective constructs, and both assays
were performed as before. StAR was much more active than StarD4 in steroidogenesis, but their
activities were more similar in activating LXR. *P<0.05 vs. empty vector.
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L X R 0 as well as L X R a (data not shown). StarD4 and StarD5 consistently stimulated L X R E
activity almost as well as S t A R and M L N 6 4 S T A R T domains, while they appeared m u c h
less active in steroidogenesis assays (see Figure 4.3). This difference was confirmed in a
combined experiment, assaying steroidogenic activity and L X R activation in C O S - 1 cells on
the s a m e plate transfected at the same time. In this experiment, S t A R was 5-fold more active
than StarD4 in steroidogenesis, but only 1.5-fold more in activating L X R s (Figure 4.7b).
T h e salt bridge mutants of StarD4 were also tested in this assay for L X R activation
(Figure 4.8). T h e two mutants that were functional in the steroidogenesis assay (see Figure
4.4c), with neither salt bridge (none) or with an unbalanced positive charge on 06 (mutant B ) ,
activated the L X R E

reporter like wild type.

However, the other mutants with less

steroidogenic activity were significantly less active or inactive in stimulating the L X R E
reporter. Therefore, salt bridge mutations in StarD4 have similar effects on activity in the
assays for steroidogenesis and L X R E activation.

empty

TO

wt

switch none both

A

B

StarD4 salt bridge mutants
Figure 4.8: L X R E reporter stimulation activities of StarD4 salt bridge mutant proteins.
COS-1 cells were transfected as before with the L X R E luciferase reporter, LXRa, and RXRa.
Expression plasmids for FLAG-tagged wild type (wt) StarD4 or the previously described salt bridge
mutants (see Figure 4.4c) were co-transfected as indicated. Luciferase activity was normalized to P-gal,
and activity of the control empty F L A G vector was set equal to one. As a positive control, the synthetic
L X R agonist T0907317 (TO) activated L X R activity as expected. Certain StarD4 mutations affected
activity. *P<0.05 StarD4 mutant vs. wild type.
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W e hypothesized that S T A R T domain overexpression activates L X R s by increasing
levels of an oxysterol L X R ligand. T h e F L A G - T o m 2 0 - S T A R T chimeras, which presumably
localize to mitochondria, showed similar effects on L X R activation as the cytosolic F L A G S T A R T s (Figure 4.9). Therefore, one possibility is that S T A R T domains deliver cholesterol
to mitochondrial C y p 2 7 to generate 27-hydroxycholesterol, analogous to pregnenolone
generation by mitochondrial P450scc in steroidogenesis. Indeed, it w a s previously shown
that S t A R can deliver cholesterol to C y p 2 7 (Sugawara et al., 1995b). T o determine whether

Figure 4.9: L X R E reporter stimulation by
Tom20-START fusion proteins.
COS-1 cells were transfected as before with the
L X R E luciferase reporter, LXRa, and RXRa.
Expression plasmids for FLAG-STARTs (alone)
and FLAG-Tom20-STARTs (fusion) were cotransfected as indicated. Luciferase activity was
normalized to P-gal, and activity of the control
empty F L A G vector was set equal to one. As a
positive control, the synthetic L X R agonist
T0907317 (agonist) activated L X R activity as
expected.
membrane

C^ <lST s & v T *.<& l.<t> r^
j r c? 4 > 4 ? 4 r * 4 r * J '

Fusions to the outer mitochondrial
protein

Tom20

showed

similar

activity to S T A R T domains alone. *P<0.05 vs.
empty vector.

an oxysterol L X R

ligand accumulates in the media of START-transfected

cells, w e

performed a conditioned media switch experiment. While T o m - S t A R activated L X R s 2.5fold in the transfected cells, conditioned media from these cells had no effect on other cells
transfected with only the L X R E reporter and L X R / R X R (Figure 4.10). A s a positive control,
synthetic L X R ligand in the conditioned media was still effective.

Therefore, any

LXR

ligand generated by S T A R T proteins failed to accumulate to high concentrations in media.
Perhaps the putative L X R ligand is short-lived, or it m a y only function in a cell autonomous
manner at high local concentrations.
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Targeting construct for StarD4 knockout mice: The cell culture experiments described in
this chapter s h o w that overexpressed

StarD4 or StarD5 have effects on intracellular

cholesterol metabolism, but it is u n k n o w n whether they mediate such functions in vivo. Gene
targeting by homologous recombination has been an invaluable tool for determining the
physiological functions of m a n y genes, so StarD4 and StarD5 knockout mice would be
informative.

W e were unable to design a StarD5 targeting construct due to gaps in the

available genomic sequences, but StarD4 w a s more amenable to this approach.
Since cholesterol is important for normal physiology and development, a traditional
global knockout of StarD4 could cause embryonic lethality or other developmental defects.
While such phenotypes would be interesting, w e also sought to address the role of StarD4 in
adult tissues.

Therefore, a conditional targeting construct utilizing Cre-Lox technology

(Nagy, 2000) w a s generated for StarD4 (Figure 4.1 la-b). E x o n 3 w a s targeted for deletion,
since loss of this 50bp exon would cause a frameshift in the remaining sequence. A n —11 k B
K p n l fragment of StarD4 w a s generated by digesting the B A C A C 0 2 0 7 9 6 . A L o x P site w a s
cloned into the BssSl site of intron 2, while a neomycin resistance cassette flanked by two
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LoxP sites was cloned into the Mfel site of intron 3. After homologous recombination of this
construct in E S cells (Figure 4.1 lb), partial Cre-mediated excision of the neomycin resistance
cassette would generate the targeted allele, with exon 3 flanked by two LoxP sites (Figure
4.11c). Mice carrying this allele would be crossed to transgenic mice expressing Cre in
various tissues, such as liver or macrophage, resulting in tissue-specific excision of exon 3
and gene disruption. Global disruption of StarD4 could also be obtained by this strategy,
either by crossing mice with the targeted allele to a germline Cre-expressing line, or by
complete Cre recombination in the targeted E S cells (Figure 4.lid). Southern blot probes
were generated to distinguish among these various StarD4 alleles in genomic D N A digested
with PstI or Hpal. Unfortunately, the StarD4 targetting construct, with a long arm of ~9 kB
and a short arm of ~1.5 kB, failed to give any homologous recombinants in almost 200 ES
cell colonies. W e decided to modify this construct by lengthening the short arm, and StarD4
knockout mice remain to be generated.
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-i_SU
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Long Arm 9154 bp
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Figure 4.11: Targeting construct for a StarD4 conditional knockout mouse.
(A) The wild type mouse StarD4 gene has six exons. The start (ATG) and stop (TAG) codons are
indicated, as well as certain restriction sites: BssSI, Mfel, K=Kpnl, P=Pstl, H=Hindlll. (B) An ~11 kB
Kpnl fragment of StarD4 was used to clone this targeting construct (see text for details). Triangles are
LoxP sites. After homologous recombination in ES cells, partial Cre-mediated excision would generate
this targeted allele (C), while complete Cre-mediated excision in ES cells or in mice would generate this
knockout allele with exon 3 deleted (D). Southern blots with the probe shown (*) would distinguish
among these four alleles (A-D) based on the size of PstI or Hpal fragments (in kB) as shown on the right.

99

Chapter Summary: This chapter describes three transient transfection cell culture assays in
which overexpressed StarD4 and StarD5 showed activity: (1) StAR-like stimulation of

steroidogenesis, (2) repression of an SREBP reporter, and (3) activation of and LXR re

StarD4 or StarD5 expression constructs from mouse or human showed similar activities (

not shown). These data strongly suggest that StarD4 and StarD5 function in intracellul

sterol metabolism or transport. Consistent with this hypothesis, the known cholesterol
binding START domains of StAR and MLN64 were also active in these assays, while PCTP
was an inactive negative control. All five START domains, which were expressed with

FLAG epitope tags, appeared evenly distributed throughout the cell. In functional assay
also tested mutant StarD4 and MLN64 proteins (with amino acid substitutions affecting

bridges in the lipid binding cavity) and START domains fused to Tom20 (a mitochondrial
outer membrane protein). A targeting construct for mouse StarD4 was cloned, though
knockout mice have yet to be generated.
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C h a p t e r 5: S t a r D 6 expression in m a l e g e r m cells

S t a r D 6 is n o t expressed in steroidogenic L e y d i g cells:

T h e prototypical S T A R T gene,

StAR, is highly expressed in steroidogenic cells of the testis, ovary, and adrenal (Stocco,
2001). Multiple tissue Northern blots showed StarD6 m R N A only in the testis (see Figure
2.12). Even sensitive R T - P C R assays failed to detect StarD6 expression in other tissues
including ovary and adrenal (data not shown).

Therefore, StarD6 is unlikely to function

globally in steroidogenesis, but it may nonetheless be expressed in the androgen-producing
Leydig cells of the testis. To test this hypothesis, w e cultured M A - 1 0 mouse Leydig tumor
cells with and without steroidogenic stimulation. As expected, stimulation with a c A M P
analog resulted in a 13-fold increase in production of the steroid pregnenolone (Figure 5.1a),
and a corresponding large increase in both StAR m R N A s (Figure 5.1b). However, StarD6
m R N A was undetectable in these immortalized Leydig cells, regardless of steroidogenic
stimulation, despite strong expression in whole mouse testis. Indeed, Northern blots of testis

B M I§
Q

MA-10
- +

Figure 5.1: StarD6 is not expressed

cAMP

in the steroidogenically active M A - 1 0
Leydig tumor cell line.

StarD6

M A - 1 0 cells were cultured for 24 hours in
control media or with 8-bromo-cAMP to
activate steroidogenesis (n=3 wells each).
(A) Media

pregnenolone

levels were

measured by ELISA. (B) Total R N A was

StAR

extracted

for Northern

blotting with

StarD6 and StAR probes.

R N A from

whole testis was a positive control for
StarD6 expression.

18S

staining of 18S r R N A shows equal R N A
loading in each lane.
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Ethidium bromide

total R N A probed for StarD6 gave good signals on radiographs after very short exposures
(less than one hour), consistent with high basal expression levels Lack of detectable

in a steroidogenically active Leydig cell line strongly argues against StarD6 expressi
this cell type of the testis.

StarD6 expression is absent in germ cell-deficient testis: There are three major cell

unique to the testis: the male germ cells and the somatic Leydig and Sertoli cells. The

Sertoli cells are located in the seminiferous tubules with germ cells, where they play
roles in spermatogenesis. To determine whether StarD6 is expressed in germ cells, we
obtained germ cell-deficient male mice with mutations in the receptor tyrosine kinase

These sterile Kit W/Wv mice fail to maintain primordial germ cells, so the adult testi

virtually all germ cells (Ohta et al., 2003), while androgen production by Leydig cell

normal and Sertoli cells are present with relatively normal morphology (De Franca et a

1994; Kurohmaru et al., 1992). StarD6 expression was undetectable in Kit W/Wv testis, b

present in the wild type littermate control and C57BL/6 testis (Figure 5.2a). StAR, ho

was still present in the Kit W/Wv testis consistent with expression in Leydig cells. T

controls were as expected: StarD6 and StAR were undetectable in liver, and the germ ce

specific GAPDH transcript was present in wild type testis but not Kit W/Wv. Expression
StAR and StarD6 in these mice was also analyzed by qPCR normalized to HPRT. The data
showed -3000-fold less StarD6 in the germ-cell deficient testis (Figure 5.2b).
This experiment strongly indicates that StarD6 mRNA is normally expressed in male
germ cells. Kit W/Wv mice have been used by many other groups to distinguish between

somatic and germ cell mRNA expression in testis (Chen et al., 1997; Sugihara et al., 19

However, there are complex interactions among somatic and germ cells in the testis, so

mediated by c-Kit: Sertoli cells express the ligand for c-Kit (Rossi et al., 2000), an
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Figure 5.2: Testis StarD6 expression is absent in Kit W / W v germ cell deficient mice.
(A) Total R N A was extracted from C57BL/6 mouse liver and testis, and from the testis of a Kit W / W v
germ cell deficient mouse and a wild type littermate. The Northern blot was probed for StarD6, StAR,
and G A P D H . (B) qPCR analysis of gene expression of in testis of the Kit W / W v and littermate control
mice.

Expression of StAR and StarD6 was normalized to hypoxanthine guanine phosphoribosyl

transferase (HPRT), and the same c D N A sample was analyzed in quadruplicate. *P<0.05 vs. control.

cells normally express c-Kit (Yan et al., 2000). Therefore, it remained possible that StarD6
was expressed in other cell types in a germ cell- or c-Kit-dependent manner.

Expression o f StarD6 in male g e r m cells: T o confirm specific StarD6 expression in germ
cells, w e obtained several Northern blots from the laboratory of Patricia Morris and probed
for StarD6 expression.

First, whole testis StarD6 expression w a s assayed in rodents at

various days of postnatal development. StarD6 m R N A w a s undetectable at early time points,
expressed by day 2 0 in mice and day 25 in rats, and increased to adult levels thereafter
(Figure

5.4).

This developmental

expression

at puberty

coincides with

germ

cell

proliferation and the differentiation of specific germ cells at the onset of spermiogenesis
( Y a m a n a k a et al., 2000).
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increases during puberty in mice and rats.
The laboratory of Patricia Morris prepared
Northern blots of whole testis total R N A at
different times of postnatal development in
mice (A) and rats (B). Equal R N A was loaded

B

in each lane (data not shown). W e hybridized
these blots with a mouse StarD6 probe.

Next, StarD6

expression w a s

assessed

populations of cells from rat testis (Figure 5.4a).

in total R N A

from

elutriator-purified

StarD6 was strongly expressed in germ

cells at different stages of development: the mitotic stem cells (spermatogonia), the meiotic
cells (pachytene spermatocytes), and the haploid cells (round and elongated spermatids),
which differentiate into spermatozoa. StarD6 m R N A w a s detected in the adult Sertoli cell
preparation, but this preparation is typically contaminated with about 1 0 % germ cells (mostly
testicular sperm); StarD6 expression w a s not detected in three Sertoli cell lines (data not
shown).

StarD6 w a s also undetectable in freshly isolated Leydig cells ( > 9 8 % pure),
Qi

f
5> .£

£ <V?
f Co
/ l l

£ « ^
<*
N/
0 $*

<^ £
£ j,^
£• «• *,o # S»
<f * V ^
Figure 5.4:

In isolated rat testis somatic

and germ cells, StarD6 m R N A is expressed
in germ cells at all stages of development.
The laboratory of Patricia Morris elutriatorpurified populations of somatic and germ cells
from rat testis, extracted RNA, and prepared a
Northern blot.

Some closely associated cells

types are difficult to separate, as the adult Sertoli
cell preparation is typically contaminated with
-10%

germ cells (data not shown).

We

hybridized this blot with probes for mouse
StarD6 (A) or StarD5 (B).
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consistent with the result in the M A - 1 0 cell line (see Figure 5.1).

In contrast, StarD5

expression was detected almost uniformly in Sertoli, Leydig, and germ cell populations
(Figure 5.4b). StarD6 m R N A expression thus appears restricted to male germ cells.
Finally, StarD6 expression was assayed in mouse isolated germ cells and staged
seminiferous tubules.

Consistent with the result in rats, mouse StarD6 was expressed

similarly in spermatogonia, pachytene spermatocytes, and round spermatids (Figure 5.5a).
Likewise, there were no large differences in StarD6 expression in seminiferous tubules at
different stages of spermatogenesis (Figure 5.5b). Therefore, StarD6 m R N A appears present
in germ cells at all stages of development. However, this does not necessarily mean that the
protein is also present at all stages. Germ cells often rely on translational regulation of
m R N A s , since they become transcriptionally inactive during the later steps in spermiogenesis
(Eddy, 1998). Indeed, the StarD6 m R N A is predicted to have long multi-exon 5'UTR with
multiple upstream A T G s (see Figure 2.11), consistent with translational regulation (Morris
and Geballe, 2000).
Figure 5.5: Mouse StarD6 m R N A
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cells and

seminiferous tubules at all stages.
The

laboratory

of Patricia Morris

prepared Northern blots of R N A from
mouse elutriator-purified germ cells (A)
or staged seminiferous tubules (B).
Equal R N A was loaded in each lane
(data not shown). W e hybridized these
blots with a mouse StarD6 probe.

5' R A C E analysis ofStarD6: T o further characterize the 5' U T R of StarD6 and to identify
the gene promoter, w e performed a 5' R A C E analysis of m o u s e and h u m a n StarD6. M o u s e
StarD6 had three non-coding exons upstream of the exon with the start codon, as predicted
from available m o u s e E S T s , while h u m a n StarD6 had only two upstream exons (Figure
-105

5.7a). A T G codons in these 5' exons give several upstream ORFs, but none extended into
the StarD6 coding region due to an in-frame T A G stop codon immediately before the A T G
start codon. Therefore, protein coding begins in mouse exon 4 and human exon 3.
5'-RACE also identified alternativefirstexons for both the mouse and human StarD6
genes. Exon lb accounted for 7 of 12 mouse StarD6 R A C E clones, while 3 clones had exon
la and two had exon lc (Figure 5.7b). Multiple transcription initiation sites were also found
in each of these threefirstexons, which were near each other in the genomic sequence. For
human StarD6, exon 1 predominated over exon 1' with 13 of 16 R A C E clones, though there
five different initiation sites in this exon (Figure 5.7c). Despite these complications, a +1 site
for promoter numbering was designated in mouse and human StarD6 based on the most
abundant initiation sites.
A TAG-ATG
mouse rn-m-fywgi—gj-EB-tri-rjrr-t. i

9

1

human

B

(2/12) (1/12)
-789A -761A
A . 1a
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-644A -620G -617G
(2/12) (3/12) (2/12)
it

-S82C -581A
(1/12) (1/12)

Exonl
-1348
t
f
FT
f
I Exonl' 1-1
-1414G -1403A -1396G -1395G -1391A
(3/16) (3/16) (4/16) (4/16) (1/16)
*
-1210A
(3/16)
Figure 5.6: Rapid Amplification of c D N A ends (5' R A C E ) results for m o u s e and h u m a n StarD6.
(A) In both mouse and h u m a n StarD6, the A T G translation initiation codon is immediately preceded by
a T A G stop codon. Upstream of this, there are three non-coding exons in mice and two in humans.
Alternate first exons and transcription initiation sites were identified for both the mouse (B) and human
(C) StarD6 genes. The initiation sites are numbered based on their distance upstream of exon 2, and
the number of R A C E clones for each site is indicated (total n=12 for mouse, n=16 for human). For
numbering the StarD6 promoter, the (*) initiation sites were designated as +1.
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A problem was noted in the 5' R A C E analysis of human but not mouse StarD6, as the
c D N A s cloned could not encode the entire predicted StarD6 S T A R T protein. Using the gene
specific R A C E primer in exon 5, several products included predicted intron 3 sequence,
while others had skipped exons (Figure 5.7a). Similar products were generated by RT-PCR
of human StarD6 using primers in exons 2 and 8. Multiple bands were amplified, cloned,
and sequenced, revealing the presence of intron 3 sequence or the absence of exons (Figure
5.7b).

The template R N A for both 5'-RACE and R T - P C R was commercially available

(Clontech) human testis R N A pooled from over 50 subjects. W e saw similar problems in
StarD4 RT-PCRs using human liver R N A from the same company (see Figure 2.4). There
m a y be frequent mis-splicing human StarD4 and StarD6 R N A s , though w e did notfindthis
in mouse R N A prepared ourselves. Alternatively, the commercially available human R N A s
m a y contain abundant heterogeneous nuclear R N A s rather than mature m R N A s .

A Predicted 5' RACE product D Predicted RT-PCR product
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Figure 5.7: Mis-spliced human StarD6 R A C E and RT-PCR products.
(A) 16 human StarD6 RACE products were generated with a gene specific primer in exon 5. Sequencing
revealed that none could encode the full predicted START domain, due to unexpected splice patterns.
(B) Primers in exons 2 and 8 were used to RT-PCR amplify StarD6fromthe same commercial source of
human testis RNA. Most RT-PCR products were longer or shorter than the predicted length (arrow).
These products were sequenced, again revealing mis-spliced mRNAs.

The StarD6 promoter: The genomic sequence upstream of the designated +1 sites for mouse
and human StarD6 was analyzed for potential promoter elements. A region of 120 bp was
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highly conserved between m o u s e and h u m a n StarD6, with 7 6 % identity (Figure 5.8a). This
region w a s upstream of m o u s e exon lb, but actually fell within m o u s e exon la. N o h u m a n
RACE

products included this sequence, and there w a s no apparent sequence homology

a m o n g the upstream exons of m o u s e and h u m a n StarD6. This is consistent with divergence
of non-coding D N A

in the upstream exons, so the conserved

120 bp w a s considered

promoter and potential factor binding sites were identified using T R A N S F A C (Matys et al.,
2003). This analysis revealed a conserved strong consensus Y Y 1 site on the negative D N A
strand. This putative Y Y 1 site agreed with the core consensus at 8 of 9 positions, including
the requisite C C A T (Figure 5.8b). T h o u g h Y Y 1 is a widely expressed transcription factor
that acts at m a n y promoters (Thomas and Seto, 1999), it has also been implicated in germ
cell specific gene expression. Similar Y Y 1 sites have been found in six germ cell-specific
genes: proacrosin, protamines 1-3, and transition proteins 1-2 (Schulten et al., 1999). Other
elements important for specific gene expression in germ cells remain to be identified in germ
cell specific genes like StarD6.

StarD6 promoter alignment

B

(-787) -167rTCCTCCGCCACCGCAGGAAGGCCGGACGCCCGCGCTCGC mouse
^.1S23).127[rTCCTCCGCJAGi|^AG^|fl|G^C(^AC^CCGCGCTCGc| human
TTTCAAACCGACCCAACATGGCGCCGGGCCGCAGGGCGC
rTTCAAACCG(C]CCCAACATGGCGCCGG^|c|^C]G]G(T|GCGC.
rGTGTAGTACCAGG-CGCCGGGAGGGATGGGGGAGGAGGG -49 (-669)
rcjC]GJCG|G£]£jGT^^
-8 (-1404)
Consensus
StarD6
proacrosin

7 6 % identical (91/120)

G C C A T C T T G
G C C A T G T T G
G C C A T T T T G

Figure 5.8: Conserved region of the mouse and human StarD6 proximal promoters.
This StarD6 upstream non-coding sequence was conserved between mice and humans, but not present
elsewhere in the genome. The distances are indicated from the designated +1 sites as well asfromthe
start of exon 2 (see Figure 5.6). A conserved putative YY1 site was identified on the negative D N A
strand (arrows). (B) The potential Y Y 1 site in the StarD6 promoter agreed well with the consensus and
with the site in proacrosin, another male germ cell specific gene. The graph indicates the strength of
the Y Y 1 consensus based on many promotersfromthe T R A N S F A C database (Matys et al., 2003).
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Targeting construct for StarD6 knockout: Given its highly specific expression in male
germ cells, StarD6 is likely to function in male fertility. Cholesterol and other sterols have
been implicated in many aspects of male fertility, so there are several pathways where a
putative sterol binding protein could act (see discussion, Figure 6.6). W e hypothesized that
male StarD6 knockout mice may be infertile, and the specific defect in sperm development or
function would indicate the role of StarD6. Since this gene is only expressed in male germ
cells, which are not essential for viabilty, there was no need to design a conditional knockout
strategy. A traditional knockout construct was cloned to inactivate the gene on chromosome
18 (Figure 5.9). The long arm was a -5.8 kB restriction fragment of StarD6 from the 5'
flanking region to intron 3, while the short arm was a ~0.7 kB P C R product from intron 5. In
this targeting construct, a neomycin resistance cassette replaced exons 4 and 5, which encode
the N-terminal -50 amino acids of the S T A R T domain.

To identify E S cells with

homologous recombination, a Southern blot probe was designed to detect different EcoRI
fragments from wild type and knockout alleles. Unfortunately, almost 150 E S cell colonies
were screened and no recombinants were detected. W e decided to generate a new StarD6
construct by targeting different exons and lengthening the short arm.

ATG
EcoRV |

R * Kpnl

stop
L

^-kMMTfT]

A ^ = 4

EcoRI

12 kB

6kB

B
•4
•
Short A r m
726bp

Long Arm 5771 bp

Figure 5.9: Targeting construct for a StarD6 knockout mouse.
(A) The wild type mouse StarD6 gene on chromosome 18 has six exons. The start ( A T G ) and stop
codons are indicated, as well as certain restriction sites: Kpnl, EcoRV, and R=EcoRI. (B) This targeting
construct for StarD6 was cloned (see text for details). A StarD6 knockout allele would be generated by
homologous recombination in E S cells (dashed lines). Southern blots with the probe shown (*) would
distinguish wild type and knockout alleles based on the size of EcoRI fragments as shown on the right.
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Chapter summary: This chapter describes the expression of StarD6 m R N A , which showed a

much more limited tissue distribution than StarD4 and StarD5. Multiple lines of eviden
indicate that StarD6 mRNA is specifically expressed in the germ cells of the testis.
However, StarD6 was not expressed in the steroidogenic Leydig cells or the epithelial

cells, both somatic cells critical for germ cell development. The 5' end of the StarD6
in mice and humans had multiple non-coding exons and upstream ORFs, indicative of

translational regulation. Therefore, even though StarD6 mRNA was present at all stages
germ cell development, protein expression may be regulated during spermatogenesis. A

targeting construct was cloned to generate StarD6 knockout mice, which are predicted t
have male fertility defects.
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C h a p t e r 6; Discussion a n d Future Directions

Here we describe a novel subfamily of three StAR-related lipid transfer proteins and
the regulated gene expression for each one. StarD4 was activated by SREBP-2, an important
transcription factor in cholesterol homeostasis (Horton et al., 2002), while StarD5 was
activated by the E R stress response, a pathway recently implicated in apoptosis of
cholesterol-loaded macrophages (Feng et al., 2003a). StarD6 expression was limited to the
germ cells of the testis. To test the hypothesis that these proteins function in the intracellular
metabolism or transport of sterols, w e overexpressed S T A R T proteins in cultured cells.

Models of StarD4 and StarDS activity in the three functional assays

StarD4 and StarD5 showed activity in three cell culture assays: (1) StAR-like
activation of steroidogenesis, (2) repression of an S R E B P reporter, and (3) activation of an
L X R reporter (Figure 6.1). The cholesterol-binding S T A R T domains of StAR and M L N 6 4
were active in these assays, while P C T P was an inactive negative control. The results of

f\ f

cholesterol ~\
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Figure 6.1: StarD4 and StarD5 showed activity in three functional assays.
In each assay, the cholesterol-binding S T A R T domains of StAR and M L N 6 4 were also active, while
P C T P was inactive. (A) W h e n co-transfected with expression plasmids for the enzymes P450scc and
3P-hydroxysteroid dehydrogenase, they stimulated steroidogenesis. (B) W h e n co-transfected with an
SRE-regulated reporter, they decreased luciferase activity. (C) W h e n co-transfected with an L X R E regulated reporter and expression plasmids for L X R a and R X R a , they increased luciferase activity.
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these experiments can be unified by a model involving cholesterol delivery to mitochondria.
T h e P450scc e n z y m e localizes to the matrix side of the inner mitochondrial m e m b r a n e , so
StAR-like steroidogenic activity reflects delivery of cholesterol substrate to this compartment
(Figure 6.1a). Sterol 27-hydroxylase (Cyp27) is another cholesterol-metabolizing e n z y m e at
the same location as P450scc (Okuda, 1994). In contrast to the steroidogenic enzyme, C y p 2 7
is expressed in liver and m a n y other cell types. Others have s h o w n that S t A R can deliver
substrate to C y p 2 7 (Sugawara et al., 1995b), so it is likely that the M L N 6 4 S T A R T domain,
StarD4, and StarD5 share this activity. Generation of 27-hydroxycholesterol is consistent
with the observed repression of S R E B P activity and stimulation of L X R activity (Figure 6.2),
since this oxysterol is an k n o w n inhibitor of S R E B P processing and agonist of L X R s
(Russell, 2000).

27-hydroxycholesterol also represents the first intermediate in hepatic

alternative bile acid synthesis, and S t A R overexpression in primary hepatocytes stimulates
this pathway (Pandak et al., 2002). Since S t A R is not expressed to high levels in liver, and
MLN64

is localized to late endosomal membranes, StarD4 or StarD5 could therefore

stimulate alternative bile acid synthesis in vivo.

cholesterol

SREBP
Insig

E R \
J
27-hydroxycholesterol — • B / V e acids

Figure 6.2: Model for StarD4 and StarDS activity via generation of 27-hydroxycholesterol.
Like the P450scc enzyme in steroidogenesis, cholesterol 27-hydroxylase (Cyp27) localizes to the
matrix side of the inner mitochondrial membrane.

27-hydroxycholesterol can repress SREBPs,

activate LXRs, and serve as the substrate for bile acid synthesis in liver by the alternative pathway.
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Other models not involving mitochondrial Cyp27 could also account for some of the
observed activities. For instance, START domains may deliver substrate to cholesterol

hydroxylase in ER and Golgi, and 25-hydroxycholesterol would repress SREBPs and activa

LXRs like 27-hydroxycholesterol (Russell, 2000). Furthermore, 25-hydroxycholesterol can

serve as a substrate for P450scc (Lukyanenko et al., 2001), so induction of steroidogen

may proceed by this alternate route rather than direct delivery of cholesterol to mito
Effects on cholesterol biosynthesis could also account for START domain regulation of

SREBPs and LXRs, as cholesterol precursors can have effects on these transcription fac

The precursor desmosterol alters the conformation of SCAP similarly to cholesterol its

(Brown et al., 2002), while 24(S),25-epoxycholesterol derived from cholesterol biosynth
is high affinity LXR ligand (Spencer et al., 2001). Finally, it is possible that these

domains have direct transcriptional effects as positive or negative cofactors for LXRs

SREBPs. There is a precedent for transcriptional activity by proteins not traditionall

considered transcription factors, as the housekeeping enzyme glyceraldehyde-3-phosphat
dehydrogenase (GAPDH) was recently shown to be a crucial component of a coactivator
complex (Zheng et al., 2003). However, four different START domains showed activity,
even though the StAR and StarD4 subfamilies share -20% amino acid identity, arguing

against specific cofactor activity for any one START protein. Given the extensive lite

that StAR delivers cholesterol to mitochondria, it is more likely that these START dom
are delivering cholesterol to Cyp27 as opposed to alternate models.

Comparison of the StarD4 subfamily to other START proteins

Unlike many other START proteins, StarD4, StarD5, and StarD6 lack additional

domains for localization or enzymatic activity. StAR and MLN64 have N-terminal domains
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that target the full-length proteins to mitochondria and late endosomes, respectively (Strauss
et al., 2003). StarD4 subfamily members lack consensus localization signals and are

predicted to be cytosolic like three other minimal START domains: full-length PCTP (de

Brouwer et al., 2002) and the artificial START-only StAR and MLN64 proteins (Arakane e

al., 1996; Zhang et al., 2002b). Consistent with this prediction, overexpressed EGFP-St
and FLAG-tagged StarD4 and StarD5 showed even distributions through the cytoplasm and
nucleus. Similar localization was observed for the FLAG-tagged PCTP and START domains
of StAR and MLN64. However, these studies do not rule out specific localization of
endogenous proteins or regulated re-localization in response to stimuli.
In other START proteins, lipid binding could serve a regulatory role, perhaps

allosterically regulating N-terminal RhoGAP or thioesterase domains. The StarD4 subfam

lacks such domains, though it is possible that they interact with other proteins to re

them upon lipid binding. However, we favor the hypothesis that StarD4, StarD5, and Sta

function like StAR and PCTP, shuttling lipids between intracellular membranes. Interac
proteins could also play roles in lipid transport, either targeting lipid transfer to

subcellular locations or facilitating loading or unloading of cavity lipids, which wou
require major conformation changes based on the START structure.
The X-ray crystal structure of StarD4 was described here, and the structures of the
MLN64 START domain (Tsujishita and Hurley, 2000) and PCTP (Roderick et al., 2002)

have also been solved. The three structures share a helix-grip fold with a predominant

hydrophobic lipid binding cavity. Charged residues in the cavities form salt bridges t
be important for protein folding or lipid binding specificity. StAR and MLN64 have a

unique salt bridge between charged residues in 05 and 06, rather than one in aC like t
StarD4 subfamily, PCTP, and most other START domains. The salt bridge in aC was

predicted to help stabilize binding of zwitterionic phospholipid head groups (Tsujishi
-114-

Hurley, 2000), but the P C T P structure showed Asp82 is too distant from the positive
quaternary amine of PC to serve this function (Roderick et al., 2002). However, Arg82

the PCTP aC salt bridge directly interacts with a phosphoryl group of PC, so this salt

was still considered a potential lipid specificity determinant (Roderick et al., 2002).
This salt bridge model predicts that the StarD4 subfamily would bind phospholipids,

yet our functional data strongly suggest sterol transfer. Therefore, we performed site

directed mutagenesis of these salt bridges in StarD4 and MLN64. Surprisingly, proteins
lacking both salt bridges (mutants designated none) showed equal activity to the

corresponding wild type proteins in assays for steroidogenesis and LXR activation. Thi

strongly indicates that cavity salt bridges are not essential for function. Others hav
loss of steroidogenic activity in the lipoid CAH StAR mutants Glul69Gly or Glul69Lys,

which eliminate the negative charge of the 05/06 salt bridge (Bose et al., 1996). Biop
studies that preceded the START structures predicted misfolding of the StAR Glul69Gly

mutant (Bose et al., 1998), but this mutant had an unbalanced positive charge in the ca
This is analogous to the MLN64 mutant B generated here, which showed a trend towards

lower activity, but when we also mutated the positive residue of this MLN64 salt bridg

double mutant protein (none) had full steroidogenic activity. Furthermore, StarD4 muta

with an Arg in 06 but Tyr rather than a negative charge in 05, showed its full activit

contrast to the CAH StAR mutants with Gly or Lys substituted in 05. This may reflect t

nature of the specific substitution, or differences among START domains in tolerance f

substitutions. Overall, the role of salt bridges in START domains is much more complic

than previously appreciated. Additional structure-function studies, as well as more ST
crystal structures with lipid ligands, will be necessary to resolve these issues.
StarD4 subfamily functions appear distinct from StAR and steroidogenesis. While

StAR expression is limited to steroidogenic cells, StarD4 and StarD5 are widely expres
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and StarD6 is only expressed in germ cells, not Leydig cells, of the testis. StarD4 and StarD5
were expressed in MA-10 Leydig cells, but steroidogenic stimulation with a cAMP analog
did not highly induce their expression like StAR, which was activated 50-fold. StarD4

StarD5 were active in the transient transfection steroidogenesis assay, so they are ca
for the phenomenon of StAR-independent steroidogenesis (Miller and Strauss, 1999).
However, they clearly cannot substitute for StAR function, as StAR mutations cause the
disease lipoid CAH even with presumably intact StarD4 and StarD5 genes.
A connection between StarD4 or StarD5 and MLN64 is possible, though there is little
evidence. All three are widely expressed, but MLN64 mRNA expression was not regulated

by SREBPs like StarD4, by ER stress like StarD5, or by LXRs (data not shown). In ES cel
heterozygous for inactivated MLN64, there is a two-fold increase in StarD4 mRNA
suggesting potential functional compensation (Strauss et al., 2003). However, MLN64 is

thought to function in cholesterol efflux from endosomes (Strauss et al., 2002), so Sta

induction could reflect SREBP activation due to altered intracellular cholesterol traf
Homozygous deletion of MLN64 in knockout mice has yet to be reported. MLN64 localizes

to the membranes of late endosomes (Alpy et al., 2001), but there is no evidence for St

or StarD5 in this compartment. They could nonetheless function in an endosomal cholest
efflux pathway, perhaps as cytosolic acceptors downstream of MLN64 and NPC proteins.
Several lines of evidence support the idea that StarD4 subfamily proteins bind and
transfer cholesterol or other sterols: StarD4 is regulated by SREBP-2, the subfamily
resembles StAR and MLN64, and the StarD4 and MLN64 lipid-binding cavities are similar

in size and shape. Most convincing, StarD4 and StarD5 showed similar activity to the S
and MLN64 START domains in three functional assays, while PCTP was inactive. Based on

lipid transfer studies of StAR and PCTP, START domain are thought to be rather specific

lipid binding proteins (Tsujishita and Hurley, 2000). This is in contrast to other prot
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SCP-2 (Seedorf et al., 2000) and SPF (Panagabko et al., 2003), which bind promiscuously to

many structurally different classes of lipids. StarD4 and StarD5 are likely involved i

fundamental processes like intracellular sterol transport or cholesterol biosynthesis.

hypothesis is consistent with their ubiquitous expression, since all cells must handle

cholesterol, as well as their abundance in liver, the central organ of cholesterol met

In contrast, StarD6 expression was restricted to male germ cells, indicating a special

in fertility. The remaining discussion will address each StarD4 subfamily gene, propos
functions consistent with observed regulation and activities.

StarD4: an SREBP-2 target gene with potential roles in cholesterol synthesis or uptake

Like many other genes in cholesterol metabolism, StarD4 expression is regulated by

sterols via SREBP transcription factors. StarD4 showed coordinate regulation with othe

SREBP target genes in three experimental systems. First, cholesterol feeding of wild t

inbred mice decreased StarD4 expression in liver. Second, culturing cells with cholest
and 25-hydroxycholesterol, a well-established treatment to inhibit SREBPs, likewise

decreased StarD4 expression. This result was observed in fibroblast (NIH 3T3), hepatom

(Hepa-1), and macrophage (RAW) cell lines. Third, liver StarD4 expression was activated
transgenic mice overexpressing processed nuclear SREBP-2, but not significantly with
SREBP-la. This is consistent with the failure of LXR agonists, which activate SREBP-lc

and lipogenesis in liver, to affect StarD4 expression. In liver, StarD4 thus appears t
poor target for SREBP-1, with preferential activation by SREBP-2.
Further studies investigated the mouse and human StarD4 promoters in transient

transfection reporter assays. 5' RACE revealed differences between the mouse and human
StarD4 genes, with mouse exon 1 encoding 14 amino acids while human exon 1 included
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only 5'UTR. Thesefirstexons were poorly conserved between the species, but both genes

showed multiple +1 transcription start sites and lack of a consensus promoter TATA bo
Two regions of upstream genomic sequence were highly conserved between species, the

proximal promoter and a distal potential enhancer region over 1 kB upstream. Lucifera
reporters driven by the mouse or human StarD4 promoters were sterol-regulated in NTH

fibroblasts, consistent with the regulation of the endogenous gene. Activity and regul
were observed for the mouse -350/+34 and human -281/-9 proximal promoter constructs,
the distal conserved region had no discernable effect on the mouse StarD4 reporter.
A consensus 9 bp SRE of Y-C-A-Y-C/A/G-Y-C-A-Y (Y=pyrimidine) was proposed
(Magana and Osborne, 1996), and with some exceptions most SREs show good agreement

with the consensus (Figure 6.3a) (Edwards et al., 2000). Three potential SREs (A-C) we

conserved in the mouse and human StarD4 proximal promoters, and two additional potent
SREs (D-E) were only present in mouse (Figure 6.3b). SRE-A (CCAgCCCAC) was the best
A Hamster LDL receptor TCACCCCAC
Human SREBP-2
Hamster HMG CoA synthase
Hamster HMG CoA reductase
Rat FPP synthase
Human squalene synthase
Rat fatty acid synthase
Mouse CTP:phohpocholine cytidylytransferase
Mouse Glycerol-3-phosphate acyltransferase
Human ATP citrate lyase
Mouse acetyl CoA synthase 1

TCACCCCAC
TCACCCCAC
CCACCCCAC
CCGCACCAT
TCTCACCAC
TCACACGAG
TCACGCCAG
TCAGCCCAT
CCACGCCAC
TCACCCCAC
TCAGCCTAG
TCAGGCTAG
TCACTCCAC
ACACCCCAT

Mouse/Human StarD4 SRE-A CCAGCCCAC
B
Human StarD4 SRE-B +TCATTCCAT
Mouse StarD4 SRE-B *TCGGTCCAT
Human StarD4 SRE-C
CCGCGCCAG
Mouse StarD4 SRE-C
AGGCACCAG
Mouse StarD4 SRE-D
ACACCCCAC
Mouse StarD4 SRE-E
CCAAGGCAG
Figure 6.3: Alignment of known SREs with StarD4 functional SRE-B and other potent

(A) Previously characterized SREs and (B) StarD4 potential SREs. Only SRE-B (*) i

functional based on mutagenesis studies. Disagreements with the proposed 9 bp SRE
YCAY(C/A/G)YCAY (Y=pyrimidine) are indicated in red.
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candidate since it was identical in mouse and human and differed from consensus only at

position 4 (lower case). This G substitution is found in several SREs including rat fa
synthase (Magana and Osborne, 1996). Surprisingly, mutation of StarD4 SRE-A in either
species did not change reporter sterol regulation, and mutations in SRE-C, SRE-D, and

E likewise had no effect. However, sterol regulation was reduced by a factor of four t
upon mutating SRE-B in either mouse (20-fold to 4-fold) or human (12-fold to 3-fold),

indicating this is a functional SRE. Interspecies conservation of SREs has been descri
the human and hamster HMGS genes (Inoue et al., 1998), and there are presumably other
examples. Human SRE-B (TCATtCCAT) agrees with the consensus except for T at the

position 5, but this substitution was described in two SREs in mouse acetyl CoA syntha
(Ikeda et al., 2001). StarD4 SRE-B in mouse (TCggtCCAT) has two additional divergent

bases: G in the position 4, like SRE-A, and G in position 3, which is also found in ha

HMG CoA reductase (Vallett et al., 1996). Residual low sterol regulation of SRE-B mutan

reporters was often observed, particularly when statin drug treatment maximally activa

SREBPs. This effect may be mediated by the other potential SREs in the StarD4 promoter
as double mutants of SRE-B and any of the other four SREs showed even less sterol
regulation than SRE-B single mutants.
The activity of mouse SRE-B, despite relatively poor consensus agreement, likely

reflects its position relative to other factor binding sites, particularly two downstr
CCAAT boxes conserved in the human StarD4 promoter. Mutations in either CCAAT box,

10 bp or 40 bp downstream of SRE-B, nearly abolished sterol regulation, as these repor

showed similar low activity in the presence or absence of sterols. All known SRE-conta
promoters have a site for NF-Y (CCAAT) or Spl (GC box) in close proximity, as SREBPs
interact with these factors to activate transcription (Bennett and Osborne, 2000). The

of the CCAAT box from the SRE appears crucial, and these elements typically lie within
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bp (Edwards et al., 2000). Sterol regulation is abrogated upon increasing the spacing beyond
17 bp in the HMGS promoter (Dooley et al., 1998) or beyond 20 bp in the FPP synthase
promoter (Ericsson et al., 1996), and the optimal spacing for the SREBP-2 promoter was
20 bp (Inoue et al., 1998). Based on such reports, neither StarD4 CCAAT box appears

optimally located at 10 and 40 bp from SRE-B. However, in the stearoyl-CoA desaturase-1
and -2 genes, CCAAT elements 5 and 48 bp from the SRE were functional (Tabor et al.,
1999). Therefore, the spacing of elements may be promoter-specific, and CCAAT elements

more distal from the SRE may be required for maximal activation of some promoters. From

these studies, it is unclear why the StarD4 promoter is a preferential target for SREB

rather than SREBP-1, but this is a major unresolved issue in the field of SREBP resear
All other known SREBP-2 target genes are involved in cholesterol synthesis (many

biosynthetic enzymes) or its uptake from plasma (the LDL receptor) (Edwards et al., 200
so we propose four models whereby StarD4 could also function in these pathways (Figure

6.4). First, as described in the introduction, the cholesterol precursors squalene, la
and every post-lanosterol sterol are hydrophobic molecules that may require a protein
such as StarD4. Cholesterol biosynthetic enzymes localize to the ER and peroxisomes
(Olivier and Krisans, 2000), so StarD4 could shuttle the precursor between enzymes in

different compartments or different membrane domains of one compartment (Figure 6.4a).

Second, movement of nascent cholesterol from its primary site of synthesis in the ER t

major compartment in the PM can be considered the final step of cholesterol synthesis.

transport pathway from ER to PM is one of the best candidates for non-vesicular transp

via lipid transfer proteins like StarD4 (Figure 6.4b). Third, cholesterol taken up via
receptor must leave endosomes by the pathway involving the NPC proteins, MLN64, and
possibly a cytosolic lipid transfer protein like StarD4. NPC1, NPC2, and MLN64 are not
regulated by sterols, but SREBP-2 regulated genes such as the LDL receptor and StarD4
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b e rate-limiting in this transport p a t h w a y (Figure 6.4c).

Finally, StarD4 overexpression

repressed SRE reporters, consistent with generation of an oxysterol that decreases SREBP
processing. If StarD4 serves this function in vivo, its activation by SREBP-2 could
negatively feedback on SREBP processing, thus preventing excessive cholesterol synthesis
or uptake (Figure 6.4d). Further experiments will be necessary to distinguish among these
hypotheses for StarD4 function.

PM
Transport cholesterol
precursor sterols between
biosynthetic enzymes

Transport nascent
cholesterol from the ER to
the plasma membrane

Efflux of LDL derived
cholesterol from late
endosomal compartment

Negative feedback on
SREBP processing and
target gene activation

Figure 6.4: Four potential functions of StarD4 consistent with S R E B P - 2 gene regulation.
See text for further details.

S t a r D S : a n E R stress activated g e n e w i t h potential roles in E R function

StarD5 s h o w s a similar tissue expression pattern to StarD4 and the proteins share
30% identity. However, StarD5 is not an SREBP target as its mRNA expression was
unregulated by cholesterol feeding in mice, by truncated nuclear SREBPs in transgenic mice
(data not shown), or by oxysterols or statin in cultured cells. StarD5 expression was also
unaffected by LXR agonists in mouse liver and cultured cells. StarD5 expression was
nonetheless increased 4-fold in free cholesterol-loaded macrophages relative to untreated or
cholesterol ester-loaded cells. Tabas and coworkers have used Western blots to show
activation of the ER stress response in these free cholesterol-loaded macrophages (Feng et
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al., 2003a). W e confirmed and extended these findings by showing increased Xbpl splicing
and increased mRNA for known ER stress target genes CHOP and BiP.
Since StarD5 was induced in free cholesterol-loaded macrophages but did not appear
to be an LXR target, we investigated its regulation by classic inducers of ER stress.

NIH 3T3 cells were treated with agents known to cause ER protein misfolding (tunicamyc

thapsigargin, Brefeldin A, and DTT), StarD5 expression was consistently increased 6- t

fold. Control ER stress targets genes were also activated, while no consistent regulat
observed for StarD4 and MLN64. StarD5 activation was specific for ER stress, as the
general protein folding stress of heat shock had no effect of StarD5 expression.
The gene regulatory elements responsible for ER stress activation of StarD5 were not
localized. The proximal 400 bp upstream of the ATG was conserved between mouse and
human StarD5, but no consensus sites for binding ER stress transcription factors were
There were two conserved CCAAT boxes, but they lacked the other components of an ER

stress response element (ERSE) or ERSE-II. Consistent with this, a luciferase reporter

driven by this proximal 400 bp of mouse StarD5 was not activated by ER stress. Since t
endogenous StarD5 mRNA is robustly induced by ER stress in the same cells, the

responsible elements must lie elsewhere in the gene. ERSEs have only been described in

proximal promoters, but these studies are based on a limited number of known target ge
(Roy and Lee, 1999).

Several classes of genes are activated by the ER stress response, and these targets fa

into two broad classes: (1) genes that help restore normal ER function and (2) genes t

trigger apoptosis if ER function cannot be restored. Since the ER is the key regulator
compartment in cholesterol metabolism, we favor the hypothesis that StarD5 plays a

protective rather than apoptotic role in ER-stressed cells. Since excess ER free chole
can cause ER stress (Feng et al., 2003a), we propose four models whereby StarD5 could
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reduce E R free cholesterol levels (Figure 6.5). First, StarD5 could transport cholesterol from
the ER to other compartments or to cellular efflux pathways, perhaps involving ABC
transporters like ABCA1, ABCG5, and ABCG8 (Figure 6.5a). Second, StarD5 could deliver
cholesterol for esterification by ER-localized ACAT, thus reducing free cholesterol levels
(Figure 6.5b). Third, since overexpressed StarD5 activated LXRE reporters consistent with
oxysterol generation, StarD5 in vivo may stimulate LXR activation of genes involved in
cellular cholesterol efflux (Figure 6.5c). Fourth, oxysterol generation itself may be a means
to unload cellular cholesterol, as more hydrophilic oxysterols are thought to leave cells more
easily than cholesterol (Figure 6.5d). It remains to be determined whether StarD5 expression
has any of these protective roles in ER-stressed cells.

Transport cholesterol from
ER to other compartments
or efflux pathways

Deliver free cholesterol to
A C A T enzyme, generating
cholesterol esters

Activation of LXRs,
which stimulate cellular
cholesterol efflux pathways

Oxysterol generation as a
direct means of cellular
cholesterol unloading

Figure 6.5: Four potential functions of StarD5 consistent with E R stress gene regulation.
A B C = A T P binding cassette transporter, C E = cholesterol esters, 27-HC = 27-hydroxycholesterol.
See text for further details.

It is notable that the models for StarD4 function generally increase cellular
cholesterol by synthesis or uptake, while the StarD5 models decrease cellular cholesterol by
efflux or esterification. Even though StarD4 and StarD5 showed similar activities in the
three overexpression assays, they could potentially have such opposing functions at
endogenous expression levels in vivo. Cholesterol-depleted cells may activate StarD4 via
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S R E B P - 2 to increase cholesterol levels, while cholesterol-loaded cells m a y activate StarD5
via the ER stress response to decrease cholesterol levels.

StarD6: a male germ cell specific gene with potential roles in fertility

Unlike StarD4 and StarD5, StarD6 expression was limited to the testis. A StAR-like
role in steroidogenesis was unlikely since StarD6 was not expressed in other steroidogenic
tissues, and further studies showed no StarD6 in steroidogenic Leydig cells of the testis.
Rather, StarD6 mRNA was expressed in male germ cells at many stages of development, and
expression was absent in germ cell-deficient mice. Germ cells themselves are not known to
have steroidogenic capacity, but roles for StarD6 in steroid hormone metabolism cannot be
ruled out. We were unable to test StarD6 function in transient transfection assays for
steroidogenesis and transcriptional regulation, since expression of the FLAG-StarD6
construct was undetectable in several fibroblast cell lines. StarD6 may thus require germ-cell
specific accessory proteins for protein stability. StarD6 may generate oxysterols, analogous
to the potential activity of StarD4 and StarD5, which could be substrates for steroidogenesis
in other cell types. For instance, 25-hydroxycholesterol produced by testicular macrophages
can be converted to steroids by Leydig cells (Lukyanenko et al., 2001). Nonetheless, we
favor non-steroidogenic roles for StarD6 in male germ cells.
The mouse genome includes an intron-less StarD6 gene on chromosome 10 nearly
identical to the gene with introns on chromosome 18. The only coding difference in the
intron-less gene is a deletion at +696 from the ATG, resulting in a frameshift right before the
TAG stop and a longer ORF by 24 codons. This intron-less chromosome 10 gene is likely a
processed pseudogene that is not transcribed, since it does not include the potential promoter
elements of the chromosome 18 gene that are highly conserved in the syntenic human gene.
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Furthermore, 5' R A C E analysis of mouse StarD6 R N A showed three alternatefirstexons in
StarD6 mRNA. All three alternate exons are on chromosome 18, while the intron-less
chromosome 10 gene only has sequence for exon lb. Alternate first exons were also
identified in the human StarD6 gene, as well as multiple transcription start sites in
mouse and human first exon.
Another unusual feature of mouse and human StarD6 mRNAs was long 5' UTRs

encoded by multiple exons, three non-coding initial exons in mice and two in humans. T
was no apparent sequence conservation in these 5' UTRs, but both contain multiple AUG
codons before the StarD6 ORF. None of the upstream ORFs could include this StarD6
START domain coding sequence, which has an in-frame stop codon immediately before the

AUG codon. Ribosomes typically bind to the 5' mRNA cap and scan to the first start cod
to initiate translation, but mRNAs with long 5' UTRs and upstream AUGs are often

regulated translationally (Morris and Geballe, 2000). For instance, the Cyp27 mRNA was

recently shown to have a long 5'UTR and upstream ORFs that regulate its translation i

(Lodhi et al., 2003). Translational regulation is especially common in germ cells, whic

compact their nuclei and arrest most transcription during spermatogenesis (Eddy, 1998).

Therefore, even though StarD6 mRNA was detected at all stages of germ cell development
protein expression may be restricted to specific stages.

Cholesterol and it biosynthetic precursor sterols have at least four important roles i

sperm development and function, and each pathway could involve a putative sterol trans

protein like StarD6 (Figure 6.6). First, meiosis activating sterols (MAS) stimulate me
germ cells (Byskov et al., 1998), and the precursor testis-MAS (T-MAS) accumulates in

post-pubertal testis (Tacer et al., 2002). Second, other post-lanosterol sterols like 7
dehydrocholesterol are surprisingly abundant in testis and epididymis, where they may

roles in sperm maturation (Lindenthal et al., 2001). Third, the precursor desmosterol i
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enriched in the membranes of sperm tails, where it is even more abundant than cholesterol
and may increase membrane fluidity for sperm motility (Connor et al., 1998). Fourth,

cholesterol efflux from the sperm head acrosomal membrane occurs during capacitation,
process necessary for fertilization (Travis and Kopf, 2002).

Lanosterol
I

Meiosis Activating
Sterol in testis (T- M A S )

I
4, 4-dimethyl-5acholesta-8, 24dien-30-ol

Enriched in testis a n d
epididymis, role in
s p e r m development?

I

M o r e abundant than
cholesterol in s p e r m
tails, role in motility?

I 7-dehydro
/
•
cholestero
desmosterol

Effluxed from acrosomal
m e m b r a n e during s p e r m
capacitation

cholesterol

Figure 6.6: Four sterols with potential roles in male germ cells, perhaps requiring StarD6.
See text for further details.

Using the anti-StarD6 antibody we generated, the laboratory of Patricia Morris has
studied StarD6 protein expression. Preliminary data localizes StarD6 to the midpiece of
mature spermatozoa in mice, rats, and humans (P. Morris, personal communication), making
a role in capacitation unlikely. Another START domain protein of unknown function,
StarD 10 of the PCTP subfamily, is also expressed in sperm, but it localizes to sperm tails
rather than midpiece (Yamanaka et al., 2000). The sperm midpiece is packed with
mitochondria that generate energy for sperm motility, and mitochondrial dysfunction has
been implicated in male infertility (Ruiz-Pesini et al., 1998). StarD6 in the midpiece may
thus play a role in mitochondrial function and sperm motility, consistent with the model that
START domains deliver sterols to mitochondria.
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K02D3.2: T h e only StarD4 subfamily gene in C. elegans

While mammals have three StarD4 subfamily genes, the nematode C. elegans has
only the K02D3.2 gene, and its six other START genes belong to other subfamilies. The

fruit fly Drosophila melanogaster, another invertebrate whose genome has been complete
sequenced, has only 4 START genes and no StarD4 subfamily member. K02D3.2 coding
sequence was based on automated genome annotation, and the START domain was
surprisingly interrupted by 60 non-START amino acids. We cloned the cDNA, revealing a

START domain lacking these extra amino acids, and thus corrected the genomic annotatio
The K02D3.2 protein was more like the StarD4 subfamily than other START
proteins, so we reasoned that K02D3.2 may be functionally orthologous to mammalian

StarD4, StarD5, or StarD6. To test this hypothesis, we generated a K02D3.2 promoter GFP
reporter worm line. This reporter was not expressed in male germ cells like mammalian
StarD6, though there may be silencing of transgenes in the worm germline. Furthermore,
reporter expression was not activated by cholesterol depletion or ER stress or like

mammalian StarD4 or StarD5, respectively. While it is possible that this reporter lack

intronic, downstream, or distal gene regulatory elements, K02D3.2 did not appear to sh
gene regulation like any of the three mammalian genes.
The K02D3.2 reporter was expressed in seam cells of embryos and larvae, but not in

adults. Seam cells are one of three major cell types of the nematode hypodermis, and t
play crucial roles in development, organizing embryonic and larval morphogenesis and

regulating body form (Koh and Rothman, 2001). There are ten bilateral pairs of seam cel
hatching, which then divide to form additional seams cells, other epidermal cells, and

neurons. The main function of seam cells is the secretion of the cuticle or exoskeleto

extracellular matrix composed primarily of small highly cross-linked collagens (Johnst
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2000).

Cuticle is essential for viability, as it maintains body shape, protects against

environmental insults, and aids locomotion (Eschenlauer and Page, 2003). One percent of

the C. elegans genome encodes over 150 cuticle collagens, as there are five stage-spec

cuticles which are molted and replaced during embryonic and larval development (L1-L4).

At the end of the final larvae stage L4, the individual seam cells fuse forming the sea

syncytia in adults (Koh and Rothman, 2001). Loss of K02D3.2 expression at the transitio

between L4 and adults correlates with this homotypic seam cell fusion event. Certain E

family GATA transcription factors are essential for seam cell development and fusion (
and Rothman, 2001), so these factors are strong candidates for regulation of K02D3.2
expression.
Since seam cells are highly active in protein secretion, they may have physiological

high levels of ER stress. In mammals, secretory cells (like insulin-producing pancreat
cells and antibody-producing plasma cells) are thought to constitutively activate the

response to protect against ER overload (Harding et al., 2002). While the ER stress res

is well characterized in C. elegans, its activation in individual cell types like seam
not been specifically described. An ER stress activated hsp-4 (BiP) GFP reporter is

expressed in a bead-like pattern consistent with seam cells, but this is only apparent
expression elsewhere is blocked by mutations in upstream ER stress mediators IRE-1 or
Xbpl (Calfon et al., 2002). K02D3.2 is most similar to ER stress activated mammalian

StarD5, so its expression may protect against ER stress. K02D3.2, however, did not appe

to be an ER stress response target gene, as tunicamycin treatment failed to induce rep

expression. Consistent with this, a whole genome microarray analysis of tunicamycin-tr

worms failed to show regulation of K02D3.2 (David Ron, personal communication). Even i

K02D3.2 is not activated by ER stress per se, its very specific expression in the dedi
secretory seam cells could nonetheless indicate a role in ER function.
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Based on a genome-wide R N A i screen, reduced expression of K02D3.2 causes

decreased lipid storage and an altered pattern of lipid deposition in the gut lining c

adult worms (Ashrafi et al., 2003). The K02D3.2 reporter, however, was not expressed in

adult gut cells, so the RNAi phenotype could be secondary to a defect in seam cells or

secretion. Such defects often give altered body shape, such as the dumpy (Dpy) phenoty

certain collagen mutations (Eschenlauer and Page, 2003), but this was not assayed in th

RNAi screen. It is difficult to reconcile the RNAi phenotype in adult gut with exclusi
expression in embryonic and larval seam cells.

It is also unclear how a putative sterol transfer protein could function in seam cells.
A detailed review of cholesterol metabolism in C. elegans was recently published
(Kurzchalia and Ward, 2003). Worms are incapable of de novo cholesterol synthesis but
require sterols from the environment, so standard laboratory growth media includes

cholesterol. When this cholesterol is omitted, there are mild defects in movement, gon

development, and, notably, shedding of cuticle during molting (Kurzchalia and Ward, 200

When all sources of exogenous cholesterol are stringently excluded, first generation w

have decreased growth and fertility, while the second generation shows larval growth a

(Merris et al., 2003). The vitellogenins, extracellular yolk proteins that resemble mam
ApoB, have been implicated as sterol transfer proteins that deliver sterol to oocytes

expressing specific receptors (Matyash et al., 2001). Nematodes appear to possess uniqu
enzymatic machinery to converts cholesterol or plant sterols into their major sterol,

dehydrocholesterol. For instance, when sitosterol is the sole sterol source, it is con

desmosterol, cholesterol, and finally 7-dehydrocholesterol (Choi et al., 2003). Worms g
in sitosterol and azacoprostane, a drug that blocks the conversion of desmosterol to

cholesterol, show the expected sterol-depletion phenotypes in growth and fertility. In

addition, these worms have defects in germ cell morphology, reduced motility, and poor
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developed cuticle (Choi et al., 2003). While cuticle defects could be secondary to other

phenotypes, these sterol depletion experiments indicate that sterols may affect cuticl
secretion in C. elegans, thus providing a potential role for K02D3.2 in seam cells.

Future Directions

The preceding discussion proposes multiple potential functions for each of the StarD4
subfamily members. These models are based on homology to the cholesterol-binding StAR
and MLN64 proteins, the regulated expression of each gene, and the effects of

overexpressing StarD4 or StarD5 in cultured cells by transient transfection. Future st
will address the hypotheses generated here.

Characterization of novel gene regulatory elements: StarD4 was shown to be an SREBP

target gene with a functional SRE in its promoter. Regulated expression was also descr

for StarD5 and StarD6, by ER stress and germ cell factors, respectively, but the respo

regulatory elements were not identified. While SREs are relatively well defined, there

been many fewer studies of ER stress-responsive and germ cell-specific elements. Futur

investigation of such elements may use the StarD5 and StarD6 promoters as model system

Further studies of the C. elegans K02D3.2 gene: This StarD4 subfamily gene appears only
expressed in hypodermal seam cells in embryos and larvae, inconsistent with a reported
RNAi phenotype on lipid storage in the gut lining cells adults (Ashrafi et al., 2003).
be useful to perform an independent RNAi study to confirm the gut phenotype, and look
other phenotypes such as defective cuticle secretion by seam cells.

Biochemical studies of recombinant proteins: The studies described here provide strong

indirect evidence for sterol binding and transport by StarD4 and StarD5, but direct ev
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is lacking. Recombinant StarD4 protein was generated for the crystallographic studies, and

bacterial expression plasmids were also cloned for StarD5 and StarD6. Similar to publi

studies of other lipid transfer proteins, in vitro experiments with recombinant StarD4

subfamily proteins could directly demonstrate sterol binding or sterol transfer betwee
membranes.

Crosslinking of photoactive cholesterol: A photoaffinity cholesterol reagent has been

developed, which is activated by ultraviolet light to covalently crosslink cholesterol

proteins in vitro or in vivo (Thiele et al., 2000). With the help of David Silver at Co

University, we treated recombinant mouse proteins PCTP, StarD4, and MLN64 (prepared by
Michael Romanowski) with photocholesterol dissolved in 0.1% ethanol in buffer.

Surprisingly, the photocholesterol crosslinked to all three proteins, including PCTP w

does not transfer cholesterol. Therefore, binding likely reflected non-specific associ

the hydrophobic sterol with protein surfaces, rather than specific binding in the hydr

cavity. This experiment included no non-START control proteins, no competing proteins,

and no membranes, which may be required for cavity lipid loading. The in vitro crossli
experiment was therefore limited, so in vivo photocholesterol labeling of FLAG-START
transfected cells may be more informative.

Ligand identification and oxysterol generation in stable overexpressing cell lines: St

gene overexpression in permanent cell lines can overcome some limitations of transient
transfection, such as low transfection efficiencies. We attempted to generate START-

overexpressing stable cell lines without success, but further attempts are underway. O

this is accomplished, two experiments will be undertaken in which collaborators identi
sterols by gas chromatography mass spectrometry. First, large amounts of the native
overexpressed FLAG-START proteins will be immunoprecipitated and the putative sterol
-131

ligand will be identified. Second, whole cell lipid extracts from control and overexpressing
cells will be analyzed to determine whether any sterol or oxysterol peak is increased by
START domain overexpression. This experiment may show that an oxysterol like 25- or 27hydroxycholesterol is generated in StarD4- or StarD5-overexpressing cells, explaining the
observed repression of SREBPs and activation of LXRs. This is a feasible approach, as
similar studies of NPC cells recently showed defective oxysterol generation (Frolov et al.,
2003). If stable cell lines cannot be generated, these studies can be performed by transient
transfection using protocols optimized for greater than 90% efficiency.

Assaying the role of 27-hydroxycholesterol: We hypothesize that the mitochondrial sterol
27-hydroxylase enzyme Cyp27 mediates the effects of START domain overexpression on
transcription. If this is the case, then co-transfection of a Cyp27 expression plasmid may
stimulate the START domain effects on LXR activation or SREBP repression. Likewise,
START domains may be inactive in Cyp27-deficient cells, from knockout mice or by RNAi.
Similar experiments could test potential roles of cholesterol 25-hydroxylase or other genes.

Identification of interacting proteins: Protein-protein interactions could be essential for the
function of StarD4 subfamily proteins, and identification of interacting partners may place
these proteins in known cellular pathways. Immunoprecipitation of StarD4, StarD5, or
StarD6 may co-precipitate interacting proteins, which would be identified by Western
blotting of candidate proteins or tryptic-digest mass spectrometry of unknown bands. Yeast
two-hybrid screens for interacting proteins are also being undertaken.

Further structure-function mutagenesis studies: We used site-directed mutagenesis to
study the role of two different salt bridges in StarD4 and MLN64 based on their respective
X-ray crystal structures. Corresponding mutations should be generated in StAR, as well as
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the additional StAR mutations known to cause lipoid C A H (Bose et al., 1996). Additional
structure-function relationships could also be tested in similar experiments.

Localization and expression of endogenous StarD4 subfamily proteins in cells and tissu

We have generated polyclonal anti-peptide antibodies against StarD4 and StarD6, and an

anti-StarD5 antibody will also be generated. If these antibodies prove effective, they
used in three experiments with endogenously expressed proteins. First, the cellular

abundance of StarD4 subfamily proteins may be estimated by Western Blots, comparing ce

extract levels to known dilutions of recombinant protein. Second, immunofluorescence m

show the subcellular distributions of endogenous proteins, testing the hypothesis that

soluble cytosolic proteins. Third, tissue immunostaining may reveal which cell types e
the protein. For instance, high liver StarD4 mRNA expression presumably reflects

expression in hepatocytes, and macrophages in atherosclerotic lesions may express high
levels of StarD5 due to ER stress. Studies of StarD6 protein expression in testis and
are being carried out in the laboratory of Patricia Morris.

Mislocalization of START domains to specific subcellular compartments: The studies
described here used mammalian FLAG-tagged overexpression vectors for isolated START

domains as well as chimeric Tom20-STARTs. The former proteins localized throughout the

cytoplasm and nucleus, while the latter presumably localized to the outer mitochondria
membrane. This prediction is based on studies of Tom-StAR by Miller and co-workers

(Bose et al., 2002), but future studies must use immunofluorescence or cell fractionati

confirm mitochondrial localization of these chimeras. We also cloned chimeric proteins
the MLN64 N-terminal (MENTAL) domain fused to various START proteins, which should
localize to the membranes of late endosomes like full-length MLN64. Other chimeric

proteins could be generated to localize the START domain to other compartments, such a
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ER, Golgi, or peroxisomes. Once localization is confirmed, these chimeras can be tested in
the various functional assays. Localization to certain subcellular compartments may

positively or negatively affect a given functional assay, perhaps indicating the relev
location for activity.

Transgenic mice: Similar to effects observed in transfected cells, overexpression of S

or StarD5 in transgenic mice could affect cholesterol metabolism in the whole organism

cloned transgenic constructs to express the human StarD4 or StarD5 ORFs in mouse liver
the human ApoE promoter and enhancer. This pLIV.7 transgenic expression construct was
originally generated by the laboratory of John Taylor (Fan et al., 1998) and has been
generate a number of transgenic mice and rabbits. No founder mice have been generated
date for StarD4 and StarD5, but injections are ongoing. In the future, it may also be

to generate transgenic mice overexpressing StarD4 or StarD5 in non-hepatic cells, such
macrophages which are essential for atherosclerotic lesion formation.

Potential role in apoptosis: Unpublished observations in our lab and others suggest th

overexpression of certain START domains may be toxic to cells. Transiently transfected

cells appear to die after several days, and we have to date been unable to generate St

StarD5 stable cell lines or transgenic mice. High levels of certain START proteins may
be expressed physiologically when necessary, as StAR mRNA is highly regulated and the

protein rapidly inactivated, and StarD4 and StarD5 are also regulated transcriptionall
These proteins could trigger apoptosis via several mechanisms, including oxysterol
generation (Panini and Sinensky, 2001) and effects on mitochondrial function and

cytochrome c release (Wang, 2001). Future studies may address the effects of StarD4 an
StarD5 on apoptotic pathways in cell culture model systems.
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Knockout mice: W e designed and cloned targeting constructs for StarD4 and StarD6, but
these failed to give homologous recombination in ES cells. The constructs are being
modified and knockout mice for all three StarD4 subfamily members will be generated.

StarD4- or StarD5-deficient mice may show obvious phenotypes in cholesterol metabolism
such as alterations in plasma lipoprotein profiles or tissue sterol levels. There may

differences in response to high dietary cholesterol, bile acid pool depletion, or othe

fat manipulations. Since cholesterol plays crucial roles in development, embryonic let

or other developmental phenotypes are possible in complete knockouts, but these may be

avoided in tissue-specific conditional knockouts. StarD6 knockout mice are predicted t

viable with potential male infertility. The normal function of StarD6 would be indicat

the specific defect in male fertility, such as altered sperm counts, morphology, or mo

Knockout cells or RNA interference of StarD4 and StarDS: Cells isolated from StarD4 or

StarD5 knockout mice, such as embryonic fibroblasts, peritoneal macrophages, or primar

hepatocytes, may show defects in cellular cholesterol metabolism. There may be altered

regulation of SREBP and LXR target genes, decreased cholesterol synthesis or esterific
defective cholesterol efflux, increased susceptibility to ER stress and apoptosis, or

phenotypes predicted by the models above. Prior to generation of knockout mice, simila

studies could be performed using RNAi techniques to decrease StarD4 or StarD5 expressi
We attempted small interfering RNA (siRNA), the transfection of double stranded RNA

oligonucleotides (Elbashir et al., 2001), but failed to reduce StarD4 or StarD5 mRNA le
Improvements in technology, such as DNA vectors that overexpress hairpin siRNAs via
transfection or viral transduction (Shi, 2003), may allow more successful studies.

Effects of StarD4 and StarD5 on atherosclerosis: There are two prominent mouse models

of atherosclerosis, the ApoE and LDL receptor deficient mice (Smith and Breslow, 1997)
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To determine the effects of candidate genes on lesion development, genetically modified

mice with transgenic overexpression or knockout of many candidate genes have been cro
to ApoE or LDL receptor deficient backgrounds (Glass and Witztum, 2001). Such studies

will be performed with the StarD4 and StarD5 transgenic and knockout mice. If ER stres

mediated macrophage apoptosis results in lesion progression, and StarD5 protects agai
ER stress, then StarD5/ApoE double knockout mice may show worse lesions. Conversely,
transgenic StarD5 overexpression in macrophages may protect against atherosclerosis.
StarD4 may likewise have important effects on atherosclerosis.
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Conclusion
The novel lipid-binding protein StarD4 was identified by microarray analysis of gene

expression in cholesterol-fed mouse liver. StarD5 and StarD6 were then identified base

homology to StarD4, and the three genes were cloned and shown to form a subfamily with
the START gene family. Functional data with overexpressed StarD4 and StarD5 proteins

indicate that the StarD4 subfamily is involved in the intracellular metabolism of cho

or other sterols. The three subfamily members show specific regulated gene expression:

StarD4 is an SREBP-2 target gene with a promoter SRE, StarD5 is activated by the ER s

response, while StarD6 is expressed exclusively in male germ cells. Since StarD4, Star

and StarD6 show different gene regulation and share only ~30% amino acid identity, eac

likely to play a distinct role in sterol metabolism. Future studies, including biochem

assays, cell biological experiments, and analysis of genetically modified mouse models

address these potential functions. Overall, the work described here has opened up a ne
field in the study of intracellular cholesterol metabolism and transport.
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C h a p t e r 7: Materials a n d M e t h o d s

Animals and diets: All animal protocols were approved by The Rockefeller University
Animal Care and Use Committee. Mice were housed at the Rockefeller University
Laboratory Animal Research Center in at the specific pathogen free, humidity- and
temperature-controlled room with a 12 hour light-dark cycle. Wild type C57BL/6 mice

(#00664) as well as the male Kit W/Wv mouse and Kit+/+ littermate control (#100410) we
obtained from the Jackson Laboratory.
For the initial cholesterol feeding cDNA microarray experiment, 6-week old
C57BL/6 male mice were fed Picolab Rodent Chow 20 (5053), which contains 0.02%

cholesterol (wt/wt), or the same diet supplemented to 0.50% cholesterol for three weeks

subsequent feeding experiments used a semi-synthetic modified AIN76a diet containing 1

kcal as fat and 0.00% cholesterol (Clinton/Cybulsky Rodent Diet (Lichtman et al., 1999)
Research Diets D12102N), which was fed to mice for one week before the start of each

experiment. In additional cholesterol feeding studies, mice were fed either this contr

0.00%o cholesterol diet or this diet supplemented with 0.50% cholesterol (Research Di
D00083101) for one week. For the time course study performed by Kara Maxwell, twenty
male C57BL/6 seven-week old mice were used. Four mice were sacrificed at day 0 on the
0.00% cholesterol diet, while the remaining mice were switched to a 0.50% cholesterol
and groups of four were sacrificed at days 1, 2, 4 and 7.
Transgenic mice expressing truncated nuclear forms of human SREBP-la (#002840)
or SREBP-2 (#003311) were originally obtained from Jackson Laboratory and backcrossed

to C57BL/6. Mice were genotyped by PCR from tail tip DNA using the primers in Table 7.
N6/N7 generation SREBP-la and N2/N3 SREBP-2 mice were used. Transgenic and

littermate control male mice were fed standard rodent chow from birth to 8 weeks. They
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were then switched to a 6 5 % protein, 1 0 % carbohydrate diet (Purina TestDiet 8092) for two

weeks to induce maximal transgene expression, since the SREBP transgenes were under th
control of the PEPCK promoter (Horton et al., 1998; Shimano et al., 1996).

Table 7.1: Primers for genotyping SREBP transgenic mice
Transgene

Primer

Sequence

hSREBP-la

forward

GCAACCAGAAACTCAAGCAGG

hSREBP-2

reverse
forward
reverse

CTCCAAACCACCCCCCTC
GCTGAGCCGGGCGATGGACGACAGC
CTGGGGGCGGGGCTGAAGAATAGGAGTTGC

For the LXR agonist study performed by Beth Duncan and Kara Maxwell, seven-

week old male C57BL/6 mice on the semisynthetic 0.00% cholesterol diet were gavaged wi
vehicle alone (5% ethanol, 95% sesame oil) or with 10 mg/kg TO901317 (Sigma T2320).

This treatment was repeated after 24 hours and mice per were sacrificed later the same
At the end of all mouse experiments, food was removed from the cage early in the

light cycle. Mice were fasted for 5-6 hours, sedated with ketamine/xylazine, and sacri

Harvested tissues were frozen in liquid nitrogen and stored at -80°C or stored in RNAl

(Ambion) according to manufacturer instructions. Liver total and free cholesterol (mg/

liver) was measured by gas chromatography with coprostanol as the internal standard, a
previously described (Sehayek et al., 1998).

cDNA microarrays: Fluorescent cDNA probes were synthesized by reverse transcribing

(Invitrogen Superscript II) 100 p.g liver total RNA (Qiagen RNeasy) in the presence of
or Cy5 dUTP (AP Biotech). cDNA microarrays with -9000 mouse ESTs were a generous

gift of Dr. Raju Kucherlapati at Albert Einstein College of Medicine (Cheung et al., 19

Standard protocols were used for preparation and hybridization of cDNA arrays, availab

online at http://sequence.aecom.yu.edu/bioinf/microarray/protocol4.html. Scanned array
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were analyzed with Scanalyze (http://rana.lbl.gov/EisenSoftware.htm), and results were
compiled using Microsoft Excel and Access software.

Real-Time Quantitative RT-PCR (qPCR): Total RNA was isolated from cultured cells

using RNeasy kits (Qiagen), or from tissues using TRIzol reagent (Invitrogen) followed
RNeasy cleanup (Qiagen). RNA was treated with Dnase I (Ambion), and 5ug was reverse

transcribed using Superscript II (Invitrogen) with oligo-dT and/or random hexamer prim

To perform relative quantification of gene expression with a standard curve, the genes

interest and the endogenous control gene (cyclophilin, 0-actin, or HPRT) were amplifie

separate tubes for each cDNA sample. Duplicate 50 ul PCR reactions were carried out wi
IX Jumpstart PCR buffer, 1.00 U Jumpstart Taq (Sigma), 3.5 mM MgCl2, 200 uM each
dNTPs, 300 nM forward primer, 300 nM reverse primer, and 100 nM 6FAM-labeled
TaqMan probe. TaqMan primer pairs and probes were typically designed using Primer
Express (Applied Biosystems) to span splice junctions. The sequences are shown for all

qPCR primers sets for housekeeping genes and START genes (Table 7.2), as well as contr
target genes for SREBPs, LXRs, and ER stress (Table 7.3). The template was 10 ul of a
1:100 or 1:250 dilution of cDNA, while the standards were a serial dilution of cDNA.
A 7700 Sequence Detection System (Applied Biosystems) was used with the default
thermal cycling profile (95°C for 10 min; 40 cycles of 95°C 15s, 60°C lmin; 4°C soak).
quencher dye (TAMRA) was the passive reference. The threshold was set at 0.05 units of
normalized fluorescence, and a threshold cycle (Q) was measured in each well. Relative
standard curves were plotted for each gene, and the mean Q for each cDNA sample was
expressed as an arbitrary value relative to standard. For each cDNA, values for genes

interest were normalized to the corresponding value for cyclophilin and expressed as a
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Table 7.2: TaqMan quantitative RT-PCR primers for normalizer and START genes
Gene Genbank primer sequence
Normalizers
^-actin

X03672

cyclophilin A

X52803

HPRT

AH003453

StarDl/StAR

AK019725

forward
reverse
probe
forward
reverse
probe
forward
reverse
probe

GAGAAGCTGTGCTATGTTGCTC
AGGAAGAGGATGCGGCA
6FAM-AGACTTCGAGCAGGAGATGGCCA-TAMRA
GGCCGATGACGAGCCC
TGTCTTTGGAACTTTGTCTGCAA
6FAM-TGGGCCGCGTCTCCTTCGA-TAMRA
GCAAACTTTGCTTTCCCTGG
TTCGAGAGGTCCTTTTCACCA
6 FAM-ACAGCCCCAAAATGGTTAAGGTTGCAA-TAMRA

START genes

StarD2/PCTP

StarD3/MLN64

StarD4 ORF

StarD4 3'UTR

StarD5

StarD6

forward
reverse
probe
NM008796 forward
reverse
probe
NM021547 forward
reverse
probe
AF480297 forward
reverse
probe
BY677271 forward
reverse
probe
AF480302 forward
reverse
probe
AF4 80303 forward
reverse
probe

CCGGAGCAGAGTGGTGTCA
CAGTGGATGAAGCACCATGC
6FAM-CAGAGCTGAACACGGCCCCACC-TAMRA
CCTTTCCCACTGTCCAACAGA
TCTTCCTCCTGTCCACATCCA
6FAM-CGTCTACACCCGCCAGCGCC-TAMRA
CACGCACAAATATGTCAGAGGG
TTGTTGGCTGACTTGAGCACA
6FAM-AGAACGGCCCCGGAGGCTTCA-TAMRA
GAGAGATGGCTGACCCTGAGA
TCAGACAGTCCTTCCAGTTTGATC
6FAM-CCCGTGGTCACAGATTGGCAGGA-TAMRA
TGCCGTGGTTTGCGG
AGGCAGGAACATGGCTTCTCTA
6FAM-CTCTGCTCCTACCCTGTCAGCTCCATGA-TAMRA
TGGCACCATCAGCTCCAAT
TCTCACAAAACCGGGCTTTG
6FAM-CCCATGTGGAACATCCATTGTGTCCC-TAMRA
AACTGTTTCCAGCAAGACCTCTAGA
TGAGCTGCTGATTCTGGGATT
6FAM-TCCACGGAAACCTATACCGCGTTGAAG-TAMRA

Northern Blotting: Multiple tissue Northern blots were purchased from Clontech. Other

blots were generated by running 10-20|i.g of total RNA per well on formaldehyde gels in

MOPS buffer, followed by capillary transfer to positively charged nitrocellulose membr
(Roche). Radiolabeled DNA probes were synthesized from 20 ng of template DNA by
random priming using the DECA prime II kit (Ambion) and 32P-dATP (Perkin Elmer).
Template DNA was typically the cloned START ORF cDNAs, which were generated using
the primers in Table 7.7. Probes were purified from unincorporated nucleotides using
ProbeQuant G-50 Micro columns (Amersham). Hybridization was performed with using

Express Hyb rapid hybridization buffer (Clontech) according to manufacturer instructio
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Table 7.3: TaqMan quantitative RT-PCR primers for SREBP, LXR, and ER stress target genes
Gene Genbank primer sequence
SREBP targets
HMG CoA
reductase
HMG CoA
synthase
squalene
epoxidase
LDLR
receptor
ATP citrate
lyase
Acetyl CoA
carboxylase
FABP5

LXR targets
ABCG5

ABCA1

M627 66

forward
reverse
probe
AA67 3053 forward
reverse
probe
BC042781 forward
reverse
probe
X64414 forward
reverse
probe
BC005533 forward
reverse
probe
BI250197 forward
reverse
probe
X70100 forward
reverse
probe

GGGAGCATAGGCGGCT
TGCGATGTAGATAGCAGTGACA
6FAM-CAACGCCCACGCAGCAACA-TAMRA
CTCTGTCTATGGTTCCCTGGCT
TCCAATCCTCTTCCCTGCC
6FAM-TGTCCTGGCACAGTACTCACCTCAGCA-TAMRA
GGAAGAGCCTCATCTCCAGTAAAG
TGTGGTGCATCCTTCATAAGGA
6FAM-CTCCGTTTCTTCCCACTTCGTTGGC-TAMRA
GGATGGCTATACCTACCCCTCAA
CGGCTCTCCCGGCTG
6FAM-TCAGCCTGGAGGACGATGTGGCA-TAMRA
CACCCCGCTGCTCGACT
TCAGGATAAGATTTGGCTTCTTGG
6FAM-TGCCCTGGAAGTGGAGAAGATTACCACC-TAMRA
CAGTCTACATCCGCTTGGCTG
CAGCTCCTTCCGCTCAGTG
6FAM-CGATTGGGCACCCCAGAGCTAAGC-TAMRA
CGACAGCTGATGGCAGAAAA
CCCATTGCTGGTGCTGG
6FAM-TGCACCTTCCAAGACGGTGCCCT-TAMRA

AY195872

TGGGATGTTCGGCAAGCT
CGCATAATCACTGCCTGCTTATT
6FAM-TGTCCTGCTGAGGCGAGTAACAAGAAACTTAA-TAMRA
ATTGCCAGACGGAGCCG
TGCCAAAGGGTGGCACA
6FAM-CCAGCTGTCTTTGTTTGCATTGCC-TAMRA

forward
reverse
probe
X7 592 6 forward
reverse
probe

ER stress targets
BiP
AJ002387

CHOP

X67083

forward
reverse
probe
forward
reverse
probe

TCTGGTGATCAGGATACAGGTGAT
TCCCACAGTTTCAATACCAAGTGTAA
6FAM-TGGTACTGCTTGATGTTTGTCCC-TAMRA
CCACCACACCTGAAAGCAGAA
AGGTGAAAGGCAGGGACTCA
6FAM-CTGGTCCACGTGCAGTCATGG-TAMRA

General Cloning and P C R : Molecular cloning followed standard techniques using T4 D N A
ligase from Invitrogen and other enzymes from New England BioLabs. All plasmid DNA
was transformed into DH5a bacteria (Invitrogen) and prepared using Qiagen kits. Except
where noted, PCR reagents were Advantage cDNA polymerase (Clontech), primers were

from Genelink, and thermal cycling was on a Perkin Elmer 9700. Standard thermal cycling
was 95°C for lOmin, 40 cycles of 94°C 30s, 60°C 30s, and 72°C lmin, and a 4°C soak. TA
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cloning of P C R products was carried out with pCR-2.1-TOPO (Invitrogen). D N A constructs
were sequence-verified at the Rockefeller University DNA Sequencing Resource Center.
DNA sequence was aligned and analyzed using the DNAStar software package. Human
RNA from liver and testis was purchased from Clontech.

Rapid amplification of cDNA ends (RACE): The FirstChoice RLM-RACE kit (Ambion)

was used according to manufacturer instructions. Briefly, total RNA (from liver for St

and testis for StarD6) was treated with phosphatase to remove 5' phosphate groups from
DNA, rRNA, tRNA, and degraded mRNAs. Next, the 5' caps of intact mRNAs were
enzymatically removed, and a RACE adaptor sequence was ligated to the 5' ends of
decapped mRNA. The RNA was reverse transcribed, and the resulting cDNA was template

for nested PCRs with 5' inner and outer primers in the adaptor and 3' gene specific i

outer primers. 5' gene specific primers served as controls, and the sequences of the g
specific RACE primer are shown in Table 7.4. RACE inner PCR products were TA cloned
and sequenced.

Table 7.4: Primers for 5' RACE analysis of mouse and human StarD4 and StarD6
Gene primer sequence
mStarD4

outer

TCATCTTCTTTGATGCTGTGATACTGGAT

inner

CCACGGGCTCTCAGGGTCAG

5'
hStarD4

outer

GGAACACAAAACCAACCACAGGGATG

inner

GGTTATATCCTCGAACAAATTCTGGTCTC

5'
mStarD6

ATGGAAGGCCTGTCTGATGTTGCTTC

outer

CAACGCGGTATAGGTTTCCGTG

inner

GTTGGGCAATTGCCTTATAGTCCATC

5'
hStarD6

CTCTGGTACGGGACAGGAAGGAGG

GGGACAGGATATGAAGTGGGAAG

outer

GCCCACGGCAAAACTTTGTGTAATG

inner

GCTGGTGATTCTGGAATTATCCCTTC

5'

GTTAAGAGATATGGAGATTTCCACAAGG
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Recombinant protein expression and crystallization: The mouse StarD4 O R F was R T - P C R
amplified from liver cDNA using the PCR primers with BamHI and Xhol restriction sites

(Table 7.7). The product was cloned into these restriction sites of the pGEX-6P-l plas
and sequence verified with the pGEX 5' and 3' sequencing primers (Amersham).
Glutathione S-transferase (GST)-tagged protein was expressed in Escherichia coli BL21

(Novagen) during overnight induction at 18°C. Fusion protein was purified by GST affin
chromatography. The N-terminal GST tag was removed by digestion with PreScission

protease (Pharmacia), and StarD4 was separated from GST and uncleaved fusion protein o

glutathione-agarose. After overnight dialysis in 20 mM Hepes (pH 8.4), 100 mM KC1, 5 mM

DTT, the target protein was further purified by Q Sepharose ion-exchange chromatograph
eluted with a 50-1000 mM KC1 gradient. The final preparations were dialyzed against 20
mM Hepes (pH 7.5), 100 mM KC1, 5 mM DTT and concentrated to 1-20 mg/mL.
The molecular weight of purified StarD4 was verified by gel electrophoresis and

matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). Size exclusi
chromatography was also performed on a GF75 column (Pharmacia). The low molecular

weight gel filtration standards (Pharmacia) chymotrypsinogen A (13.7 kD), ovalabumin (

kD), and bovine serine albumin (67 kD) eluted from the column at 44.75, 50.75, and 57.3
mL, respectively, while StarD4 eluted at 56.6 mL.

Crystallization conditions for purified StarD4 protein were tested with Crystal Screen
and Crystal Screen II (Hampton Research), and crystals formed in conditions 45 and 46

Crystal Screen. Crystallization conditions were optimized, such that diffraction-quali

StarD4 crystals were obtained at 4°C by sitting-drop vapor diffusion against a reservo
containing 0.1 M sodium cacodylate (pH 6.5), 0.2 M magnesium acetate, 16% (wt/vol)
polyethylene glycol 8000, and 22% (vol/vol) glycerol.
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For structure determination, selenomethionine-containing

StarD4 crystals were

generated. Michael Romanowski collected diffraction data and solved the X-ray crystal

structure at 2.2 A resolution as described (Romanowski et al., 2002). Residues 1-23, 22

224, and five residues from the N-terminal cloning artifact (Gly-Pro-Leu-Gly-Ser) wer

visible in the electron density map and were omitted from refinement. Cavity volumes w

measured and cavity plots generated with the VOIDOO program using a probe radius of 1.
A (Kleywegt and Jones, 1994). The structure was modeled and visualized using O (Jones

al., 1991) or PyMOL (Liang et al., 2003) software. The StarD4 structure has the Protei
Data Bank (www.rcsb.org) identification 1JSS, while MLN64-START (Tsujishita and
Hurley, 2000) and PCTP (Roderick et al., 2002) are 1EM2 and 1LN1-3, respectively.

C. elegans K02D3.2 cloning and GFP reporter: Four primers in the K02D3.2 ORF (Table
7.5) were used to amplify this cDNA from a C. elegans cDNA library (a gift of Shai
Shaham). Products were TA cloned and sequenced. While the forward exon 1 ORF primer

at +1 to +22 from the ATG gave PCR products with reverse primers, the -68 to -44 forwa
primer and the splice leader 1 (SL1) primer failed to amplify.

Table 7.5: RT-PCR primers for cloning the K02D3.2 cDNA
location

primer

sequence

exon 1 (ORF ATG)
exon 2 (ORF)
exon 7 (ORF stop)

forward
forward
reverse

ATGCCTGCCACAGAGACCAGCG
GCGCATTCCGAACAGAACTTGTGCTG
CTAGTTTTCCAAATGGGCAGCACACC

exon 5 (ORF)

reverse

GGGGATTAAGCATGAGAAGTGTGGGATAAG

-68/-44 from ATG
splice leader 1 (SLl)

forward
forward

ACAGTTCAGCGTCACATAATTCCAG
GGTTTAATTACCCAAGTTTGAG

To generate the K02D3.2 GFP reporter, a region spanning from -2700 from the ATG
in the 5' flanking region to +114 in exon 1 was PCR amplified from C. elegans genomic
DNA (a gift of Shai Shaham). The PCR primers (Table 7.6) gave the expected 2.8 kB
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product with Hindlll and B a m H I tails, which was T A cloned. This product was subcloned

into the pPD95.69 GFP reporter vector (originally generated by the Andy Fire lab and a

of Shai Shaham). At the 5' junction, the pPD95.69 Xbal was ligated to Spel from the TA

vector polylinker. The 3' junction in exon 1 was with BamHI, giving an in frame fusion

between exon 1 of K02D3.2 (encoding 38 amino acids) and the GFP reporter. Both junctio
were sequence verified with the indicated primers (Table 7.6).

Table 7.6: Primers for the K02D3.2 GFP reporter
K02D3.2 reporter cloning primers:
-2700 forward
+114 reverse

Hindlll
BamHI

gtttaagcttCTGGAGCGATAAACGTTCCACCGGTC
gtttggatccTTCGGAATGAAGTTGCCATTCCAAAGAGTGC

pPE95. 69 sequencing primers:
upstream
downstream

forward
reverse

TCACTCACAACGATGGATACGC
TTCACCCTCTCCACTGACAG

Elliot Perens co-injected worms with the pPD95.69-K02D3.2 reporter (25 ng/ul) and

the dominant marker encoding rol-6 (50 ng/ul) (Mello et al., 1991). Two C. elegans lin
were generated, and both displayed fluorescence only in the seam cells of embryos and

larvae. Worms were maintained on standard growth media that contains 5 ug/ul cholester

Media lacking added cholesterol (though trace amounts of cholesterol may be present in

agar or the bacterial lawn (Calfon et al., 2002)) or containing 5 ug/ul tunicamycin we
used, but did not affect the reporter expression pattern over two generations.

Cell Culture, media, and treatments: All cultured mammalian cells were grown at 37°C i
5% CO2. MA-10 cells (a gift of Jonathan Smith) were cultured in Waymouth's media with
15%o horse serum. To stimulate steroidogenesis, MA-10 cells were cultured in 1 uM 8bromo-cAMP for three hours. Media was withdrawn and pregnenolone levels were
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measured by ELISA (Diagnostic Biochem Canada). R N A was extracted for gene expression
analysis by qPCR and Northern.
All other cell types (NIH 3T3, HEK 293, COS-1, RAW, and Hepa-1) were obtained
from ATCC and maintained in Dulbecco modified Eagle's medium (DME) with 10% fetal

bovine serum. NIH 3T3 cells were grown as fibroblast-like cells and were not different
to adipocytes. Lipoprotein-depleted serum (LPDS) was prepared from FBS by raising the

density to 1.25 mg/mL with KBr and ultracentrifuging in a Ti60 rotor (Beckman) at 45,0
rpm overnight. The upper lipoprotein-containing fraction was removed, and LPDS was
dialyzed against 150 mM NaCl to remove KBr and filtered sterilized (Nalgene).
Cells were treated with various drugs and agents from Sigma. To regulate SREBP
activity with sterols and statin, lOOOx stock solutions were made for cholesterol (10

and 25-hydroxycholesterol (1 mg/ml) in ethanol, as well as mevinolin/lovastatin (1 mg/m
To ER stress cells, lOOOx stocks were made for tunicamycin (2.5 mg/ml in methanol),

thapsigargin (2 mM), Brefeldin A (10 mg/ml in ethanol), or DTT (2 M). Other lOOOx stoc

were 10 mM T0901317 and 1 mg/ml for 22(R)-hydroxycholesterol, both in ethanol. To trea

cells, these agents were added to media containing LPDS or FBS at a final concentratio

lx, thus 1:1000th of the stock concentrations above. Vehicle control experiments showe

effect of 0.1% ethanol or methanol in the various assays. All treatments were preforme
subconfluent cells in six well plates for 18-20 hours, after which RNA was extracted.

Transient transfection experiments: Before all transfection assays, cells were split i

well plates at ~104 cells per well and grown overnight. The next day, each well of 50-

confluent cells was transfected with 200-400 ng of total plasmid DNA using Lipofectami
PLUS reagent (Invitrogen).
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For StarD4 and StarD5 reporter experiments, each well of N I H 3T3 cells was

transfected with 200 ng of luciferase reporter and 20 ng of CMV-{3gal expression vecto

nomalization. After 3 hours, the serum-free transfection media was replaced with 0.5 m
experimental media. For StarD4 reporter experiments, 3 media were used: control (DME

with 10%o LPDS), sterols (10 ,ug/ml cholesterol; 1 u.g/ml 25-hydroxycholesterol), or st

j4.g/ml mevinolin). In the StarD5 reporter ER stress assays, the media were control (D
with 10% FBS) versus tunicamycin (2.5 ug/ml). After 18-20 hours, cells were lysed with

passive lysis buffer and assayed for luciferase and Pgal activities (Promega). Lucifer
relative light units were normalized to Pgal units (absorbance at 420 nm), and results

expressed as this ratio. Data are presented as mean and standard deviation of triplica
The other luciferase reporter experiments were peformed similarly. In the assays for
START domain effects on SREBP reporters, each well of HEK 293 cells was transfected
with 200 ng of SREx3 luciferase reporter, 20 ng of pgal, and 100 ng of FLAG-tagged
START expression plasmid. In the assays for START domain effects on LXR reporters,

each well of COS-1 cells was transfected with 200 ng of LXRE luciferase reporter, 50 n
Pgal, 25 ng of LXR, 25 ng of RXR, and 100 ng of FLAG-START. For both experiments,

cells were cultured after transfection in DME with 10% FBS for 18-20 hours before lysi
For the steroidogenesis assay, each well of COS-1 cells was transfected with 100 ng
of F2/P450scc, 100 ng of 3p-HSD, and 100 ng of FLAG-START. After transfection, cells
were grown in DME + 10% FBS for 48 hours. Media was withdrawn and progesterone
levels were measured by ELISA (Diagnostic Biochem Canada).

START expression plasmids: START domain coding sequences were PCR amplified from

liver or testis cDNA using the primers in Table 7.7, which had restriction site (itali
5' tails. These PCR products were generally cloned into BamHI and Xhol sites of the
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p C M V - T a g 2 B epitope tagging mammalian expression vector (Stratagene).

The mouse

StarD5 sequence has an internal BamHI site, so it was cloned using PstI instead. Mouse

StAR has an internal Xhol site, but was cloned using this enzyme by partial digestion.
expression plasmids were sequence verified using T3 and T7 primers to assure correct
START domain sequence and in-frame fusion of the N-terminal FLAG epitope tag. Mouse
StarD4 and PCTP had coding SNPs characteristic of the C57BL/6 strain (StarD4 A121,
T152; PCTP G205, G324, G379). There were silent mutations in human StarD4 (A426G)
and StarD5 (C21G), and all other START domains agreed with predicted sequence.
Table 7.7: Primers for cloning the FLAG-START expression plasmids
qene

type

primer

tail

mStarD4

ORF

mStarD5

ORF

mStarD6

ORF

hStarD4

ORF

hStarD5

ORF

forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse

BamHI
Xhol
PstI
Xhol
BamHI
Xhol
BamHI
Xhol
BamHI
Xhol
BamHI
Xhol
BamHI
Xhol
BamHI
Xhol
BamHI
BamHI
BamHI
BamHI

mStAR

START

mPCTP

ORF

mMLN64

START

MLN64

MENTAL

Tom20

ORF
no stop

sequence
gtcgtggatccATGGCTGACCCTGAGAGCCCG
gtcgtctcgagTCATGCCTTGCGTAGACCTTTTCG
gtcgtctgcagATGGACCCGTCCTGGGCCACGCAAG
gtcgtctcgagTCAGTGATGGAACTTCCTCACTGCCTTC
gtcgtggatecATGGACTATAAGGCAATTGCCCAACAAAC
gtcgtctcgagCTACGGTTTAATGGCAGAATGTCCTTC
gtcgtggatecATGGAAGGCCTGTCTGATGTTG
gtcgtctcgagTCATAAAGCTTTTCGTAAATCACCATAG
gtcgtggatecATGGACCCGGCGCTGGCAGC
gtcgtctcgagTTACTCATGGAATTGCTTCACTGCTTTCTG
gtcgtggatccGAAGCAACACTCTATAGTGACCAGG
gtcgtctcgagTTAACACTGGGCCTCAGAGGCAGG
gtcgtggatccATGGCGGGGGCCGCATGCTGCTT
gtcgtctcgagTTAGGTTTTCTTGTGGTAGTTCTGACACG
gtcgtggatccGGGTCTGACAATGAATCAGATGAGG
gtcgtctcgagTCAAGCTCGGGCCCCCAGCTC
gtcgtggatccATGAGCAAGCGACCTGGTGATCTGGC
gtcgtggatccTGCAAAGGATTCTGGGGGAGAGTAGAAC
gtcgtggatccATGGTGGGCCGGAACAGCGCC
gtcgtggatccTTCCACATCATCTTCAGCCAAGCTCTG

To generate the FLAG-Tom20-START fusions, the mouse Tom20 coding sequence

was PCR amplified from liver cDNA with primers lacking the 3' stop codon but with BamH

tails at both ends (Table 7.7). This Tom20 product was cloned into FLAG-START plasmids
at the BamHI site between the FLAG tag and START domain (for mouse StAR, PCTP,

MLN64, StarD4, and StarD6, as well as human StarD5). SacII digests identified clones wi
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the correct orientation of Tom20, and these were sequence verified for the correct T o m 2 0
sequence and in-frame fusion. To generate F L A G - M E N T A L - S T A R T fusions, the mouse
M L N 6 4 N-terminal ( M E N T A L ) domain was likewise R T - P C R amplified from liver c D N A
with B a m H I tailed primers (Table 7.7), and cloned into F L A G - S T A R T s via BamHI. Kpnl
digests identified clones with the correct M E N T A L orientation before sequence verification.
To generate the mouse StarD4 and M L N 6 4 salt bridge mutant expression plasmids,
the F L A G - S T A R T vectors were modified using the QuikChange II site-directed mutagenesis
kit (Stratagene). Briefly, a pair of oppositely directed primers with the desired mutation(s)
was used to replicate both plasmid strands with a high fidelity Pfu D N A polymerase. The
methylated parental D N A

was digested with Dpnl, while the mutant strands were

transformed into bacteria for nick repair, generating mutant plasmids.

Three types of

mutagenic primers were designed for each gene, one targeting both residues of the a C salt
bridge, and two others targeting the charged P5 and P6 residues individually.

The six

forward mutagenic primers are shown in Table 7.8, and the six corresponding reverse
primers were complementary. In addition to the desired changes for amino acid substituitons
(underlined), the primers also introduced silent mutations (lower case) that added or removed
restriction sites. This allowed screening for mutants based on restriction fragment length
polymorphisms (RFLPs), though this was not ultimately necessary as mutagenesis efficiency

Table 7.8: Mutagenic primers for StarD4 and MLN64 salt bridge mutants
qene

substitution(s)

RFLP

forward primer

StarD4

R92M, D96N

-AgeI

CCAGGGCCCTGGATGTTGGACTGGAAtCGGTTAATGACC

Y177D

+BspHI

GAGAATTGTTGTGTcATGaGaGACACCACTGCTGGGC

S136R

+SalI

CCGAGAGAGTTTGTcGAcTTCCGCTATACTGTGGGC

M307R, N311D

+MluI

GCAGCCTGAGAGaCGCGTGCTGTGGGACAAGACGGTGAC

D332Y

-BspEI

CCTTGTCTCCTATTATGTGTCATCaGGAGCTGCAGGTGG

R351S

+XhoI

MLN64
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GACTTTGTGAATGTCTCGaGaATTGAGCGGCGCAGAG

was > 9 0 % . To generate the double and triple mutations, mutant plasmids were subjected to
additional rounds of mutagenesis. All mutations were confirmed by DNA sequencing.

StarD4 and StarS luciferase reporters: The mouse StarD4 proximal promoter was PCR
amplified from C57BL/6 genomic DNA using a forward primer at -1335 and reverse primers
at either +34 or +137 (Table 7.9). The forward primer had a Sacl tail, and the reverse
primers had Hindlll tails. These PCR products were TA cloned. To generate the -1335

StarD4 reporters, the entire Sacl/Hindlll fragment was subcloned into these sites in t

basic luciferase vector (Promega). To generate -874 reporters, Bgfll (which cuts at -87
and Hindlll digested fragments were cloned into these sites of pGL3. To generate -350

reporters, such as the -350/+34 reporter used in most experiments, BamHI (which cuts at

350) and Hindlll digested fragments were cloned into the BgllUHindill sites of pGL3. Th
human StarD4 proximal promoter from -521 to -8 was similarly PCR amplified from
genomic DNA with BamHI and Hindlll tails, and cloned into pGL3.

Table 7.9: PCR Primers for cloning StarD4 and StarD5 reporters
qene location primer tail sequence
mStarD4

-1335
-350
+34
+137

forward
forward
reverse
reverse

Sacl
Sacl
Hindlll
Hindlll

gcttctgagctcGAGTGCGTGTGCATGTTCAGACATTG
gcttctgagctcGGATCCAATCCTACAAACCCTTACGCTTAGG
gcttctaagcttGGATGTCAGGCGGTCAACAACTCC
gcttctaagcttCTCTCTCCCCTCTACAGGGGGCAGC

hStarD4

-521
-282
-8

forward
forward
reverse

BamHI
Sacl
Hindlll

gcttctggatccGTCAGGCTAAGCAGGAGGCAGAGAGC
gcttctgagctcCCCAACCAATCCAAACCTGCAGGC
gcttctaagcttTCGCAGCCAACTGGAAGGCAC

mStarD5

-1 from ATG
-200 from ATG
-400 from ATG

reverse
forward
forward

Hindlll
Kpnl
Kpnl

gcttcaagcttCCGCCAACGTGCAGGCTCCC
gcttcggtaccGAGCTGCCTGAGACCCGCCCAGAG
gcttcggtaccTGGTGTGTACCCCTCCTGCCTAC

Mutations were generated in the mouse -350/+34 and human -521/-8 reporters using
the GeneEditor in vitro Site-Directed Mutagenesis System (Promega) according to

manufacturer instructions. Briefly, double stranded plasmid template was denatured, and
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mutant strand was synthesized using one oligo to mutagenize the region of interest and

another to alter the ampicillin resistance cassette. The chimeric DNA with both mutant

wild type strands was transformed into mismatch repair deficient bacteria. Bacteria we

grown in the GeneEditor antibiotic selection mix, which selected for the modified amp
resistance. DNA from these cells was isolated and normal bacteria were transformed to
produce mutant plasmids. The mouse and human StarD4 mutagenic oligos to eliminate

potential sterol regulatory elements (SREs) are indicated in Table 7.10. The mutation

designed to add or remove restriction sites so mutant clones could be identified by RF
All wild type and mutant reporter constructs were sequence-verified.

Table 7.10: Mutagenic primers for StarD4 promoter elements
reporter

site

RFLP

mutagenic primer

mStarD4

SRE-A

-Eael

CTGGCTCCGGCACGCCCACACGCAC

SRE-B

+BamHI

GCACGCGGAATCGGTGGATCCTCGGAGGCCAA

SRE-C

+EaeI

TTCACGCTGAGGCACTGGCCAATCCCAGCGAAC

SRE-D

+StyI

CTCCCGCTAACACCCTAGGGAAGTTCCCCTCC

SRE-E

+BamHI

CTCGCCTTCACCAAGGATCCCTTCTGCCTTCTGATTG

CCAAT-B

+StuI

CATCCTCGGAGGCCTGTCGGCTCCCTTCAC

CCAAT-C

+BamHI

SRE-A

+ApaI

SRE-B

+BamHI

SRE-C

+EaeI

CACACGCTCCCGCGCTGGCCAATCCGAACAAG

CCAAT-B

+PmlI

CCATTTATCGGCCACGTGTCAGCCCTCCACACGC

CCAAT-C

+BamHI

hStarD4

GCTGAGGCACCAGCGGATCCCAGCGAACACAC
CGGCTCGGGCGGGCCCACACCCA
CACACCCACGCGGAATGGATCCATTTATCGGCCAC

CTCCCGCGCCAGCGGATCCGAACAAGCG

A potential SREBP-binding E box was reported in the p G L 3 polylinker, between the
Sacl and Bglll sites (Annicotte et al., 2001). The mouse -350/+34 and human -521/-8
StarD4 reporters were previously cloned into the Bgfll and Hindlll sites and included this
potentially confounding element. Therefore, additional forward primers with Sacl tails for
mouse -350 and human -282 (Table 7.9) were generated to P C R amplify and re-clone these
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reporters.

These modified Sacl/Hindlll cloned wild type and SRE-B mutant reporters

showed the same activity and regulation as the previous BglH/Hindlll versions. Additio
mutations were generated in the modified reporters using GeneEditor as before: CCAAT
boxes were eliminated from the wild type reporter, and additional SRE mutations were
to SRE-B mutant mouse StarD4 reporters.

StarD5 luciferase reporters were also generated, though 5' RACE was not performed

to identify the true transcription start site. The putative StarD5 proximal promoter w
amplified from C57BL/6 genomic DNA, using forward primers at -400 or -200 from the
ATG and a reverse primer at -1 (Table 7.9). The forward primers had a Kpnl tails, and

reverse primer had Hindlll, so the products were subcloned into these sites of pGL3 ba

Other reporter and expression plasmids: The SREx3 luciferase reporter was a gift of Doug
Thewke and Michael Sinensky, and was generated by subcloning the sterol-regulated
promoter region from the pTK(Kx3) CAT reporter (Dawson et al., 1988) into pGL2 basic
(Promega). The LXRE luciferase reporter, as well as the expression plasmids for human

LXRa and RXRa, were gifts of Jonathan Smith and originally generated in the laboratory

Ron Evans (Forman et al., 1997). The two ER stress activated pGL3 reporters, BiP promot
and the artificial 5xATF6 (Ye et al., 2000), were gifts of Ron Prywes. For the

steroidogenesis assay, the F2 expression plasmid for P450scc and its electron transpor

(Harikrishna et al., 1993) was a gift of Walter Miller, and the 3P-HSD expression plas
(Zhang et al., 2002b) was a gift of Jerry Strauss.

Antibodies, Western blots, and immunofluorescence:

T w o antigenic peptides were

designed for mouse StarD4 based on their locations in the X-ray crystal structure and
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predictions of antigenicity (using DNAStar Protean software). The epitopes were conserved
between mouse and human StarD4, but not in other START proteins. Bethyl Laboratory
synthesized the 52-67 and 153-168 peptides, conjugated them to KLH, and immunized

rabbits with both peptides in adjuvant. Immune serum was generated and each antibody w

affinity-purified over a cyanogen-bromide linked peptide column. Likewise, two affinit
purified rabbit antibodies against mouse StarD6 peptides 29-44 and 154-169 were also
generated.
For Western Blots, whole cell lysates were prepared in lysis buffer with protease
inhibitor cocktail (Sigma). Cultured cells were scraped from the plate with a rubber

policeman, or liver tissue was homogenized. Protein concentrations were measured using

BCA reagent (Pierce) relative to a standard curve of bovine serum albumin (BSA). 40-50

of protein was loaded in each well of pre-cast 8% or 12% polyacrylamides gels (Invitro
for SDS-PAGE. Proteins were transferred to nitrocellulose membranes (Invitrogen), and

blots were blocked in PBS-casein (Pierce). For StarD4 Western blots, the primary antib

was anti-StarD4 52-67 (1:250) and the secondary was goat anti-rabbit HRP (1:2000, Sigma
For FLAG Western blots, the primary antibody was anti-FLAG M2 (1:500 Sigma) and
secondary was goat anti-mouse IgG HRP (1:2000, Sigma). Blots were washed in PBSTween and developed using NEN Renaissance Chemiluminenscence Reagent (Perkin
Elmer).
For immunofluorescence, HEK 293 cells were grown on chamber slides and

transfected with FLAG-START expression plasmids. After overnight incubation, cells wer
rinsed with PBS, fixed and permeabilized with methanol at -20°C, rinsed with PBS, and
blocked with PBS casein (Pierce). The primary antibody was anti-FLAG M2 (1:1000,
Sigma) and the secondary antibody was Cy3-coupled goat anti-mouse IgG (1:10,000,
Sigma). Cells were mounted and viewed on a fluorescence microscope.
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Additional methods: To generate the EGFP-StarD4 fusion, the mouse StarD4 O R F was P C R

amplified using the primers in Table 7.7, except both primers had BamHI tails. The pro
was cloned into the Bglll and BamHI sites of pEGFP-Cl (Clonetech), and the proper
direction and in-frame GFP fusion were confirmed by sequencing. Six well plates of NIH

3T3 or HEK 293 cells were transfected using ljig of DNA per well, and cells were imaged

the next day by fluorescence microscopy. Table 7.11 shows additional RT-PCR primers fo
Xbpl (see Figure 3.15) and human StarD6 (see Figure 5.7).

Table 7.11: Additional RT-PCR primers for mouse Xbpl and human StarD6
Primers for Xbpl splicing assay:
Xbpl
Xbpl

forward
reverse

AAACAGAGTAGCAGCGCAGACTGC
GGGATCTCTAAAACTAGAGGCTTGGTG

Primer for RT-PCR of human StarDG:
exon 2 (5'UTR)
exon 3 (ORF)
exon 8 (ORF)

forward
forward
reverse

GGATTTGGAGAGGAGCCCCAGTAGTTAC
ATGGACTTCAAGGCAATTGCCCAACAAAC
TCATGAATGACTATTATGATGAAATCCACGTC

Knockout and transgenic mouse constructs: To generate the conditional StarD4 knockout
construct (see Figure 4.11), the BAC AC020796 containing the 129 strain mouse StarD4
gene was obtained from Lawrence Berkely Laboratories. This BAC was digested with Kpnl,

and the ~11 kB fragment of StarD4, spanning from the 5' flanking region into intron 3,

cloned into the Kpnl site of pSP72 vector (Promega). A LoxP site flanked by two restri
sites on each side (BssSl-Hpal-LoxP-Pstl-BssSl) was generated by synthesizing the

complemenatary oligos in Table 7.12. This double stranded oligo with BssSI sticky ends

cloned into the BssSI site in StarD4 intron 2. The neomycin resistance cassette flanke
two LoxP sites (LoxP-neo-LoxP) from the vector pKSloxPNT (Hanks et al., 1995) was

subcloned into the Kpnl and Clal sites of pBluescript(KS+) (Strategene), then a the Lo

neo-LoxP fragment was generated by EcoRI digest. The EcoRI fragment was cloned into th
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Mfel site of StarD4 intron 3. This generated the targeting construct with a long arm of 9154

bp, a short arm of 1426 bp, and a targeting region of 254 bp including exon 3. Both cl

junctions and the LoxP site orientations were sequence-verified, using forward and rev

sequencing primers in introns 2 and 3 and in the neomycin resistance cassette (Table 7

The targeting construct was transfected into 129 strain ES cells by the Rockefeller Un
Gene Targeting Facility. To screen for ES clones with homologous recombination, a

Southern blot probe in StarD4 intron 3 downstream of the targeting construct was desig

The 289 bp probe template was generated by PCR using the primers in Table 7.12. Southe
Blot of genomic DNA from ES cells showed only the wild type 3.6 kB PstI fragment, and
none of almost 200 clones showed the targeted 2.3 kB fragment.
To generate the StarD6 knockout construct (see Figure 5.9), the BAC RP23-5B18
containing the C57BL/6 strain mouse StarD6 gene was obtained from Research Genetics.
This BAC was digested with Kpnl and iscoRV, and the ~5.8 kB Kpnl fragment of StarD6,

spanning from the 5' flanking region into intron 3, was cloned into the Kpnl/'EcoRV si
pBluescript(KS+) (Strategene). This was the long arm of the targetting construct. The
arm, a 726 bp fragment of intron 5, was generated by PCR from C57/BL6 genomic DNA

using the primers in Table 7.12. The forward primer had an Spel site and the reverse p

had a Sacl site, so the short arm fragment was cloned into these sites downstream of t

arm in pBluescript. Finally, the neomycin resistance cassette £coRI fragment (describe

above for the StarD4 knockout), was cloned between the long and short arm in the EcoRI

of pBluescript. The targetting construct thus replaced exons 4 and 5 of StarD6, includ

start codon, with a neomycin cassette. Cloning junctions were sequence-verified with t

neomycin cassette primers described above. The targeting construct was transfected int

C57BL/6 strain ES cells by the Rockefeller University Gene Targeting Facility. To scre
for ES clones with homologous recombination, a Southern blot probe in the 5' flanking
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region upstream of the targeting construct was designed. The 293 bp probe template was
generated by PCR using the primers in Table 7.12. Southern Blot of genomic DNA from ES
cells showed only the wild type 12 kB .EcoRI fragment, and none of almost 150 clones
showed the targeted 6 kB fragment.
To generate transgenic mice overexpressing StarD4 or StarD5 in liver, human StarD4

and StarD5 ORFs were PCR amplified using the primers in Table 7.7, except with a Kpnl t
on the forward primer and Xhol on the reverse primer. The human sequences were used so
that transgene mRNA expression could be distinguished from the endogenous mouse genes.

These ORFs were cloned into the Kpnl/Xhol sites of pLIV.7, a transgene construct in whi
liver expression is driven by the human ApoE promoter and enhancer (Fan et al., 1998).

Both constructs were sequence verified using primers in the pLIV.7 vector (Table 7.12).

Sacll and Spel digestion isolated the linear ~6.5 kB transgene fragments from the vect
fragments were purified by ethanol precipitation such that the OD 260/280 was greater

Table 7.12: Primers for knockout targeting constructs and transgenes
Primers for StarD4 knockout:
LoxP site oligo
intron 3 probe
intron 2 seguence
intron 3 sequence
neomycin sequence

forward
reverse
forward
reverse
forward
re ve r s e
forward
reverse
forward
reverse

acgagttaacATAACTTCGTATAATGTATGCTATACGAAGTTATctgcagc
tcgtgctgcagATAACTTCGTATAGCATACATTATACGAAGTTATgttaac
GGTACCCTGTTAGTGTATATTTAATTCCAGGGAAG
GGATCCAGGAGTTTGCTGTGAGACC
GAAGTCATTGGATCCCTGAGCTACTG
GTACATGGTGATTGTCACATAGGTGG
CCTCAGAAGAGTTTAATGGGTATCTG
AAATTCAGATCTGTATCTGTCTACTGC
GCTAAAGCGCATGCTCCAGAC
CCAAGTTCTAATTCCATCAGAAGCTG

Primers for StarD6 knockout:
intron 5 short arm
5' probe

forward
reverse
forward
reverse

gactactagtACATCTTCCCATTTACAGCCATCGTCG
(Spel tail)
gtcagagctcCTAGATACAAACACAGGTAAACTTCAGTAAG (Sacl tail)
CTCTGCCAGTGTTCAGTAGAGTTTATGAATTC
GTCCTTGGAGAAGACACAGGTACC

Primers for pLIV. 7 transgene sequencing:
hApoE exon 4
pLIV.7 downstream

forward
reverse

TAGGGTCCACCCCAGGAG
GCAGATGCGTGAAACTTGGTGAATC
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1.9 and the the O D 260/230 ratio was greater than 1.6. Pronuclear injection of transgene

DNA was carried out at the Rockefeller University Transgenic Facility, and 33 potenti
founder mice were generated. Genotyping of tail tip DNA by PCR with the respective
human StarD4 or StarD5 ORF primers failed to reveal any founders.

Data analysis and statistics: For all quantitative assays, the control and experimenta

were compared by a two-tailed type 2 Students T-test, with the threshold for signific
P<0.05. Data was analyzed in Microsoft Exel and graphed in Prism (Graphpad). All bar
graphs show the mean with standard deviation error bars.
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